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Abstract 
There are records of animals used for experimental research more than 2000 years ago 
(Hajar, 2011) and nowadays such use is controlled. UK animal research regulations date 
to 1876, and were most recently revised in 2013. The appropriate use of animals in 
biomedical research allows the elucidation of crucial information that can be used to 
enhance human and animal life while being humane.    
Two Xenopus species (African Clawed Frogs), are major model organisms used to study 
Cell and Developmental Biology. As in most animal models, mRNA levels during 
development are used as a proxy for protein abundance. However, recent proteomic 
analysis has revealed that, for at least half the genes, this assumption is wrong in 
vertebrate models. To visualize and assay proteins and to test their function, antibodies 
are needed. There have been many attempts to generate Xenopus-specific antibodies 
by traditional methods. These, however, had limited success and the lack of these 
antibodies imposes a severe research bottleneck.  
This project tested different approaches to raising antibodies and compared their 
suitability.  
Libraries of VHH (camelid single chain antibodies) raised against Xenopus protein 
mixtures were acquired from a collaborator and screened for Xenopus-specific VHHs; 
only VHHs against yolk proteins were isolated. To improve on this, antigen generation 
strategies were used both in vitro and in human cell cultures. Two proteins were 
successfully expressed in vitro, but yields were lower than expected. HEK (Human 
Embryonic Kidney) cell expression was also successful. However these DNA-binding 
transcription factors proved challenging to solubilise and purify.  Finally, commercially 
synthetized peptides were used to immunise llamas with a single antigen and their 
plasma was screened for an immune response with positive results. Experiments to test 
whether VHH would have advantages in Xenopus compared with conventional 
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antibodies were carried out with a donated VHH against human β-catenin. To understand 
the differences between raising VHH and conventional antibodies, a sheep was 
immunized with kash5 and the resulting antibody characterized. There are proteins, 
usually closely related members of the same family, which are difficult to tell apart using 
standard antibody detection. For these, a different approach to visualising the 
endogenous protein was undertaken. As proof of principle, the endogenous locus of 
Xenopus Gata2 was tagged with HA using CRISPR cas9 to target the site, followed by 
homologous DNA repair to add the tag. This approach showed low incidence but the 
positive insertion of the HA tag into the C-terminal of Gata2. 
Overall, this work has shown that Xenopus transcription factor proteins can be expressed 
in vitro and in vivo, however, either the quantity obtained or their solubility makes these 
products not suitable to raise antibodies against them. The alternative of using long 
peptides or MAPs (Multiple Antigenic Peptides) became a suitable option. The 
successful tagging of an endogenous protein was shown to also be possible approach. 
This approach showed low effectivity but a few cases of HA tag insertion at the C-terminal 
of Gata2 were nevertheless observed. 
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Statement of Aims 
The primary objective of this work is to find ways to detect and visualise proteins in the 
Xenopus embryo. More precisely, to develop an efficient way of raising Xenopus-specific 
antibodies and to tag endogenous genes.  
The project can be subdivided into these different parts: 
a. Development of VHHs (single chain camelid antibodies)  
1. Analysis of previously generated VHH libraries (library screening) 
2. Generation of Immunogens (protein expression) 
3. Generation of VHH library (llama immunisation) 
4. Use of β-catenin VHH as proof of principle 
5. Test whether VHHs can act as neutralising antibodies for protein 
knockouts in embryos 
b. Tagging the endogenous gene (gata2) 
1. Use of CRISPR-Cas9 technology to insert an HA-tag on the 3’ end 
of gata2 
2. Identification and screen of GA tadpoles 
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1 Introduction 
1.1 General introduction  
The South African clawed frog, Xenopus laevis (Xla), has been used extensively as a 
model system to study development, cell biology and biochemistry; and more recently 
human genetic diseases (Bowes et al., 2008; Harland & Grainger, 2011). Due to the 
ease of egg production and manipulation, together with other advantages, Xenopus has 
served as a contributor to the discovery of genes and gene regulatory systems with 
crucial functions in development. A summary of how Xenopus evolved as a model 
organism is given later in this chapter. 
Researchers traditionally prefer to assess the formation of RNAs as an assay for gene 
activity due to ease, and as a consequence, the production of Xenopus-specific 
antibodies has widely been put aside by the Xenopus community (Xenopus Community 
White Paper 2014). This lack of antibody production was also enhanced by the fact that 
many of the proteins of interest to the Xenopus community are transcription factors, 
which are usually found in complexes, making protein production and purification for 
antibody raising challenging. From 1235 known transcription factors, only 295 out of 796 
antibodies generated passed the ENCODE testing regime (ENCODE Project 
Consortium, 2012). Moreover, companies that make human or mouse antibodies, do not 
see a profitable market for raising antibodies against Xenopus-specific proteins due to 
the relatively small market compared to other systems. The currently available Xenopus-
specific antibodies can be obtained from the EXRC 
(https://xenopusresource.org/about_antibodies), and a full list of antibodies that were 
explicitly developed against or cross-react with Xenopus proteins can be obtained from 
Xenbase (http://www.xenbase.org/reagents/antibody.do).  
In 2017, the National Health Institute (NIH, USA) funded the project “Production and 
characterization of monoclonal antibodies to Xenopus Proteins”, Project # 
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1R24OD021485-01A1 (University of Massachusetts Amherst, USA), to address the 
issue highlighted for a decade as the main reason why Xenopus is not as advanced as 
other model organisms in some aspects of research (according to the Xenopus 
community White Paper, USA, 2012).  
This project focuses on testing different ways of visualising proteins in Xenopus. The use 
of conventional antibodies, VHHs and epitope tagging of the endogenous loci are 
explored with the aim of understanding the strengths and weaknesses of these 
approaches.  
The aim is to explore two pathways to obtain antibodies against Xenopus proteins. One 
method follows the conventional approach of synthesising the antigen as a peptide and 
injecting it into a (in this case) sheep; while the other explores the expression of antigens 
in HEK cells and immunising a Llama glama, which produces single-chain antibodies as 
well as conventional antibodies. Ideally, for a direct comparison this would be done with 
the same protein. A limitation, however, of this study was the need to provide different 
antibodies to members of the Xenopus research community as part of the EXRC’s work. 
This precluded the use of the same protein in the different approaches. 
Conventional antibodies are usually produced in chickens, rabbits, goats, sheep or rats. 
In this project, a sheep was immunised to assess the feasibility of producing antibodies 
in this manner. A member of the community designed the antigen used for immunisation 
as this project was funded by the BBSRC to generate reagents for the community, 
therefore complying with the grant’s service element.  
In 1989, a novel type of antibody was identified, first in the sera of dromedaries and later 
on in various members of the Camelidae family (Hamers-Casterman et al., 1993; 
Rocchetti, Hawes, & Kriechbaumer, 2014). These novel antibodies, known as 
nanobodies or VHHs, are very small in size (15-18 kDa) and contain the full coding 
sequence in a single exon (Muyldermans, 2001). They are easily produced in 
microorganisms and are highly soluble and robust. Their single-domain nature and strict 
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monomeric behaviour support easy cloning and fast selection from libraries.  Moreover, 
because VHHs prefer to associate with concave-shaped epitopes (e.g., catalytic sites of 
enzymes), they can recognise places that are inaccessible or cryptic for conventional 
antibodies (De Meyer, Muyldermans, & Depicker, 2014). 
The advantages of using VHHs over conventional antibodies, together with the discovery 
of the protein versus mRNA expression level discrepancies in Xenopus embryos 
(Peshkin et al., 2015; Wühr et al., 2014), has made the generation of Xenopus-specific 
VHHs and their assessment one of the priorities for the scientific community using this 
powerful model organism.  
There are, however, proteins that even the most specific antibodies made to date could 
not identify. These are for example proteins of the same family which are very similar in 
sequence but have distinct developmental functions. In the past, an antibody raised 
against one would react against the other providing conflicted results, therefore, 
discriminating between these closely related proteins is essential.  
 Also for newly discovered proteins and proteins of low immunogenicity (Brizzard, 2008), 
where the protein cannot be purified or the purified protein fails to raise an immune 
response, antibodies are difficult to raise. A way of tagging the endogenous gene would 
allow the specific visualisation and study of such proteins.  
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1.2 Xenopus as a model organism 
To understand why visualising frog proteins is essential, it is first necessary to see how 
this model organism works and what it can do.  
Biomedical studies rely significantly on experimental research to elucidate the mysteries 
of human biology. For ethical reasons, experimental studies are very limited and 
extremely controlled in humans. One of the alternatives is to use animals as platforms to 
study the biological and biophysical aspects of life.  Here we focus on the use of animals 
in the fields of embryology and developmental biology, and how Xenopus became the 
most used amphibian model. 
Xenopus was first described in the early 1800s as Bufo laevis, by a French naturalist 
(Daudin, 1802), and received its current name in 1827 (Gurdon & Hopwood, 2000). The 
Zoological Society of London reported the first spawning of Xenopus laevis outside Africa 
in 1894. However, it was not until 1906 that the developmental stages of the Xenopus 
embryo were published, together with protocols of husbandry for raising Xenopus as a 
laboratory animal (Bles, 1906). By the 1920s, Xenopus was preferred over local 
amphibian species at schools and universities because of the number of offspring that 
were produced from a single animal. However, it was not until 1930 that induced 
ovulation of Xenopus was mentioned in a scientific paper (Gurdon & Hopwood, 2000; 
Hogben & Winton, 1930). 
A historically relevant fact was that in the early 1900s, pregnancy testing was invented, 
with the first Pregnancy Diagnostics Station opening in 1929 producing 6000 tests per 
year  (Crew, 1936).  This test was done in mice, injecting them five times a day for three 
days with women’s morning urine, then killing them and analysing the ovaries to see if 
they were enlarged; this would mean positive for pregnancy. In 1939, it was reported by 
the Edinburgh laboratories that the same test could be achieved in Xenopus with only 
one injection and results obtained 8-12 hours later (Cabrera, 1969). Tens of thousands 
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of tests were performed in the next two decades by this laboratory and others, and 
Xenopus were acquired all over Europe and America for such tests (Gurdon & Hopwood, 
2000). By the 1960s, alternative methods of pregnancy testing, which didn’t require live 
animals, were emerging thus replacing the Xenopus pregnancy test.  
By this time, researchers worldwide had access to established Xenopus colonies, and 
two advantages over other species were becoming prominent: the ease of induced 
ovulation which simplified microsurgery timing and biochemical studies for which 
abundant material was needed. The development of embryonic fate maps (Dale & Slack, 
1987); the elucidation of the Xenopus genome (Session et al., 2016); the development 
of an online database for all information related to Xenopus (Karpinka et al., 2015); the 
increasing use of Xenopus as a disease model (Tandon, Conlon, Furlow, & Horb, 2017); 
the award of two Nobel prizes for cell cycle, control (Hunt, 2001) and nuclear 
reprogramming (Gurdon, 2012); and the high number of published papers using 
Xenopus as a model organism are all signs of the importance and impact that research 
carried out in this model has had, and will have in society.  
Mesoderm induction, dorsalization and neural induction studies (Slack, Dale, & Smith, 
1984; Tarin, 1971, 1972), cell cycle regulation studies (Aimar, Vilain, & Delarue, 1983; 
Allan & Vale, 1991; Gerhart, Wu, & Kirschner, 1984; Moor, 1988; Yamano, Gannon, 
Mahbubani, & Hunt, 2004), the development of the whole-mount In situ hybridization 
technique (Harland, 1991) and the loss of function studies that elucidated the Wnt 
signalling pathway (Heasman, Kofron, & Wylie, 2000; Hoppler, Brown, & Moon, 1996) 
are all very good examples of key findings and methods developed that allowed the 
growth and expansion of Xenopus as a model organism. Furthermore, the development 
of transgenic lines (Kroll & Amaya, 1996; Offield, Hirsch, & Grainger, 2000) re-inforced 
established methods such as loss of gene function by morpholino injections and 
established the study of late development and organogenesis (Beck & Slack, 2001; Nutt, 
Bronchain, Hartley, & Amaya, 2001).  
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The turn of the century marked the accelerated expansion of areas where Xenopus was 
used as a model organism. This growth was stimulated by the establishment of the 
European Xenopus Resource Centre based in the UK, and later the National Xenopus 
Resource, based in USA (Pearl, Grainger, Guille, & Horb, 2012), both providing 
resources and intellectual knowledge to researchers using this model. The release of an 
online Xenopus dedicated database namely Xenbase (Bowes et al., 2009) and the 
creation of the Xenopus laevis isogenic line (J-line) which allowed the mapping and 
publication of the Xenopus laevis genome (Harland & Gilchrist, 2017; Session et al., 
2016) were of invaluable importance.  
The emergence of Xenopus tropicalis of as a parallel model with a diploid genome and 
a shorter generation time (Hirsch, Zimmerman, & Grainger, 2002; Klein et al., 2002), also 
re-enforced the use of Xenopus laevis as a model organism, since now researchers 
could do genetic studies on a close relative of Xenopus laevis. Moreover, the techniques 
and tools used in Xenopus laevis were mostly transferable to Xenopus tropicalis (Khokha 
et al., 2002). In the early 2000s numerous high-quality papers demonstrating the usability 
of Xenopus as a genetic model organism were published (Abu-Daya, Khokha, & 
Zimmerman, 2012; Goda et al., 2006; Khokha et al., 2009). Another considerable 
advantage of the early Xenopus embryo is that single cells can be isolated and analysed 
on a proteomic, transcriptomic and metabolomics level (Briggs et al., 2018; Onjiko, 
Moody, & Nemes, 2015; Sun et al., 2016). These resources allowed Xenopus to re-
emerge in this new genetic era and potentially open new paths to the understanding of 
development on a single cell level.  
The decline in publications using Xenopus since the 1980s can probably be attributed in 
part to the lack of Xenopus specific reagents (Figure 1. 1).  
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Figure 1. 1. Amphibian publications per 5 years periods, comparing Xenopus with other 
amphibians used for developmental studies, based on PubMed search (April 2018). 
Research using Xenopus as an experimental model had its peak time in the late 1990s, according 
to publications per year. The drop in publications since could be attributed to a variety of factors, 
such as the lag in generating Xenopus specific reagents and the difficulties that this model 
encounter being allo-tetraploid when the genetic era began. However, the release of the Xenopus 
genome in 2010 (Hellsten et al., 2010), favoured this model. The continuous decline in 
publications in the last 15 years is considerable. However, Xenopus is still the most used 
amphibian model for research (according to PubMed search). 
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1.3 Embryonic development of Xenopus 
The life cycle of Xenopus laevis has been intensely studied and described, from the life 
cycle (Grobman, 1958) to the fate mapping of an individual cell (Dale & Slack, 1987; 
Gurdon, 1995) and the availability of gene expression patterns and quantitative mRNA 
measurements on Xenbase (Bowes et al., 2008). In summary, oocytes are produced and 
matured inside the female, laid and then fertilised with sperm. In the laboratory, this can 
be done in vitro or by natural mating.  The fertilised egg starts dividing about 2 hour’s 
post-fertilisation, reaching gastrulation after 14 hours if the temperature is kept constant 
at 18ºC. By 30 hours, organs start to develop and 70 days later metamorphosis from a 
tadpole to froglet starts. It is recorded that Xenopus laevis can reach adulthood six 
months after metamorphosis (A. Jafkins and G. Nicholson, personal communications) 
(Figure 1.2 A). 
When the sperm fertilises the egg by entering the animal hemisphere (Figure 1.2 B), the 
female genetic material mixes with that of the male usually in equal quantities. However, 
the remainder of the molecular content of the embryo is inherited from the mother. The 
oocyte matures inside the female and when it is laid it contains all the essential proteins 
and material needed for the fertilised egg to develop until around stage 8 when most 
zygotic transcription in the embryo starts (Newport & Kirschner, 1982). Development of 
the fertilised egg occurs very rapidly in the first few hours with the first division occurring 
90-120 minutes post fertilisation; then there is a synchronised cell division every 25-30 
minutes for 7 hours until the mid-blastula stage embryo of around 5000 cells, when the 
embryo starts to divide asynchronously. This point is also marked by the onset of cell 
motility and zygotic transcription. After these 12 divisions, when the embryonic genome 
is activated and at the blastula stage, three distinct germ layers can be identified, 
ectoderm, mesoderm and endoderm. By 10 hours, the embryo is composed of 10 000 
cells and undergoes gastrulation. During gastrulation, the germ layers rearrange to form 
the outer layer or ectoderm, the middle layer or mesoderm and the inner layer, or 
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endoderm. At the neurula stage (14 hours), the neural plate becomes visible in the dorsal 
ectoderm, this will form the central nervous system (CNS). By the tailbud stage (24–42 
hours), a larva with a neural tube located between the epidermis and the notochord has 
formed, and organogenesis starts with the differentiation of cells into specific types. A 
free-swimming tadpole is formed in 4 days (Dale & Slack, 1987; De Robertis, Larraín, 
Oelgeschläger, & Wessely, 2000; C. M. Jones & Smith, 2008; Méreau, Sommer, 
Lerivray, Lesimple, & Hardy, 2007; Saka, Tada, & Smith, 2000).  
Developmental biologists historically used assays for RNA, not only to study gene activity 
in the early embryo, but also to infer the presence of a protein when studying its function. 
In 2014 and later in 2016, questions arose about the value of making such an assumption 
when it was published that the mRNA levels in the early Xenopus embryo did not 
correlate to the actual protein levels present at the same stage (Peshkin et al., 2015; 
Wühr et al., 2014). For example, some maternal proteins stayed in the embryo longer 
than expected and some RNAs were not translated until much later in development. 
These revolutionary papers are discussed below and highlight the importance of being 
able to identify, visualise, follow and isolate proteins at these early stages if one is to 
understand development and cell behaviour accurately.  
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1.4 Xenopus transcriptome, proteome and metabolome 
The first published Serial Analysis of Gene Expression (SAGE) dates to 1995 when 
Velculescu and colleagues described how by isolating a transcribed tag, cloning it into a 
vector and counting the tags by sequencing, it was possible to obtain a representation 
of nearly every transcript in that population of cells, a transcriptome (Velculescu, Zhang, 
Vogelstein, & Kinzler, 1995).  It was not until 1997 that the same author published the 
first whole organism transcriptome, the Yeast transcriptome (Velculescu et al., 1997). 
One of the first published transcriptome studies in Xenopus was related to the amphibian 
skin secretions and a non-invasive methodology of sampling individuals for such studies 
(Chen et al., 2003); and in 2006, endoderm formation studies via transcriptomic analysis 
were performed which demonstrated the complexity of the process. This postulated that 
new studies were needed to understand the complete endoderm gene regulatory 
network (Sinner, 2006). Xenopus transcriptomic studies, comparing Xenopus laevis and 
Xenopus tropicalis transcriptomes, also helped elucidate the link between gene 
expression and morphological evolution, accentuating that the critical differences 
between species are in the earliest embryonic stages (Yanai, Peshkin, Jorgensen, & 
Kirschner, 2011).  
However, it was not until much later that more relevant transcriptomic data for 
developmental biology emerged. Although, microarrays began to give transcriptomic 
information in Xenopus from the start of the century (Altmann et al., 2001) it was not until 
RNA-Seq allowed a much deeper analysis of the transcriptome that major advances 
were made. In 2016, a study of transcriptome kinetics in Xenopus development (Owens 
et al., 2016) elucidated the rapid changes in gene expression during embryonic 
development which dictate cell fate decisions by ultra-high frequency sampling of 
Xenopus embryos. Transcriptome analysis became very useful in the study of 
developmental pathways, and the in-depth studies of the effects that disrupting such 
pathways have on the embryo. An excellent example of this is the Sperman organiser 
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transcriptome studies performed by Ding et al. (Ding, Ploper, et al., 2017) in which they 
measured the effects that β-catenin, Wnt, Nodal, and Siamois alterations have on the 
early Xenopus embryo transcriptome. 46 RNA-Seq libraries were created and analysed, 
each from embryos treated with β-catenin depletion, regenerating dorsal and ventral half-
embryos, and the overexpression of Wnt8, Siamois, and Cerberus mRNAs among 
others. These studies confirmed how the effects of β-catenin/ Wnt signalling in early 
development are regulated by stage-dependent mechanisms and how the dorsal and 
ventral regions of the embryo communicate with each other. 
Such genome-wide studies were encouraged by the release of the complete Xenopus 
laevis genome (version 9.1) by the Joint Genome Institute (JGI) in 2017. The ease by 
which Xenopus embryos can be manipulated and the availability of the new genome 
provided the grounds to make transcriptome studies on dorsal and ventral parts of the 
early embryo (Figure 1. 3 A) where novel genes were discovered and identified to be 
expressed in a specific section of the embryo (Ding, Colozza, et al., 2017). Also in 2017, 
a transcriptomic insight into genetic diversity of protein-coding genes in Xenopus laevis 
was published by Savova et al (Savova; et al., 2017), in which they crossed the isogenic 
J-strain (Harland & Gilchrist, 2017) with outbred albinos and looked at the coding 
variation between the offspring. This helped elucidate some of the selection pressures 
affecting duplicated genes in Xenopus laevis. Their findings also contributed to improving 
the genomic sequence, generating better sequence alignment, probe design, and 
proteomic analysis.  
In summary, these analyses of genome-wide gene expression and mRNA levels have 
helped to generate a more integrated view of the relationship between the genome, gene 
expression and phenotypes. However, information about post-transcriptional control of 
gene expression, changes in protein expression levels, changes in protein synthesis and 
degradation rates or protein post-translational modifications cannot be achieved with 
these techniques  (Lee, 2001). 
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Figure 1. 3. RNA levels assayed in the early embryo. 
pri-mir427 expression over the first 12 hours post-fertilisation (hpf) in rdRNA data and in situ 
hybridisations. Staining of the embryo correlates with RNA-seq temporal data, showing examples 
of most abundant transcripts for comparison (A) (Owens et al., 2016). Dorsal and ventral 
dissections scheme, and the experimental flowchart. Wild-type stage 10.5 Xenopus embryo (B-
top), and the dissection of the dorsal and ventral lip (B-bottom). Outline of the RNA-seq analysis 
pipeline used to analyse gene expression on the dissected embryos (Ding, Colozza, et al., 2017).  
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Xenopus developmental stages from 2-cell stage embryo through to tailbud stage 33 and eight 
developmentally active genes were taken to illustrate the difference in expression between 
Xenopus laevis and Xenopus tropicalis transcription activity. These two very related species have 
distinct genetic activity in the early stages of development, tending to normalise as development 
progress (A) (Yanai et al., 2011). Advances in technology over the years made possible the 
molecular analysis of biological systems at multiple levels (DNA, mRNA, protein and activity and 
function), that in turn made it possible to start to understand the relationship between genotype 
and any particular phenotype in living organisms (B) (modiffied from Lee, 2001). 
Figure 1. 4. Xenopus laevis and Xenopus tropicalis gene expression comparison through 
the early stages; levels on which developmental biology can be studied. 
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Historically, transcriptomics and single mRNA studies provided a dataset that 
established the mRNA abundance, and so it was thought in the vast majority of cases, 
the protein level in a given environment. To add an extra level of understanding to the 
developmental processes, in 2001 Kelvin Lee proposed a method by which to look at the 
complete protein complement of the genome. Protein studies were enlightening but 
highly limited by the slow technological advance (Lee, 2001).  
By 2014, technology had developed and revolutionised the way scientists had to think. 
Development of quantitative proteomics in early stage Xenopus laevis embryos (Sun et 
al., 2014) and the release of a revolutionary article, which provided evidence of major 
discrepancies between the mRNA levels and protein levels would be the beginning. The 
expression of many stored maternal transcripts is activated by cytoplasmic 
polyadenylation that allows for translation at specific embryonic stages (reviewed in 
(Richter, 1999); but the extent to which translational regulation dominates the control of 
protein levels in the early vertebrate embryo remained unappreciated until proteomic 
analysis became possible. The lack of correlation between message and protein levels 
can obscure essential details of development (Sun, Champion, Huber, & Dovichi, 2015). 
Figure 1. 5 A provides a graphic representation of the relative mRNA and protein levels 
in the Xenopus egg.  
Some proteins co-exist together with their respective mRNAs (dark blue). However, 
some mRNAs have no proteins expressed at the studied time (orange), and some 
proteins have no mRNA present (light blue). These findings had a prominent effect on 
the scientific Xenopus community, as most developmental studies carried out in this 
model organism used mRNA as a proxy for protein. In the same year, thanks to the 
advances in mass-spectrometry, single-cell proteomics in fertilised Xenopus eggs 
became possible which provided a deeper understanding of cell lineages and 
heterogeneity during development. These and other published studies reinforced the 
earlier discrepancy findings (Figure 1. 5 B (Lombard-Banek, Moody, & Nemes, 2016; 
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Peshkin et al., 2015; Smits et al., 2014; Sun et al., 2016)). Figure 1. 5 A and Figure 1. 5 
B illustrate the differences between mRNA and protein levels in some stages of 
development. More so, hundreds of mRNAs guiding critical tissue-specific functions are 
mainly regulated at the translation but not transcript level (Fujii, Shi, Zhulyn, Denans, & 
Barna, 2017; Werner et al., 2015). Fujii and colleagues also highlighted the importance 
of translational regulation and its vital role in development. Post-translational 
modification, such as phosphorylation, also play a significant part in regulating the 
proteome (Peuchen et al., 2017). 
The dominance of translational regulation in the early embryo is not limited to frogs. As 
technology improves and it became possible to analyse smaller embryos, the same 
phenomenon has been reported in mice (Gao et al., 2017).  
There are 42,878 known Xenopus laevis proteins, according to UniProt (Bateman et al., 
2017; Sun et al., 2014); and the mRNA levels (transcription and degradation rates), 
protein levels (zygotic vs maternal (Figure 1. 6); translation and degradation rates) and 
protein post-translational modifications, all determine development. Therefore, to study 
gene activity and development, all of these aspects have to be considered. Only in this 
way can a complete picture of the actual state of the function that a gene has in that 
particular cell type, at a specific moment in time be determined.   
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Figure 1. 5. mRNA and protein levels in the Xenopus laevis egg. 
mRNA levels that have no correlated protein are represented in orange; these are mainly 
transcription factors and zinc finger proteins (A). Shown in blue are mRNAs that have been 
matched with a corresponding protein, and in light blue on Figure B, proteins that have no mRNA 
present. These few proteins are maternal and correspond mainly to blood plasma proteins (Wühr 
et al., 2014). (B) Xenopus laevis fertilised egg single cell proteome vs transcriptome analysis. 
Protein (measured in fentomoles) and mRNA (measured in reads per kilobase of transcript per 
Million mapped reads) levels correlate for some genes, however they are considerably different 
for others (Smits et al., 2014).  
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Figure 1. 6. Protein amounts in pmol per developmental stage and time in hours post 
fertilisation. 
Maternally acquired proteins stored in the oocyte are more abundant than previously believed. 
Transcription of developmentally essential proteins is a slow process, and even at stage 33, only 
half of the total proteins in the embryo are generated by zygotic transcription  (Peshkin et al., 
2015). 
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1.5 Antibodies and Research 
Antibodies have been successfully raised against some Xenopus proteins, often by 
immunising rabbits to generate polyclonal antibodies. These were mainly generated in 
research laboratories as tools to investigate specific, mostly biochemical and 
developmental questions (J. Maller, E. Jones and T. Hunt antibody collections). One of 
the largest collections known to the general research community was generated in a cell 
biology laboratory by Dr James Maller (University of Colorado, USA). These antibodies 
allowed the elucidation of key pathways in the Xenopus oocyte and egg extract systems, 
as they target mainly cell cycle components focusing on protein kinases that regulate 
mitosis (J. Gautier et al., 1990; J. Gautier, Norbury, Lohka, Nurse, & Maller, 1988; X. J. 
Liu, 2006; James L. Maller, 2012; Qian, Erikson, Taieb, & Maller, 2001; Wang, Fisher, 
Wahl, & Peng, 2011). Tim Hunt (Francis Crick Institute), who worked on cell cycle 
regulation also generated a variety of antibodies against key proteins (Kobayashi et al., 
1991; Minshull, Golsteyn, Hill, & Hunt, 1990; Strausfeld et al., 1994). 
Another collection was developed by Prof. E. A. Jones (University of Warwick UK) 
against key organ markers for the kidney and heart, and some to the nervous system 
and muscle proteins (Balakrishna et al., 2011; E. A. Jones, 2003; Lyons et al., 2009; 
Miller et al., 2011; Naylor, Collins, Philpott, & Jones, 2009; Simrick, Massé, & Jones, 
2005; Vize, Jones, & Pfister, 1995). These were produced by injecting tissue extracts 
into mice, followed by isolating and characterizing monoclonal antibodies. Of the three 
major Xenopus collections, these are the only unlimited resource. 
These antibodies were characterised by the laboratory of origin and are generally of very 
limited availability to the broader research community. The only exception being the 
monoclonal collection from the Jones lab. Outside these collections, laboratories 
occasionally make one or two antibodies against Xenopus proteins they are studying. 
Some examples of these polyclonal antibodies raised in rabbits are against Xcdc6 
(Coleman, Carpenter, & Dunphy, 1996), Uhrf1 and Dnmt1 (E. M. Taylor, Bonsu, Price, 
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& Lindsay, 2013), αxSvv1, αxSvv2, αxEIAP and αxXIAP (Tsuchiya, Murai, & Yamashita, 
2005); in sheep Ilf3 (Whitley et al., 2014); or in goats  xVelo1 (Nijjar & Woodland, 2013). 
Some of these antibodies have been deposited at the EXRC and so become available 
to the community (https://xenopusresource.org/).  
Antibodies that work in Xenopus, such as those described above, will be critical for 
understanding protein function and control in the early embryo.  
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1.6 Heavy chain-only antibodies (HCAbs, camelid 
single-domain antibody, VHH, Nanobodies) 
Immunoglobulin G (IgG) is one of the most abundant proteins in vertebrate serum, 
accounting for about 10–20 % of plasma protein. It is the major class of the five classes 
of immunoglobulins in human beings, IgM, IgD, IgG, IgA, and IgE (Schroeder, Cavacini, 
& Cavacini, 2010). The soluble IgG glycoprotein is produced in vertebrates by B 
lymphocytes as part of the immune system, these cells recognise and affinity mature in 
vivo to target the immunogen (Schroeder et al., 2010). The IgG are usually composed of 
two identical heavy chains and two identical light chains (Press, Givol, Piggot, Porter, & 
Wilkinson, 1966). In the early 1990s, a new type of antibody was discovered composed 
only of heavy chains (Hamers-Casterman et al., 1993) (Figure 1.7). These single-chain 
antibodies are commonly referred to as nanobodies, VHH or Nbs. They have the 
particular characteristic that all their coding region is in one single exon. These 
fragments, once isolated from the conventional variable regions, can be cloned and 
manipulated with traditional genetic engineering methods (Harmsen et al., 2000). Their 
vast range of applications, outstanding stability and ease of manipulation shows in the 
numerous reviews recently published about them (Beghein & Gettemans, 2017; Hu, Liu, 
& Muyldermans, 2017; Leow et al., 2017; W. Liu et al., 2018).  Therefore, use of VHHs 
may expand the range of techniques offered by conventional antibodies against Xenopus 
proteins.  
For example, when antibodies to full-length proteins were coupled with organic dyes and 
used as primary antibodies, the distance between the dye and the protein usually 
produced linkage errors, a loss of accurate staining at the molecular level (De Meyer et 
al., 2014). VHHs instead, preserve their stability and fold into functional antigen-binding 
entities when fused to a fluorescent protein such as GFP (chromobodies) that are too 
small to produce linkage errors. It has been shown that after expression and binding their 
specific antigen, these molecules serve as tracers for in vivo intracellular target 
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localisation studies (Figure 1.8), avoiding the need for genetic modification of target 
proteins with fluorescent tags (Herce, Deng, Helma, Leonhardt, & Cardoso, 2013). In 
2006, Rothbauer and colleagues showed real-time detection of dynamic changes in 
chromatin, nuclear lamina and the cytoskeleton in animal cells by using VHHs 
(Rothbauer et al., 2006). 
In another context, Rocchetti and colleagues found that they could inhibit or alter the 
function of molecules in plants and animals using nanobody technology (Rocchetti et al., 
2014). Historically, depleting a protein in order to study its function in a living organism 
was usually achieved at the gene level (genetic mutations) or at the RNA level (RNA 
interference and morpholinos) (Caussinus, Kanca, & Affolter, 2013). Another good 
example is that of the potato, where it was shown that the correct organelle could be 
targeted by a nanobody that would inhibit the function of the potato starch branching 
enzyme more efficiently than an antisense construct (Jobling et al., 2003). In 2014, a 
VHH that disrupts fascin F-actin bundling was published (Van Audenhove et al., 2014), 
quickly followed by other VHHs from the same laboratory that acted blocking different 
parts of the same pathway (CORNb2 and  SH3) (Bertier et al., 2017; Van Audenhove, 
Debeuf, Boucherie, & Gettemans, 2015).  
The ability of VHHs to interfere with protein conformation, localization or function, 
together with their size, specificity and stability have made VHHs become significant 
candidates as therapeutic and diagnostic molecules in medicine, moreover, some have 
already made it to clinical trials (De Meyer et al., 2014; Deckers et al., 2009; Klooster et 
al., 2007).  
Conventional antibodies are used in chromatin immunoprecipitation (ChiP), where a 
protein of interest is pulled out of a chromatin preparation to determine the DNA binding 
sequence associated with it (Hebbes, Clayton, Thorne, & Crane-Robinson, 1994; 
Tsanev, 1983). This method is a very powerful tool allowing the study of gene 
expression, cell differentiation, or disease by looking at the interactions of nuclear 
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proteins with DNA (Furey, 2012).   ChiP has been successfully used to map the 
localization of post-translationally modified histones, histone variants, transcription 
factors, or chromatin modifying enzymes (Park, 2009). However practical limitations of 
mainly requiring large numbers of cells and a lack of antibody development, have 
highlighted the need for improvement of this method, in turn allowing a more complete 
picture of biological processes in the cell, especially transcriptional regulation (Furey, 
2012).    
Technological advances allowed chromatin immunoprecipitation techniques to be 
coupled with DNA microarray hybridisation (ChIP-chip) and high-throughput sequencing 
(ChIP-Seq) for genome-wide identification of DNA–protein interactions (Buck & Lieb, 
2004; Robertson et al., 2007). In 2013, VHHs were proved a novel class of affinity 
reagents for ChIP-chip and ChiP-Seq (Nguyen-Duc, Peeters, Muyldermans, Charlier, & 
Hassanzadeh-Ghassabeh, 2013), as well as for ChiP with DNA microarrays (ChIP-on-
chip), leading to the discovery of novel transcription factor binding sites (Nguyen-Duc et 
al., 2013).  
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Figure 1. 7. Conventional antibodies, Fab fragments and VHH structures. 
Size comparison between conventional antibody, composed of 2 light chains and two heavy 
chains (150 kDa), the heavy chain only antibody (90 kDa), fab fragment (50 kDa) and VHH (15 
kDa) (Mujić-Delić, De Wit, Verkaar, & Smit, 2014) (A). Gelsolin-VHH crystal structure, composed 
of three complementarity-determining regions (CDR1 in yellow, CDR2 in magenta and CDR3 in 
red), alternated with four framework regions (FRs, in green) (Beghein & Gettemans, 2017) (B).  
B 
A 
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Figure 1. 8. VHH used to visualize mouse brain structures in vivo and ex vivo. 
Two-photon microscopy was used to visualize the injected VHH R3VQ-S-AF488 in a one-year-
old PS2APP mouse. The mouse brain structures indicated by yellow arrowheads correspond to 
vascular Aβ and white arrowheads parenchymal Aβ deposits, at 1 minute and 30 minutes post 
injection compared to T0 (A). The strongest signal was obtained 4 hours post injection (B), just 
before sacrifice. Immunodetection of the injected VHH on ex vivo brain section stained amyloid 
plaques by extrinsic R3VQ throughout the brain (C). In this study, two alpacas were immunized, 
one with AD phospho-tau (pTau) enriched brain extracts and the other with a mono-
phosphorylated peptide derived from the C-terminus of the tau protein (pS422 peptide) coupled 
to the KLH protein. These two libraries were combined and screened as one, were a single clone 
was found to recognise the tau protein (Herce et al., 2013).  
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1.7 Importance and contribution of the proposed 
research 
A comparison between the proteomes and transcriptomes of vertebrate embryos has 
shown that monitoring proteins rather than mRNA will make a critical combination 
towards understanding cellular and developmental processes. For researchers to 
identify and understand the genetic regulatory networks that control life, proteins’ levels, 
and their interaction with one another, RNA and DNA levels must all be determined. The 
importance of having good antibodies against proteins in the most successful model 
organism in which to study early development, Xenopus, is therefore clear. 
The development of tools which allow the detection, isolation and visualisation of proteins 
in the early Xenopus embryo would have a cascade effect on the use of Xenopus as a 
model system. With Xenopus specific antibodies the number and quality of studies 
performed on this system would flourish. For example, the ability to use VHHs fused to 
fluorescent proteins would allow researchers to follow proteins in vivo in the early 
embryo. The possibility of endogenously tagging proteins is another method that could 
be used to differentiate between closely related proteins. Likewise, the development of 
these new techniques in Xenopus will encourage new routes of research, for example 
as important controls for protein knockouts. 
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1.8 Target proteins for antigen production and antibody 
generation 
The nature of this project, the invaluable link between the EXRC and the wider 
community, had a key input on the targets chosen to work on. A list was generated with 
the “most wanted” antibodies from the community: ankrd6, armc8, ascl1, atoh1, 
B56alpha, β-catenin, bicc1, ccdc55 (kash5), ccdc78, ccna1 (cyclin A1), ccne1 (cyclin 
E1), cdk1 (cdc2), cdk2, cdknx (XicI), cetn1, ctnnb1, dazl, delta1, dlgap5, dvl1, dvl2, dvl3, 
etv2, eya1, fli1, fus , gata2, gli1, hairy1, mark2, mark3, mkln1, myt1, ncor2  (smrt), nde1, 
ndel1, neurod1 , ngn2 (neurog2), ngn3  (neurog3), nudc, pafah1b1 (liz1), pi4k2a, pi4k2b, 
pkl1, pkl2, pkl3, ppp2r5a, prickle3, rarα2, ror2, rusc2, six1, ska1, ska2, snai2, tal1, tbp2, 
tbx18, tcf21, tra2b, ube2i, vangl2, wnt4b, wt1. 
The current knowledge about each gene, its product and function was assessed for 
ascl1, ctnnb1 (β-catenin), ccdc55 (kash5), cdk1 (cdc2), cdk2, cdknx (XicI), delta1, fli1, 
gata2, hairy1, myt1, ncor2 (smrt), ndel1, neurod1, ngn2 (neurog2), pafah1b1 (liz1) and 
rarα2. An example of this for gata2 is shown below. This is limited to a single gene due 
to space considerations. A brief description of the relevant gene/protein/target region is 
given at be beginning of each chapter. 
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1.8.1 Gata2 - GATA binding protein 2 
Gata2 encodes a member of the GATA family of zinc-finger transcription factors that 
have two highly conserved zinc finger motifs and recognise a six-nucleotide motif 
T/AGATAG/A in the promotor of target genes (Bresnick, Lee, Fujiwara, Johnson, & 
Keles, 2010; Rodrigues, Tipping, Wang, & Enver, 2012). The encoded protein plays an 
essential role in stem cell maintenance with key roles in blood cell biosynthesis and 
proliferation, as well as the endocrine cell lineages (Hsu et al., 2011; Ostergaard et al., 
2011). 
In Xenopus, gata2 expression is particularly strong in early development as zygotic 
expression starts at MBT and rapidly decreases from stage 20 onwards (Walmsley et 
al., 1994; Zon et al., 1991). RNA is localised to ventral blood islands, non-neural 
ectoderm, epidermis, hemangioblasts and foregut primordium (Watanabe et al., 2017).  
The gata2 gene has been studied in Xenopus as one of the major transcription factors 
active during gastrulation and early development (Figure 1. 9). Its association with stem 
cell maintenance, hematopoietic development and proliferation have also promoted its 
study in mammals. However, only one polyclonal antibody was known to recognize the 
Xenopus protein and was used in mouse studies before the Xenopus protein expression 
was characterized (Roget Patient, personal communication). The coding region of gata2 
is 1392 base pairs long, the protein 464 AAs. This relatively small size, allowed the 
consideration of cloning and expressing the full-length protein, but primers were 
designed to express the N- or C- terminus of the protein avoiding the zinc finger domain 
conserved between the six family members. Protein folding predictions with Phyre2 and 
Psipred suggest this protein does not have a complex folding structure (Figure 1. 9 D). 
Thus all the sequence could be considered as an antigen.  
To test whether the antibody generated against this protein would not bind, or is not likely 
to bind to a non-gata2 protein in the Xenopus embryo, a BLAST of the selected antigen 
sequences against the protein database of Xenbase was carried out (Figure 1. 10). The 
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outcome of this search provided in silico confirmation that an antibody generated using 
the chosen Gata2 sequences would interact only with the Gata2 protein in the Xenopus 
embryo. The limitations of using BLAST to do this check were however revealed when a 
manual CLUSTAL alignment was performed with the whole Xenopus gata family (Figure 
1. 11). The N- terminus of the C- terminal antigen was shown to align to other members 
of this family. The failure of BLAST to detect this sequence identity was due to the 
number of EST clones in the database and demonstrates the need for considered 
bioinformatics approaches to antigen selection.      
 
Gata2 protein sequences 
MEVATDQPRWMAHHAVLNGQHPDSHHPGLAHNYMEPTQLLPPDEVDVFFNHLDSQ
GNPYYANSAHARARVSYSQAHARLTGSQMCRPHLLHSPGLPWLESGKTALSAAHHH
NPWTVSPFGKAPLHPAAAGGSLYPGTGSSACPSSSHSSPHLFGFPPTPPKDVSPDP
GTAASPPSSSRLEDKDSIKYQMSLSEGMKMEGGSPLRSSLAPMGTQCSTHHPIPTYP
SYVPAAHDYSSGLFHPGSLLGGPASSFTPKQRSKSRSCSEGRECVNCGATATPLWR
RDGTGHYLCNACGLYHKMNGQNRPLIKPKRRLSAARRAGTCCANCQTSTTTLWRRN
ANGDPVCNACGLYYKLHNVNRPLTMKKEGIQTRNRKMSNKSKKNKKGSECFEELSR
CMQEKSSPFSAAALASHMAPMGHLAPFSHSGHILQTPTPIHPSSSLSFGHPHHSSMV
TAMG* 
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Figure 1. 10. Xenopus laevis Gata2 protein sequence alignment against the Xenopus laevis 
protein database (Xenbase BLAST). 
The Gata2 protein sequence was tested in silico using BLAST for cross-reactivity with other 
Xenopus proteins, especially the other 5 members of the Gata family. The sequence did not 
recognize any other protein than Gata2, minimizing the chances of cross-reactivity with other 
Xenopus proteins. 
  
  
32 
 
 
  
Gata5      ------------------------------------------------------------ 0 
Gata4      ------------------------------------------------------------ 0 
Gata6      MDLSEDSWSGGTRLSPENSFFPCPIKQSPGTSPPPSPCSHVGSSECLRSEPDRSQQNIST 60 
Gata1      ------------------------------------------------------------ 0 
Gata2      ------------------------------------------------------------ 0 
Gata3      ------------------------------------------------------------ 0 
                                                                        
 
Gata5      ------------------------------------------------------MYPSLA 6 
Gata4      ------------------------------------------------------MYQSIA 6 
Gata6      EGRPSASYHPLGLSHPEDLILFRDLDHINKLVVPNREPRYSSTLPEPPSGD---MYQTLT 117 
Gata1      ----------------MDYTTLTTQDP---------DPNYTESGLASTSEDSQFLYGL-- 33 
Gata2      --MEVATDQPRWMAH---HAVLNGQHPD--SHHPGLAHNYMEPTQLLPPDEVDVFFNHLD 53 
Gata3      --MEVSAEQPRWVSHPHHPALLNGQHTD--SHHQ--VHNYMDPSQYPPPEDMDVLFNID- 53 
                                                                 ::     
 
Gata5      LTANHAQPAYSHDTPNFLHS---TGSPPVYVPTSRMPAMLQS--LPYLQTCDTAHQGHHL 61 
Gata4      MATNHGPPGYEG-AGSFMHSAT-AATSPVYVPTTRVSSMIPS--LPYLQTSGSSQQSSPV 62 
Gata6      ITAAQGPLGYDPSPGTFMHS---AASSPVYVPTSRVGSMLTS--ISYLQGTGASQGTHSV 172 
Gata1      -GGESSPGHYGGAVSSRAVGGF------------RHSPVFQTFPLHWPETSAGI------ 74 
Gata2      SQGN---PYYANSAHARARVSYSQAHARLTGSQMCRPHLLHSPGLPWLESGKTALSAAH- 109 
Gata3      AQGNHVPSYYSNSVRTVPR--Y---PPPHHGSLVCHPSILQS----WT-DGRKSLGGPH- 102 
                    *                            :: :    :              
 
Gata5      ANHPGWAQT---------------------ANESHAFNASSPHT--PSGFSYSHSPPVGN 98 
Gata4      ASHNMWAQA---------------------GAESSAYNPGTSHPPVSPRFTFSSSPPITA 101 
Gata6      N--SHWSQA---------------------TSESSSYSSSSPHP--SSRYHYSPSPPMAN 207 
Gata1      ----PSNLTAYG------RSTGTLSFYPSAASALGP--ITSPPLYSASSFLLGSAPPAER 122 
Gata2      -HHNPWTVSPFGKAPLHPAAAGGSLYPGTGSSACPSSSHSSPHLF-----GFPPTPPKDV 163 
Gata3      -AASAWNL-PFAKPSIHHNSPGGLSVYPSASSASLATGHSSPHLF-----TFPPTPPKDV 155 
                                                   :             :**    
 
Gata5      SSARDGG-------------------YQSPLIMGGSA--R-DQYGNTLVRTGSY------ 130 
Gata4      ASTREVS-------------------YSSPLAISANG--R-EQYSRGL--GATY------ 131 
Gata6      GSTRDTG-------------------YSSSLAVSGRD--QYAPLARPL--NGSY------ 238 
Gata1      EGS---------------------PKFLE-----TLKTERASPLTSDLLPLEP------- 149 
Gata2      SPDPGTAASPPS-SSRLEDKDS--IKYQMSLSE-GMKMEGGSPLRSSLAPMGTQCSTHHP 219 
Gata3      SPDPSISTPGSTSSSRHEEKECVVSKYQVSLGDPGMKLESSH-PRNSMSGIGGVPSAHHP 214 
                                     :                    :             
 
Gata5      PSPY-SYVGADMPPSWATGHFEGSMLHSLQGRQ-PLPGRISSLEFLEEFHGEGRECVNCG 188 
Gata4      SSPYPAYMSPDMGAAWTASPFDSSMLHNLQNRAGPVASRHPNIEFFDDF-SEGRECVNCG 190 
Gata6      GSPYTPYMTPQLTSAWPAGPFDNTMLHSLQSRGAPISVRGAPGDVLDEL-PESRECVNCG 297 
Gata1      ---------------RSPSILQVGYI------GGGGQEF------SLFQSTEDRECVNCG 182 
Gata2      IPTYPSYVPAAH--DYSSGLFHPGSL-----LGGPASSFTPKQRSKSRSCSEGRECVNCG 272 
Gata3      ITTYPDY--------YGAGLFQPGSI-----LDGSPTHFPSKPRPKTRSSTEGRECVNCG 261 
                             . :.   :                         *.******* 
 
Gata5      AMSTPLWRRDGTGHYLCNACGLYHKMNGINRPLIKPQKRLSSSRRAGLCCTNCHTSTTTL 248 
Gata4      AMSTPLWRRDGTGHYLCNACGLYHKMNGINRPLIKPQRRLSASRRVGLCCANCHTTTTTL 250 
Gata6      SVQTPLWRRDGTGHYLCNACGLYSKMNGLSRPLIKPQKRVPSSRRIGLACANCHTTTTTL 357 
Gata1      ATVTPLWRRDMSGHYLCNACGLYHKMNGQNRPLIRPKKRLIVSKRAGTQCSNCHTSTTTL 242 
Gata2      ATATPLWRRDGTGHYLCNACGLYHKMNGQNRPLIKPKRRLSAARRAGTCCANCQTSTTTL 332 
Gata3      ATSTPLWRRDGTGHYLCNACGLYHKMNGQNRPLIKPKRRLSAARRAGTSCANCQTTTTTL 321 
           :  ******* :*********** **** .****:*::*:  ::* *  *:**:*:**** 
 
Gata5      WRRNSEGEPVCNACGLYMKLHGVPRPLAMKKESIQTRKRKPKNIGKGKTSTGSSTSANN- 307 
Gata4      WRRNAEGEPVCNACGLYMKLHGVPRPLAMKKEGIQTRKRKPKNLSKSKTSTGQSGSDSL- 309 
Gata6      WRRNTEGEPVCNACGLYMKLHGVPRPLAMKKEGIQTRKRKPKNLNKSKSSSSNGNSSHHI 417 
Gata1      WRRNASGDPVCNACGLYYKLHNVNRPLTMKKEGIQTRNRKVSSRSKKKKQLDNPFEPPKA 302 
Gata2      WRRNANGDPVCNACGLYYKLHNVNRPLTMKKEGIQTRNRKMSNKSKKNKKGSECFEELSR 392 
Gata3      WRRNANGDPVCNACGLYYKLHNINRPLTMKKEGIQTRNRKMSSKSKKSKKIHDSLEDY-- 379 
           ****:.*:********* ***.: ***:****.****:** .. .* ...  .  .     
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Figure 1. 11. Gata binding protein family sequence alignment. 
Gata2 binding protein sequence aligned to the other 5 members of the Gata family. Upon the 
alignment of the Gata family protein sequences, regions of similarities between the sequences 
were found. These findings questioned the usability of BLAST as an accepted approach to test 
protein similarities in silico. In Figure 1.11, the extended number of EST sequences present in the 
databases, produce a large number of hits that are, in this case, all Gata2; however, the 
sequences that partially align are not shown. Protein sequences used in expression vectors are 
highlighted in 4 distinct ways, yellow, underlined, font colour blue and red.     
  
Gata5      --SP-SS-----VTNTDPTPVLKTEPNITSHYPGQAIVPVSQGQS-----QTDDLVNGSH 354 
Gata4      --TP-STS--STNSTGEEMRPIKIEPGLSPPYGHSS--SISQASSLSTITSHGPSSYPMS 362 
Gata6      TMTP-TST--TSSTNSDD--C--IKNGS-PS-QNTA--PVV-TSSLMSAQQTGSASPDSN 465 
Gata1      GVEEPSPYPFGPLLFHGQMPP----------MGHMI--NPP--H---HFLQSPRISHSAP 345 
Gata2      CMQE-KSSPFSAAALASHMAP----------MGHLA--PFSHSG---HILQTPTPIHPSS 436 
Gata3      ---Q-KSSSFSPAALSRHMSS----------LSHIS--PFSHSS---HMLTTPTPMHPPS 420 
                .                                                       
 
Gata5      ELKYIPEEYTYSPSAL---SQQSVPLRQESWCALALA-- 388 
Gata4      SLKLSPQNHH-----STINSSPQASSKHDSWNNLVLA-- 394 
Gata6      ILKYTGQDGLYSAVSLSSASEVAASVRQDSWCALALA-- 502 
Gata1      AVSYRQAA----------------------SG--VTPP- 359 
Gata2      SLSFGHPH----------------------HSSMVTAMG 453 
Gata3      SLAFGPHH----------------------PSSMVTAMG 437 
            :                                .     
 
pEneo-3C-2Strep-8H s-Gata2-CTer; pEneo-3C-3FLAG-Gata2-CTer; pOPINFS-Gata2- CTer; 
pOPINTTGneo-Gata2; pOPINGM-Gata2- CTer 
pOPINF - Gata2
pOPINE - Gata2 
pOPINE-Gata2-Short; pOPINF-Gata2-Short 
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2 Materials and Methods 
Throughout this thesis a wide variety of methods were used, ranging from traditional 
cloning and protein expression to the use of ground breaking techniques such as 
generating and screening camelid single-chain antibodies and CRISPR technologies. 
Consumables were acquired primarily from Sigma Aldrich, Fisher Scientific and VWR; 
enzymes were from NEB; antibodies from Abcam and Santa Cruz Biotechnology; 
primers and oligonucleotides were from Gene Tools and Thermo Fisher; plasmids were 
from the EXRC and Addgene. 
In 2016, we noted animal welfare issues with Santa Cruz antibodies and stopped using 
them at that point. 
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2.1 Nucleic acid techniques 
2.1.1 Restriction digests 
Restriction digests were carried out according to the manufacturer’s instructions. In 
synthesis, between 1 µg and 4 µg of the plasmid were incubated at the suggested 
temperature for optimal efficiency of the enzyme, together with the enzyme and its 
corresponding buffer. The reaction was typically set up in 20 µl total volume and 
incubated for 2 hours, unless otherwise stated. In a 20 µl reaction, 2 µl of 10x buffer and 
a maximum of 2 µl of enzyme (20 units) was used. 
 
2.1.2 DNA and RNA separation and visualization though agarose gel 
electrophoresis 
Agarose gels of 1-4 % were used to separate and visualize nucleic acids by their size. 
The gels were prepared in TBE and ethidium bromide (10 µg/ml) was included in the gel. 
They were run at 40-120 V until the blue dye was ~2/3 of the way down the gel.   
The samples were mixed with a loading dye before loading into the gel, to aid 
visualisation of the sample with the naked eye. This also contained glycerol, making the 
sample dense and forcing it to fall into the agarose well. The purple (6 X) loading dye 
from NEB was used (catalogue number B7024S).  
After exposure to the current, the gels were visualized with UV light in a Gel-Doc and 
photographed. If the DNA/RNA had to be extracted, the appropriate bands were excised 
from the gel before photographing (as the excessive exposure of the DNA/RNA to UV 
light degrades DNA) and gel extracted using either the Qiaquick gel extraction kit or the 
Gene Clean method, according to manufacturer’s instructions. 
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2.1.3 Ligation by T4 DNA ligase 
Thermo Fisher Scientific T4 DNA ligase (EL0011) was used to ligate sequences of 
interest with pre-digested vectors, following the manufacturer’s instructions.  
The ligation reactions typically contained a 3:1 insert to vector ratio in molar quantities, 
and was incubated overnight at 16ºC. If the ligation was unsuccessful, then the molar 
ratios and the incubation temperatures were optimized.   
 
Table 2. 1. T4 DNA ligase reaction components. 
T4 DNA ligase 
buffer (10 x) 
Vector DNA    
(4 kb)  
Insert DNA     
(1 kb)  
Nuclease free 
water 
T4 DNA ligase 
3 µl 
50 ng  
(0.020 pmol) 
37.5 ng  
(0.060 pmol) 
To 30 µl 2 µl 
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2.1.4 pGEM®-T Easy Vector Systems (Promega A1360) 
Historically, primers were designed with extra bases outside the restriction site, and 
amplicons digested before annealing to the pre-digested destination vector. The rate of 
insertion via this method was unreliable. The pGemTeasy TA cloning vector allows the 
direct cloning of PCR products into a vector efficiently. The amplification of the target 
sequence with a Taq polymerase results in amplicons containing an A overhang at the 
3’ end of the molecule, facilitating the base pairing with the T overhangs on the TA 
cloning kit vectors. These overhangs base-pair non-directionally with the aid of T4 DNA 
ligase. For these reactions, between 100 ng and 500 ng of fresh PCR product was mixed 
with 50 ng of pGemTeasy vector and the corresponding buffer, incubated at room 
temperature for 1 hour or at 4ºC overnight, before transforming into E. coli DH5α 
competent cells. Once the pGemTeasy sub-clone was prepared, the required insert was 
excised by restriction digest and ligated into its final destination vector. This proved much 
more efficient than direct cloning of the PCR product. 
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2.1.5 Transformation of E. coli DH5α 
E. coli DH5α competent cells were taken from - 80°C freezer and set on ice to thaw 
before adding 50-200 pg of DNA. The cells were incubated on ice for 30 minutes (for 
kanamycin resistant plasmids, is essential to have a 10 minutes recovery phase at 37°C 
at this point) before heat shock at 42°C for 45 seconds and placed back on the ice for 2 
minutes to reduce damage to the cells. One ml of LB broth (with no antibiotic) was added 
and the cells incubated for 1 hour at 37°C (shaking at 200 rpm or static). 100 µl of the 
resulting culture were spread on LB plates (with the appropriate selective antibiotic) and 
grown at 37ºC. Colonies were picked 12 to 16 hours later.  
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2.1.6 Polymerase chain reaction (PCR) 
Polymerase chain reactions were all performed in an Applied Biosystems Veriti 96 well 
Thermocycler. The conditions were adjusted according to the polymerase GoTaq® G2 
Hot Start Master Mixes from Promega; unless otherwise stated. Conditions are shown in 
Table 2. 2 and reactions set up in Table 2. 3. Table 2.4 and Table 2.5 outline primers 
used in Chapter 5 for the amplification of kash5 from cDNA. 
 
Table 2. 2. PCR reaction standard conditions. 
Step Temperature Length  
Initial denaturing 94ºC 2’ 
29 cycles 
Denaturing 98ºC 10” 
Annealing  60ºC 30” 
Extension 68ºC 2’ 
Final extension  68ºC 2’  
Hold 4ºC   
  
Table 2. 3. Standard PCR reaction (25 µl). 
Reagent Quantity 
Polymerase master mix 12 µl 
Primer Fw (10 µM) 1.5 µl 
Primer Rv (10 µM) 1.5 µl 
DNA (50-200 ng) 1-2 µl 
ddH2O 8-7 µl 
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Table 2. 4. kash5 gene specific primers for Xenopus laevis. 
Xenopus laevis kash5 primer Sequence 
Xla Kash5 EcoRI Fw gaattcggcaaagtagggctatacaatg 
Xla Kash5 EcoRI Fw1 gaattcgggctatacaatgtataaacacctagg 
Xla Kash5 EcoRI Fw2 gaattctcccctttaactagtaattgcatagc 
Xla Kash5 XhoI Rv ctcgagcctttaaactggaggtggag 
Xla Kash5 XhoI Rv1 ctcgagggaggtggagaagggtaatgc 
Xla Kash5 XhoI Rv2 ctcgagaatgcaagtccagatgaggc 
 
 
Table 2. 5. kash5 gene specific primers for Xenopus tropicalis. 
Xenopus tropicalis kash5 primer Sequence 
Xtr Kash5 EcoRI Fw gaattcactctccaggaatacatctgc 
Xtr Kash5 DK fwd BamHI gttaggatcctataagctgcagggtacctg 
Xtr Kash5 DK rev EcoRI atagaattcttacaactgaatacacggaacgatgctg 
Xtr Kash5 DK rev HindIII ataaagcttttacaactgaatacacggaacgatgctg 
Xtr Kash5 DK rev NotI atagcggccgcttacaactgaatacacggaacgatgctg 
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2.1.7 RNA extraction from embryos 
Embryos were collected in batches of #1 = 5 embryos or #2 = 25 embryos, and frozen 
at -80ºC for a maximum of 12 weeks. 
The embryos were mechanically homogenised in NETS buffer (Table 2. 6) by pipetting 
up and down (#1 = 200 µl; #2 = 400 µl) and the homogenate added to an equal amount 
of buffered phenol. The samples were vortexed for 30 seconds and centrifuged at 16000 
xg for 4 minutes. 
The aqueous top layer was carefully removed and transferred to a fresh tube containing 
an equal amount of 50 : 50 phenol : CHCl3, vortexed for 30 seconds and centrifuged at 
13000 xg 4ºC for 4 minutes. The aqueous top layer was carefully placed in a clean tube 
containing 2.5 x volumes of ethanol, vortexed and incubated overnight at -20ºC. 
Following overnight incubation, the sample was centrifuged at 13000 xg at 4ºC for 30 
minutes. The supernatant was removed, and the pellet was left to air-dry for 10 minutes. 
The dry pellet was re-suspended in 90 µl of ddH2O and aliquoted into 2 x 45 µl.  
Two microliters of each sample were removed and placed on ice, to the rest 5 µl 10 x 
DNase Buffer and 2 µl of DNaseI enzyme (Thermo Fisher Scientific, EN0521) were 
added and incubated at 37ºC for 30 minutes. Two microliters of the reaction were taken 
out and left on ice. 
Following the DNaseI treatment, 50 µl ddH2O and 100 µl phenol were added and the 
solution vortexed 30 seconds followed by centrifugation at 13000 xg and 4ºC for 4 
minutes. The top aqueous layer was transferred to a clean tube with 10 µl 3 M NaAc pH 
5.5 and 250 µl of ethanol. The tubes were incubated at -20ºC for 2 hours to precipitate 
the RNA. The samples were centrifuged at 13000 xg and 4ºC for 10 minutes, the ethanol 
removed and the pellet air-dried before re-suspending in #1 = 10 µl and #2 = 20 µl of 
ddH2O. 
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Table 2. 6. NETS buffer recipe for RNA extraction from Xenopus embryos 
NETS buffer 
30 mM NaCl 
1 mM EDTA 
20 mM Tris, pH 7.5 
1 % SDS 
ddH2O 
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2.1.8 cDNA synthesis from Xenopus total RNA 
To synthesize cDNA, Superscript 3 (Invitrogen) was used following the manufacturer’s 
instructions. The reactions were set up in clean microcentrifuge tubes as shown in Table 
2. 5 and incubated at 50ºC for 60 minutes before freezing at -20ºC until needed. 1-2 µl 
of this material were used in each RT-PCR.  
Table 2. 7. cDNA synthesis from total RNA by reverse transcription. 
Reagent Amount used 
RNA 4-5 µl 
10 x reaction buffer 2 µl 
100 µM random hexamers/nonamers 2 µl 
2 mM dNTP mix 4 µl 
Superscript 3 reverse transcriptase  0.25 µl 
ddH2O to 20 µl 
 
To check the cDNA integrity by PCR, a housekeeping gene was amplified, in this case, 
ODC (forward primer 5′ GGA GCT GCA AGT TGG AGA 3′, reverse primer 5′ CTC AGT 
TGC CAG TGT GGT C 3′). The expected product size was ~250 bp (Figure 2. 1). 
Table 2. 8. Isolation and amplification of a specific region from total cDNA 
Reagents Amount used 
Polymerase (2 x green ready mix) 10 µl 
Primer Fw (10 µM) 1.5 µl 
Primer Rv (10 µM) 1.5 µl 
cDNA 1-2 µl 
ddH2O 6-5 µl 
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Figure 2. 1. cDNA synthesised from Xenopus total RNA by reverse transcription. 
To check the cDNA integrity, a housekeeping gene (ODC) was amplified. Lanes 1, 2 and 3 
represent three reverse transcription reactions, and lanes 4, 5 and 6 the amplification of the ODC 
gene from the same 3 reactions. Reaction number 2 produces a single band of just around 250 
bp when amplified with the ODC primers, correlating with the expected size for the ODC amplicon. 
The cDNA from reaction number 2 was used further.  
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2.1.9 In vitro protein production by the 1-Step Human High-Yield Mini IVT 
Kit (Thermo Scientific, 88885) 
2.1.9.1 Cloning of target site into a suitable vector 
Several vectors were considered, however, PCR2.1 TOPO was chosen to clone the 
insert into since this vector does not have restriction sites for either SalI or NdeI (enzymes 
to be used downstream).   
 
2.1.9.2 PCR  
The sequences of interest (neurog2 and xic1) were obtained from plasmids stored at the 
EXRC (European Xenopus Resource Centre). These sequences were amplified with the 
primers below under standard PCR conditions (see Polymerase chain reaction section).  
Table 2. 9. Primer sequences used to amplify neurog2 and xicI, which later were cloned 
into the pT7CFE1-cGST-HA-his vector to express Neurog2 and XicI protein in vitro. 
neurog2  
Fw CATATGATGGTGCTGCTCAAGTGCG 
Rv GTCGACAATGAAAGCGCTGCTGGCAG 
xicI 
Fw CATATGATGGCTGCTTTCCACATCGC 
Rv GTCGACTCGAATCTTTTTCCTGGGGG 
 
2.1.9.3 TOPO TA cloning. 
The appropriate reagents were mixed and incubated for 5 minutes at room temperature 
(22-23°C). Once the TOPO Cloning reaction was performed, the clones were 
transformed into E. coli DH5α cells following standard procedures (see Transformation 
section). 
 
2.1.9.4 Sub-cloning into pT7CFE1-cGST-HA-his 
The pT7CFE1-cGST-HA-his vector was included in the 1-step human high-yield mini IVT 
kit. This vector was digested with NdeI and SalI; the amplified inserts were ligated using 
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a standard T4 DNA Ligase protocol (see Ligation by T4 DNA ligase section), transformed 
and grown up. Correct plasmids were obtained as checked by restriction digestion of 
mini-preps and sequencing. 
 
2.1.9.5 Protein expression using the 1-Step Human High-Yield Mini IVT Kit  
Protein expression was performed following the manufacturer’s instructions. To measure 
protein production, standard western blot, silver staining and BCA protein assay methods 
were combined.  
 
2.1.10 HEK cell protein expression using pOPIN plasmids and the In-Fusion 
system. 
2.1.10.1 Destination Vectors 
The OPPF (Oxford Protein Production Facility) designed a series of vectors which 
expressed proteins in multiple hosts: E. coli, mammalian cell lines (e.g. HEK293T cells) 
and insect cell lines (e.g. Sf9 cells), allowing parallel screening in multiple hosts (Bird, 
2011). These vectors, in combination with the In-Fusion™ enzyme, have produced an 
efficient cloning procedure in which the PCR product is cloned directly into the final 
expression vector.  
The pOPIN vectors encode a variety of tags to aid solubility and purification of the 
resulting proteins: 
a. pOPINF-his-tag at the N-terminal (Plasmid 26042) 
b. pOPINM-MBP (maltose binding protein) tag + his-tag (Plasmid 26044) 
c. pOPINJ-GST (glutathione-S-transferase) tag + his-tag (Plasmid 26045) 
d. pOPINE – his-tag at the C-terminal (Plasmid 26043) 
The empty backbones were acquired from Addgene (www.addgene.org).  
Upon arrival, stocks were generated following transformation and growth using the 
NucleoBond MidiPrep Kit (Macherey-Nagel) instructions. This was followed by the 
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linearization and gel purification of the vector using the MinElute Gel Extraction Kit 
acording to the manufacturer’s instructions (Qiagen). 
Table 2. 10. . Digestion of pOPIN vectors. 
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pOPINE NcoI 2 PmeI 2 303 7 
CutSm
art 
10 79 100 37 
pOPINF KpnI 2 HindIII 2 1027 2 
NEBuff
er 2.1 
10 84 100 37 
pOPINM KpnI 2 HindIII 2 1736 1.5 
NEBuff
er 2.1 
10 84.5 100 37 
pOPINJ KpnI 2 HindIII 2 400 5 
NEBuff
er 2.1 
10 81 100 37 
 
2.1.10.2 Proteins of Interest 
Following input from the community, a list of proteins of interest was generated whose 
expression had previously been attempted in E. coli with limited success. 
a. XicI 
b. Neurog2 
c. Gata2 
d. ETV2 
e. FliI 
f. SCL 
g. xHairyI 
h. xMit1 
i. xNeuroD 
j. xDeltaI 
k. RARα2 (N-terminal) 
l. RARβ 
m. Ncor2 (SMRT) 
As proof of principle, we decided to only work on 3 of these proteins (underlined) in the 
first instance with the aim of subsequently moving to a larger scale.   
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2.1.10.3 Primer design 
Primers were designed using the SnapGene program (GSL Biotech LLC, n.d.). These 
were designed to amplify a fusion protein-specific sequence together with a 15-30 bp 
sequence at the 5’ and 3’ end homologous to termini of the digested vector. Vector maps 
and primers sequences can be found in Appendix I. 
 
2.1.10.4 PCR with specific primers to isolate insert and add specific 
ends to enable the In-Fusion reaction  
PCR reactions were carried out with 20-30 ng of plasmid containing the desired 
sequence and specific primers (see 2.1.6). Resulting amplicons were analysed by gel 
electrophoresis and used if a single band of the expected size was observed. If multiple 
bands were present, the correct size amplicon was gel extracted and purified using the 
MinElute Gel Extraction Kit using the manufacturer’s instructions (Qiagen). 
 
2.1.10.5 DpnI treatment 
OPPF recommend that “if the PCR template has the same antibiotic resistance as your 
target pOPIN vector you must DpnI treat your PCR reaction” (Bird, 2012) to remove 
template plasmid before transformation. 
The DpnI enzyme has specificity for methylated DNA and digests template without 
digesting the PCR product. The DpnI enzyme is active in most PCR reaction buffers and 
can therefore be added to the PCR product. Thus, 2.5 μl of DpnI enzyme were added to 
20 μl of PCR reaction mix and incubated at 37°C for 45 minutes in the thermal cycler. 
The reaction was stored at -20°C until further use. 
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2.1.10.6 Cloning enhancer treatment 
Following PCR, the products showed a discrete single band. Clontech recommends 
treating products composed of a single amplicon with Cloning Enhancer, a proprietary 
enzyme mix for removing background plasmid DNA and PCR residue. This step 
eliminates the need for PCR insert purification before cloning. 
For this treatment, 2 μl of Cloning Enhancer (Clontech) were added to 5 μl of PCR 
product and incubated at 37°C for 20 minutes; the temperature was raised to 80°C for a 
further 25 minutes and the treated product was used immediately or stored at -20°C until 
needed. 
 
2.1.10.7 In-Fusion reaction 
The In-Fusion PCR Cloning System (Clontech) allows the fusion of extended PCR 
fragments with a region of homology at both 3’ and 5’ ends to the homologous ends of a 
linearised vector. The composition of the In-Fusion reaction has not been disclosed by 
the company. One theory found in Researchgate (/www.researchgate.net) is that it “uses 
vaccinia virus DNA polymerase”, however this is not an official comment. The public 
knowledge about In-Fusion goes as far as knowing that is a methods consisting of a 
single-tube enzymatic reaction based on homolog fragment ends and it requires 
incubation at 50ºC. 
The In-Fusion reactions components are shown in Table 2. 11. Once assembled, the 
reaction was incubated at 50°C for 15 minutes, followed by the transformation into E. coli 
Stellar competent cells (provided with the In-Fusion kit) using standard methods.  
DNA from transformants was prepared as mini-preps (Qiagen) and sent for sequencing 
(Source Bioscience).   
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Table 2. 11. In-Fusion reaction components. 
 
5 x In-Fusion 
HD Enzyme (μl) 
Linearized 
Vector (μl) 
PCR fragment 
(μl) 
dH2O  
(μl) 
pOPINF 2 2 1.5 4.5 
pOPINE 2 4.5 1.5 2 
+ve control 2 2 1.5 (control) 4.5 
-ve Control 2 2 0 6 
 
2.1.11 Cas9 RNA synthesis 
Cas9 was transcribed from its containing plasmid (a kind gift from Dr Marko Horb) by 
SP6 polymerase using the mMachine Kit (Ambion) following the manufacturer’s protocol. 
Three distinct reactions were set up to generate Cas9 RNA by transcription with 
variations on the starting DNA template (see table below), all such reactions produced 
good quality RNA with yields ranging from 200-3000 ng/µl.  
Table 2. 12. Transcription of Cas9 by SP6 polymerase. 
 Reaction 1 Reaction 2 Reaction 3 
2 x NTP/CAP analog (µl) 10 10 10 
10 x Reaction mix (salts, buffer, 
dithiothreitol, and other 
ingredients) (µl) 
2 2 2 
1 x SP6 enzyme mix (Buffered 
50% glycerol containing RNA 
polymerase, RNase 
Inhibitor, and other components) 
(µl) 
2 2 2 
Linear template DNA 120 ng/µl 
(µl) 
3 4 5 
dH2O (µl) 3 2 1 
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2.2 gRNA production 
gRNAs were designed to anneal to a particular sequence in the genome, guiding Cas9 
to make the double-stranded cut 3 bp away from the PAM site (Mojica, Díez-Villaseñor, 
García-Martínez, & Almendros, 2009). The sequence of gRNA that anneals to the target 
sequence is 20-25 bp long (uppercase). To the 5’ of this sequence, the T7 polymerase 
promoter sequence was added. To the 3’ of the target sequence, 15 bp were added that 
anneal to a standard oligonucleotide, which encodes a part of the gRNA that contains a 
secondary structure that binds to the Cas9 protein.  
gRNA #1:  
5’ taa tac gac tca cta taG ATA AAT AAT AAC TCT GAC GTG Ggt ttt aga gct aga a 3’ 
gRNA #2:  
5’ taa tac gac tca cta taC CAC ACC ACT CCA GCA TGG TGA Cgt ttt aga gct aga a 3’ 
gRNA #3:  
5’ taa tac gac tca cta taT GCT GAG AAG ACA GTG TAA Cgt ttt aga gct aga a 3’ 
gRNA #4:  
5’ taa tac gac tca cta taG TCA CCA TGC TGG AGT GGT Ggt ttt aga gct aga a 3’ 
The gRNAs were synthesised as described in Nakayama et al. 2014. In summary, the 
designed gRNA encoding sequences were annealed to a universal single-stranded 
sequence and filled in using Taq polymerase to make a double-stranded DNA sequence.  
Universal 3’ gRNA sequence: 
5’ AAA AGC ACC GAC TCG GTG CCA CTT TTT CAA GTT GAT AAC GGA CTA GCC 
TTA TTT TAA CTT GCT ATT TCT AGC TCT AAA AC 3′  
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Table 2. 13. Components and steps to synthesise double stranded DNA from ssDNA by 
touch down PCR 
PCR master mix 50 µl  Initial denaturing 94ºC 5’ 
Custom gRNA (100 µM) 2 µl  Denaturing 94ºC 20” 
Universal gRNA  (100 µM) 2 µl  Annealing 58ºC 15” 
MgCl2 (25 mM) 2 µl  Extension 68ºC 15” 
dH2O 44 µl  Final extension 68ºC 5’ 
Reaction total 100 µl  Hold 4ºC - 
 
When a strong band was visible from the PCR product on an agarose gel, RNA was 
synthesised using 6 µl of the PCR product in the Megashortscript™ T7 Transcription Kit 
(Thermo Fisher AM1354) following the manufacturer’s instructions; the RNA product was 
then visualised on a 1.5 % agarose gel. 
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2.3 Microbiological techniques 
2.1.1 Bacterial strains and phage used 
2.3.1.1 TG1 and BL21 cells for phage infection 
Cells for phage infection were obtained from the Sokol lab at Mount Sinai Hospital (New 
York, USA). To grow a stock, an LB plate with no antibiotic was streaked with a sterile 
tip containing an aliquot from the stock vial. After overnight incubation at 37ºC, a single 
colony was used to inoculate 4 ml of 2xYT media containing no antibiotic. The starter 
culture was left to grow overnight at 37ºC shaking at 220 rpm. The starter culture was 
used to inoculate 400 ml of 2xYT media with no antibiotic (1/100). This culture was 
incubated to an OD600 of 0.3 to 0.6. Cells were centrifuged at 1000 xg for 15 minutes at 
4ºC. The supernatant was discarded and the cell pellet re-suspended in 10 ml cold 
filtered TSB medium on ice. Cells were incubated for 10 minutes on ice and aliquoted as 
500 µl before snap freezing in liquid nitrogen and storage at -80ºC until further use. 
Table 2. 14. TSB (transformation and storage buffer) and 2xYT medium used to grow 
different strains of E. coli DH5α cells 
TSB 2xYT 
LB or YT 1 x Bacto-tryptone 1.6 % 
NaCl 43 mM Yeast extract 1 % 
PEG 10 % NaCl 85 mM 
DMSO 5 % dH2O 
MgCl2 10 mM pH 7.0 
MgSO2 10 mM  
Glycerol 10 %  
dH2O  
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2.3.1.2 HBV88 cells – Electro-competent cells 
HBV88 cells, originally a gift of A. Hayhurst to the Sokol lab (Mount Sinai Hospital, USA), 
contain a chloramphenicol resistance plasmid encoding a suppressor tRNA upon 
arabinose induction. These cells were made electro-competent (ready for 
electroporation) using low-temperature growth in low salt YENB media, followed by 
extensive washing.  
Bacteria were streaked on M9/chloramphenicol/thiamine minimal agar (to select for the 
F’-episome). A single colony was cultured in 2 ml of M9 medium for 8 hours, and 200 μl 
of the culture was added to 2 x 50 ml liquid M9 before incubating overnight at 37°C 
shaking at 220 rpm. 10 ml of the culture were added to six 400 ml flasks of YENB 
supplemented with chloramphenicol to make an OD600 of 0.05 and incubated at 30°C 
until the OD600 reached 0.4 - 0.6 (approximately 3 hours at 37°C or 6 - 7 hours at 25°C).  
After chilling the cultures on ice for 5 minutes, cells were pelleted in 6 bottles at 4080 xg, 
4°C for 20 minutes. The following procedures were performed in the cold room.  Each 
pellet was re-suspended gently in 50 ml ice-cold deionised water and transferred into 2 
x 50 ml conical tubes (approximately 25 ml each); ice-cold water was added to 50 ml. 
Cells were pelleted at 4080 xg at 4°C for 15 minutes and re-suspended in 25 ml of ice-
cold water. Water was added to 40 ml and the cells re-pelleted in the same conditions. 
Cells were washed in 25 ml with ice-cold 15 % glycerol, pelleted again and finally re-
suspended in 8.7 ml of 15 % glycerol. Competent cells were aliquoted into 48 x 270 μl in 
Eppendorf tubes (pre-chilled), frozen in dry ice and stored at -80ºC. Transformation 
efficiency of 5x108 / μg (instead of expected 109) with pecan126 was achieved. 
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Table 2. 15. M9 minimum agar and YENB medium. 
M9 minimum agar YENB 
Sodium phosphate dibasic (anhydrous), 
Na2HPO4 
Yeast extract 0.75 % 
Sodium chloride, NaCl Nutrient broth 0.8 % 
Ammonium chloride, NH4Cl H2O 
1 M Magnesium sulphate, MgSO4 pH 7.0 with NaCl  
0.1 M Calcium chloride CaCl2  
10 % (w/v) glucose (or another carbon 
source) 
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2.3.1.3 M13K07 helper phage:  
TG1 cells were grown in LB broth at 37°C with shaking (220 rpm) until an OD600 of 0.8 
was reached. Helper phage (NEB catalogue #N0315S, 1 x 1011pfu/ml) were diluted 10-
4, 10-5, 10-6 and 10-7 -fold. Ten microliters of the diluted M13K07 were mixed with 100 μl 
of TG1 cells and poured with 3 ml top agar onto 10 cm LB plates with no antibiotic. The 
plates were cultured at 37°C for 14-16 hours. Several individual plaques were picked, 
suspended individually in 3 ml of 2xYT media supplemented with kanamycin in 15 ml 
round bottom tubes and cultured overnight at 37°C. The cultures were centrifuged at 
13000 xg for 2 minutes, the supernatant collected and the titre measured by diluting the 
phage and plaking with TG1 and top agar as described above. The titre obtained was 2 
x 1012 pfu/ml.   
Table 2. 16. Top agar, agar used to propagate phage recipe. 
Top agar   
Bacto-tryptone 1.6 %   
Yeast extract 1 %   
NaCl 85 mM   
Granulated agar 0.75 %   
H2O   
pH 7.0 with NaCl  
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2.3.1.4 Preparation of E. coli DH5α competent cells (from pre-existing 
stock) 
Cells from an existing stock were streaked on an agar plate with no antibiotic and 
incubated overnight at 37°C. Four colonies were picked, incubated individually in 5 ml 
LB broth with no antibiotic and incubated with shaking overnight at 37°C. These starter 
cultures were used to inoculate 4 x 500 ml of LB Broth that were incubated at 37°C with 
shaking until the OD600 reached 0.5 (~3.5 hours). The cultures were then cooled at 4ºC 
for 5 minutes, transferred to 1 L bottles and centrifuged using a JLA8.1000 centrifuge, at 
4000 xg for 5 minutes. The supernatant was discarded and the pellet re-suspended in 
cold FB1 buffer (Table 2. 17). The cells were incubated on Ice for 90 minutes and 
centrifuged at 4000 xg for 5 minutes. The supernatant was discarded and the pelleted 
cells re-suspend in ice-cold FB2 (Table 2. 17). Cells were aliquoted into 500 µl and snap 
frozen in liquid nitrogen before being stored at -80ºC until further use. 
Table 2. 17. FB1 and FB2 solutions composition to propagate E. coli DH5α cells. 
FB1  (30 ml for every 100 ml culture) FB2 (4 ml for every 100 ml culture) 
100 mM RbCl 10 mM MOPS 
50 mM MnCl2 10 mM RbCl 
30 mM Potassium Acetate 75 mM CaCl2 
10 mM CaCl2 15 % Glycerol 
15 % Glycerol  pH 6.8 with KOH, filtered sterilise  
pH 5.8, filter sterilise (No KOH)  
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2.3.2 Expression of single-domain antibodies and preparation of 
periplasmic extract  
A single colony obtained by the incubation of a VHH bacterial library on ampicillin 
selective plates was used to inoculate 2 ml of 2xYT medium supplemented with ampicillin 
and incubated in a rotary shaker at 200 rpm and 30°C overnight.  
For small-scale preparations, the 2 ml overnight culture was split into 2 parts. 1.4 ml was 
centrifuged to test for the presence of the inserts by DNA preparation and 100 μl was 
used to inoculate fresh 2xYT medium (2 ml).  
For large-scale preparation, the pre-culture was added to 50 ml of 2xYT supplemented 
with ampicillin and incubated at 30°C, 200 rpm to an OD600 of approximately 0.3–0.5 as 
measured in a cell density meter. If master plates were to be made, one drop of the 
culture was placed on an LB plate supplemented with ampicillin and incubated at 37°C 
overnight. IPTG was added to the remaining culture to achieve a final concentration of 1 
mM and incubated at 27-30°C and 200 rpm overnight or at 37°C for 4-6 hours. 
The cells were pelleted for 20 minutes by centrifugation at 4°C and 3000 ×g and then re-
suspended in ¼ of the initial culture volume of pre-chilled TES buffer. The cell 
suspension was kept on ice for at least 30 minutes before an osmotic shock was given 
by adding 1.5 volume of cold TES/5; it was incubated on ice for at least another 30 
minutes. The mixture was centrifuged for 20 minutes at 13000 xg and 4°C forcing the 
proteins to leave the periplasmic space and mix with the supernatant. NaCl was added 
to the supernatant to 300 mM before storage, as this stabilises the proteins.  
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2.4 Protein techniques 
2.4.1 Total protein extract from Xenopus embryos 
Embryos were collected at the desired stages, medium carefully removed and embryos 
frozen at -80ºC (5 - 10 embryos for each protein extraction).  Two different solutions were 
tested when extracting proteins from the embryo, NETS buffer and EEB buffer. No 
difference was observed in the quality of the proteins extracted, however the latter was 
preferred for convenience. The embryos were mechanically homogenised by pipetting 
up and down in 100 µl NETS buffer (Table 2. 18) or 100 µl EEB. Please note, when 
extracting proteins, the SDS was left out of the NETS buffer, to avoid the solubilisation 
of yolk proteins. To the homogenised samples, 200 µl of Freon was added, the mixture 
was vortexed for 20 seconds and centrifuged at 4ºC, 13000 rpm for 15 minutes. The 
aqueous upper phase was carefully removed, transferred to a fresh tube, mixed the 
same volume of 2 x SDS loading dye or 2x β-mercaptoethanol sample buffer and heated 
at 95ºC for 3 minutes. The denatured protein was loaded onto the SDS-PAGE gel or 
stored at -20ºC. Alternative methods for denaturing proteins were tested, by heating the 
proteins with the SDS loading dye for 20 minutes at 55ºC, and the combination of 20 
minutes at 55ºC followed by 95ºC for 3 minutes. The latest was preferred as it denatured 
proteins to an extent where they could be visualised as well defined bands on an SDS-
PAGE. 
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Table 2. 18. NETS Buffer vs Embryo Extraction Buffer (EEB) reagents. 
NETS EEB 
30 mM NaCl 10 mM HEPES, pH 8.5 
1 mM EDTA 1 mM EDTA 
20 mM Tris, pH 7.5 2 mM MgCl2 
1 % SDS 10 mM β-glycerophosphate 
ddH2O 1 mM dithiothreitol (DTT) 
EDTA-free protease inhibitor EDTA-free protease inhibitor 
 
 
Table 2. 19. Protein loading dye composition. 
2x SDS sample buffer 2x β-mercaptoethanol sample buffer 
0.125 M Tris-HCl, pH 6.8  100 mM Tris-Cl, pH 6.8 
4 % SDS 2 % SDS 
0.15 M DTT 4 % β-mercaptoethanol 
20 % Glycerol 20 % glycerol  
0.01 % Bromophenol Blue 0.00125 % Bromophenol Blue 
Stored at -20ºC Stored at room temperature 
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2.4.2 Western blot 
2.4.2.1 SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis) 
The resolving gel (recipes below) was made by adding first the 30 % acrylamide solution 
and resolving buffer to the dH2O, followed by the 10 % APS and TEMED, since these 
agents produce the rapid polymerisation of the gel. The solution was poured in the plates 
leaving a 1.5 cm space at the top. 1 ml of water-saturated butanol was added to form a 
layer at the top of the resolving gel and left to stand to allow the full polymerisation of the 
gel. The butanol was washed off and the gel rinsed thoroughly with dH2O.  
The stacking gel was made by mixing the 30 % acrylamide solution and the stacking 
buffer with the dH2O, before adding the 10 % APS and TEMED. This solution was poured 
immediately on the top of the resolving gel, and the appropriate comb was inserted. At 
least 10 minutes were allowed for the gel to polymerise. The gel was then placed in the 
electrophoresis tank together with 1 x Tris-Glycine SDS running buffer, before removing 
the combs. A protein marker was loaded into the first lane, followed by the samples. The 
gel was run at 65 V until the samples had run through the stacking gel, then the voltage 
was increased to 150 V to 200 V for a further 40 minutes to 1 hour.  
When the blue dye reached to bottom of the gel, the gel was removed from the glass 
plates and transferred to nitrocellulose membrane for western blot or stained with 
Coomassie blue. 
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Table 2. 20. Recipe for 10 ml of polyacrylamide gel mix; separating and stacking gels 
 
5 ml of 6 % 
Stacking Gel: 
10 ml of 10 % 
Resolving Gel 
10 ml of 12 % 
Resolving Gel: 
10 ml of 14 % 
Resolving Gel: 
dH2O 2.8 ml   4.2 ml   3.5 ml   2.8 ml   
30 % 
acrylamide 
(37.1 : 1 
acrylamide : 
bis) 
1 ml   3.3 ml   4 ml   4.7 ml   
4x resolving 
buffer 
 2.5 ml   2.5 ml   2.5 ml   
Stacking buffer 1.2 ml      
10 % APS 100 µl   100 µl   100 µl   100 µl   
TEMED 10 µl   10 µl   10 µl   10 µl   
 
2.4.2.2 Membrane transfer 
The western blot apparatus insert was opened and placed on a tray containing transfer 
buffer with the black side down. Inside the following items were placed: a fibre pad, 2 x 
Whatman 3 mm paper pads, the gel, the membrane, 2 x Whatman 3 mm paper pads 
covering the membrane and another fibre pad. This “sandwich” was placed on the 
apparatus with the black side facing the black from the transfer apparatus (black to 
black), this ensures the correct orientation for transfer. The tank was filled with western 
transfer buffer and set to run at 30 mA overnight or 300 mA for 2 hours.  
Table 2. 21. Western blot tris-glycine membrane transfer buffer. 
 
Membrane transfer buffer 
200 mm Tris Base 
150 mm Glycine 
0.1 % SDS    
20 % Methanol 
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2.4.2.3 Membrane Blocking  
Upon transfer, the nitrocellulose membrane was washed with ddH2O for 5 minutes at 
room temperature and incubated in 25 ml of blocking buffer for 1 hour at room 
temperature or overnight at 4⁰C. The blocking buffer was then replaced with fresh 
blocking buffer containing the primary antibody for 1 hour at room temperature or 
overnight at 4⁰C. 
Table 2. 22. Blocking buffer composition and TBSTw recipie 
5 % w/v non-fat dry milk (Marvel ®) 5 % w/v non-fat dry milk powder dissolved in TBStw 
1 % Blocking Reagent (Roche, 
11096176001) 
1 % dissolved in maleic acid buffer 
5 % BSA (Fisher Scientific, BPE9701) 5 % BSA powder dissolved in TBSTw 
TBSTw 20 mM Tris, 150 mM NaCl, 0.1 % Tween 20 
 
2.4.2.4 Primary Antibody Incubations 
Two types of primary antibody were used, unconjugated and conjugated to the label. 
Detailed procedures are given corresponding to the primary antibody used. 
 
2.4.2.5 For Unconjugated Primary Antibodies 
After blocking, the membrane was incubated in fresh blocking solution containing the 
primary antibody at the appropriate dilution with gentle agitation for 1 - 2 hours at room 
temperature or overnight at 4°C. For the his-probe (G-18 SC-804 LOT H2304) the 
dilution used was 1/1000 unless otherwise stated. 
Following the primary antibody incubation, the membrane was washed three times for 5 
minutes each with 10 – 15 ml of TBSTw and incubated with the species-appropriate 
HRP-conjugated secondary antibody. A 1/2000 dilution of the Anti-Rabbit IgG-
Peroxidase conjugated (Sigma A0545) secondary antibody was incubated with the 
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membrane in fresh blocking buffer with gentle agitation for 1 hour at room temperature 
unless otherwise stated.  
The membrane was washed twice for 5 minutes each with 15 ml of blocking solution, 
once for 5 minutes with TBSTw and once with PBS for 5 minutes before proceeding with 
detection. 
 
2.4.2.6 For HRP-Conjugated Primary Antibodies 
After blocking, the membrane was incubated in fresh blocking solution with the primary 
antibody at the appropriate dilution with gentle agitation for 1 - 2 hours at room 
temperature or overnight at 4°C. 
The membrane was washed twice for 5 minutes each with 15 ml of blocking solution, 
once for 5 minutes with TBSTw and once with PBS for 5 minutes before proceeding with 
detection. 
 
2.4.2.7 Protein detection 
For protein detection, the membrane was incubated either for 1 minute with 10 ml of ECL 
solution #1 and 10 ml of ECL solution #2 (Table 2. 23), or for 5 minutes with 7 ml Clarity 
Western ECL Substrate Solution A and 7 ml of Clarity Western ECL Substrate Solution 
B (Bio-Rad, 170-5061). Visualization was performed using an ImageQuant LAS4000 
following the manufacturer’s instructions. 
Table 2. 23 ECLI and ECLII buffer composition for chemiluminescence detection of HRP-
conjugated antibodies. 
ECL solution #1 ECL solution #2 
2.5 mM luminol 0.021 % hydrogen peroxide 
0.9 mM p-coumaric acid 10 mM tris, pH 8.5 
10 mM tris, pH 8.5  
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2.4.3 In vitro protein expression 
Mini IVT Kit (Thermo Scientific, 88885) 
Target proteins were cloned into the pT7CFE1-NHis-GST-CHA vector and protein 
synthesis was performed using a 1-Step Human High-Yield Mini IVT Kit following the 
manufacturers’ instructions with no modifications to the protocol.  
2.4.4 In vivo protein expression 
HEK cell expression 
2.4.4.1 HEK293T cell maintenance 
NOTE: All cell manipulations were carried out in a Class 2 laminar flow hood. 
 
2.4.4.1.1 Media preparation 
HEK293T cells were cultured in DMEM supplemented with a variety of other components 
depending on whether they were only growing or if they were transfected.  
Table 2. 24. Complete DMEM 
DMEM 500 ml 
FCS 50 ml 
L-glutamine 5 ml 
NEAAs (100x) 5 ml 
   
Table 2. 25. DMEM + 2 mM L-Glutamine 
L-glutamine 1 ml 
DMEM 99 ml 
 
Table 2. 26. DMEM + 1 mM L-Glutamine + 2 % FCS 
L-glutamine 1 ml 
DMEM 195 ml 
FCS 4 ml 
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Table 2. 27. Freezing Media 
FCS 90 % 
DMSO 10 %  
 
2.4.4.1.2 Passaging to maintain and propagate cells 
HEK293T cells were maintained by passaging them every 3-5 days, upon reaching 80-
90 % confluency. These cells were cultured in a variety of flasks, mainly T75 and T175. 
Once the cells reached 80-90 % confluency, the old medium was removed and sufficient 
trypsin solution (TrypLE Express, Gibco® or equivalent) was added to cover the surface. 
The flask was placed in the 37ºC incubator for 3-5 minutes until cells had dissociated. 
DMEM medium supplemented with 10 % FCS was added as three times the volume of 
trypsin used. The added media inactivated the trypsin and protected the cells from lysing. 
Cells were transferred into Falcon tubes and centrifuged at 1000 xg for 3 minutes. The 
supernatant was discarded and the cells re-suspended in fresh medium supplemented 
with 10 % FCS. Cells were counted and flasks seeded following manufacturer’s 
guidelines before incubating at 37°C in a 5 % CO2 and 95 % air environment. 
 
2.4.4.1.3 Freezing cells 
Cells were treated as if they were going to be passaged, with the difference that when 
they were re-suspended after centrifugation, freezing medium (Table 2.25) was used 
instead. The cells were aliquoted into 2 ml cryovials and stored at -80ºC for 1-2 days 
(maximum 2 weeks). These were then transferred to liquid nitrogen storage and tested 
after 2-3 days on liquid nitrogen for freezing efficiency. 
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2.4.4.1.4 Thawing cells 
DMEM with 10 % FCS (25 ml) was prepared in a T75 flask before rapidly thawing a vial 
of cells in a water bath at 37°C. Upon thawing, the full content of the vial was added to 
the T75 flask and incubated at 37°C in a 5 % CO2 and 95 % air environment until 
confluent (2-4 days). Cells were passaged as previously described.   
 
2.4.4.2 Small-scale HEK293T cells transient transfection  
Small-scale HEK293T transfection was achieved using the JetPRIME reagent (Polyplus, 
114-01) following the manufacturer’s instructions. In summary, cells were seeded and 
allowed to reach 60 % to 80 % confluency at the time of transfection. Transfection was 
performed with a 1:2 DNA to jetPRIME® reagent ratio and in the presence of serum. 
The Jet prime buffer was aliquoted into microcentrifuge tubes and the DNA added. The 
samples were mixed by vortex for 10 seconds and microcentrifuged for 10 seconds at 
full speed. The JetPrime Reagent was added to the Buffer-DNA mix, vortexed for 10 
seconds and centrifuged for 10 seconds. The mixture was then incubated at room 
temperature for 10 minutes exactly. The transfection mix was added to the cells and 
incubated for 4 - 8 hours at 37°C in a 5 % CO2 and 95 % air environment. After the 
incubation period, the medium was changed to fresh DMEM supplemented with 2 % L-
glutamine and 10 % FCS and further incubated for 24 - 48 hours. 
Cells and medium were subsequently collected and stored separately at -80°C until 
analysed. 
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2.4.4.3 Medium-scale HEK293T cells transient transfection 
Cells were seeded at 7.5 x 105 cells/ml in 5 ml of complete DMEM and incubated 
overnight at 37°C in a 5 % CO2 and 95 % air atmosphere. Once they were 80 % 
confluent, 87.5 μg of plasmid DNA was mixed with 2.6 ml of DMEM supplemented with 
NEAAs (non-essential amino acids) and 1 mM L-glutamine. Separately, 154 μl of 1 mg/ml 
branched polyethylenimine (PEI) was mixed with 2.6 ml of DMEM containing 1 mM L-
glutamine. The DNA-containing DMEM and the PEI-containing DMEM were mixed and 
incubated for 10 minutes at room temperature. The medium was removed from the T175 
flask and replaced with 45 ml of fresh DMEM containing 2 % FCS, 1x NEAAs and 1 mM 
L-glutamine. After 10 minutes of incubation, the DNA/PEI mixture was added to the cells 
and incubated at 37°C in a 5 % CO2 and 95 % air atmosphere for 3 days. 
Cells and medium were subsequently collected and stored separately at -80°C until 
analysed. 
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2.4.4.4 Large-scale HEK293T cells transient transfection 
HEK293T cells were transfected as previously described by Chamberlain and co-
workers  (Nettleship et al., 2015). In summary, four confluent T175 flasks of cells were 
used to inoculate four expanded surface roller bottles (Greiner Bio-One) containing 250 
ml of medium each. These were incubated at 37°C in a 5 % CO2 and 95 % air 
environment, rotated at 0.3 rpm for the first 24 hours and at 1.0 rpm thereafter. The cells 
were cultured for 5-6 days until they were approximately 70 % confluent. On the day of 
transfection, two 500 ml DMEM bottles were supplemented with L-glutamine to 2 mM. 
100 ml from each bottle were removed and placed in a T75 flask; namely Flask1 and 
Flask2. To the remaining 400 ml of supplemented medium 8 ml of heat-inactivated FCS 
were added and left aside. To Flask1, 3.5 ml of 1 mg/ml polyethyleneimine (PEI), pH 7.0 
was added. To Flask2, 2 mg of DNA was added. Flask1 and Flask2 were mixed for 
exactly 10 minutes. Meanwhile, the old medium from the roller bottles was taken out and 
replaced with 200 ml of the previously supplemented DMEM. After the 10 minutes 
incubation, 50 ml of the DNA/PEI mix was added to each bottle and incubated at 37°C 
in a 5 % CO2 and 95 % air environment rotated at 1.0 rpm for one week (Table 2. 2).   
Cells and medium were subsequently collected and stored separately at -80°C until 
analysed. 
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Figure 2. 2. Large-scale transient transfection of HEK293T cells. 
Two bottles of DMEM were supplemented with 2 mM L-glutamine before transferring 100 ml of 
each bottle to a different flask. One of the remaining 400 ml DMEM bottle was supplemented with 
2 % heat-inactivated FCS. To one of the flasks containing 100 ml DMEM, 1 mg/ml 
polyethyleneimine (PEI), pH 7.0 was added, and to the other 2 mg of purified DNA were added. 
Flask1 and Flask2 were mixed for exactly 10 minutes. Meanwhile, the old medium from the roller 
bottles was discarded and replaced with 200 ml of the previously supplemented DMEM. After the 
10 minutes incubation, 50 ml of the DNA/PEI mix was added to each bottle and incubated at 37°C 
in a 5 % CO2 and 95 % air environment rotating at 1.0 rpm for one week. Cells and medium were 
subsequently collected and stored separately at -80°C until analysed. 
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2.4.4.5 Harvesting expressed proteins 
2.4.4.5.1 Secreted proteins 
The supernatant containing the protein was collected, centrifuged at 6000 xg for 15 
minutes to remove any detached cells and filtered through a 0.22 μm bottle top filter 
before being stored at 4°C.  
 
2.4.4.5.2 Intracellular proteins 
The supernatant was removed, centrifuged at 6000 xg for 15 minutes and discarded. 
The pelleted cells and T175 flask were frozen at -80°C. To lyse the cells and isolate the 
intracellular proteins the M-PER™ Mammalian Protein Extraction Reagent (Product No. 
7850) was used supplemented with Halt™ Protease Inhibitor Cocktail Kit (Product No. 
78410) according to the manufacturers’ instructions. In summary, the culture medium 
was removed from the adherent cells, and the cells washed with PBS. The appropriate 
amount of M-PER® reagent (Table 2. 28) was added and shaken gently for 5 minutes 
while on ice. The lysate was collected, transferred to a microcentrifuge tube and 
centrifuged at 14000 xg for 5-10 minutes to pellet the cell debris. The supernatant, 
containing the extracted protein was transferred to a new tube for further analysis. 
Table 2. 28. M-PER® reagent recommended quantities per sample volume. 
Plate Size/Surface Area Volume of M-PER® Reagent 
100 mm2 500-1,000 µl 
60 mm2 250-500 µl 
6-well plate 200-400 µl per well 
24-well plate 100-200 µl per well 
96-well plate 50-100 µl per well 
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2.4.4.6 Sonication and solubilisation of HEK cell-expressed proteins  
2.4.4.6.1 Cells lysis by sonication  
The previously frozen cell pellets were thawed on ice and re-suspended in 20 ml 
sonication/lysis buffer (below). Sonication was allowed to happen on ice with the Sonic 
Dismembrator, Ultrasonic Processor from Fisher Scientific. The total sonication time was 
1 minute 30 seconds and a temperature cut off of 15ºC was used. Cycles of 5 seconds 
pulse and 9.9 seconds rest with 40 % intensity were applied until the sample appeared 
homogeneous.   
 
2.4.4.6.2 Solubilisation 
Deoxycholic acid was added to 1 % (w/v) to the crude lysate and stirred for 1 hour at 
room temperature to break down the fat contents of the sample.  DNaseI was also added 
(200 µl of 28.4 U/ml) with additional stirring for 1 hour at room temperature or 4 hours at 
4ºC to eliminate the DNA content of the sample. 
Cellular debris was removed by centrifugation at 14000 xg for 20 minutes at 4ºC; the 
pellet was resuspended in 20 ml of sonication/lysis buffer and further stirred for 30 
minutes at room temperature. The lysed cells, were centrifuged at 14000 xg for 20 
minutes at 4ºC and the pellet was resuspended in 20 ml of solubilisation buffer, stirred 
overnight at 4ºC, centrifuged at 14000 xg for 20 minutes at 4ºC and the supernatant 
retained; this contained the solubilised protein.  
Table 2. 29. Sonication/lysis buffer and solubilisation buffer recipes. Filtration with a 0.45 
µm filtered is required before use. 
Sonication/lysis buffer Solubilisation Buffer 
50 mM Tris-HCl, pH 8.0         8 M urea 
1 M NaCl 130 mM NaCl 
1 mM EDTA 20 mM Tris, pH 8.6  
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2.4.5 Protein purification 
2.4.5.1 Affinity Purification using his-Spin Trap  
The solutions used for this purification were obtained from GE Healthcare (#11003400). 
Upon the collection and lysis of the expressing cells, 1.8 ml of supernatant containing 
the expressed proteins was collected. The samples were centrifuged for 10 minutes at 
13000 xg to remove any cells that had been carried through. Samples were loaded into 
the affinity columns 600 µl at the time and purified according to the manufacturer's 
instructions. Two elution steps were carried out for each sample and stored at 4ºC 
together with the used columns. 
 
2.4.5.2 Affinity Purification using AKTA start 
All solutions that were used on the AKTA Start were filtered with a 0.22 µm filter, as this 
reduces the risk of tubes clogging. The AKTA Start was set on a “Manual Run” and 
flushed through with water at 5 ml/min for 2 minutes. All lines were flushed with water. 
The column (1 ml hisTrap FF column (GE Healthcare Life Sciences, UK)) was 
connected, making sure no air bubbles were introduced to the system. To do this, first, 
the top of the column was connected and then the bottom, by clicking off and connecting 
to the system. The whole system was flushed with solution A at no more than 3 ml/min, 
then the “elution line” was flushed with solution B. The whole system was flushed a 
second time with solution A, avoiding the “elution line”. This step primes the system, 
reducing the risk of contamination. 
The filtered sample was loaded, allowed to flow through the column to bind and washed 
with at least 5 volumes of solution A to elute the non-binding proteins. A gradient of 0 – 
100 % solution B over 10 minutes was set, as the optimal imidazole concentration for 
elution of these proteins was unknown. The fractions collected were 1 ml each, and a 
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peak on the UV absorbance reflected the successful elution of the protein. The flow-
through was also kept to be analysed. 
Once the protein was eluted, the column was washed with solution A for 5 minutes and 
switched to solution B for a further 3 minutes to make sure everything was eluted. The 
AKTA Start and the column were cleaned thoroughly before storing by flushing filtered 
20 % ethanol through for 10 minutes. The AKTA Start was stored filled with 20 % ethanol. 
Table 2. 30. Binding buffer (solution A) and elution buffer (solution B) used with the Akta 
Start for protein purification. Solutions were filter sterilised using a 0.22 µm filter and 
stored at room temperature. 
Solution A Solution B 
50 mM Tris-HCL, pH 7.5   50 mM Tris-HCL, pH 7.5   
500 mM NaCl 500 mM NaCl 
20 mM Imidazole 500 mM Imidazole 
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2.5 Antibody purification techniques 
Antibody purification was carried out in three steps. First, the total IgGs in the serum 
were isolated by caprylic acid extraction. Secondly, specific IgGs were isolated by affinity 
purification. Lastly, the affinity-purified antibodies were desalted on a G25 column.   
 
2.5.1 Caprylic acid extraction 
Antisera from Sheep that had undergone an immunisation series of Kash5 protein was 
used as starting material. Two volumes of 60 mM sodium acetate, pH 4.0 (20 ml) were 
mixed with 10 ml of antisera. While stirring, 750 µl of 100 % caprylic acid was added 
(final concentration 2.5 %). The mixture was left stirring for 20-30 minutes (until it turned 
white) and centrifuged at 5100 xg for 15-20 minutes. The supernatant was transferred 
into a fresh tube and the total IgG present in the serum assessed by UV spectroscopy. 
 
2.5.2 Dialysis 
For 10 ml starting material, 20-25 cm of pre-boiled 18/32 inch diameter visking tubing 
(stored in 70 % ethanol) was rinsed well with distilled water.  One end of the tubing was 
tied off and the cleared supernatant pipetted through the other end, before securing the 
top. The tubing containing the IgG was placed into a 1 L 1 x PBS and stirred gently 
overnight at 4°C.  
The following day, the IgG concentration was evaluated using UV spectroscopy, and the 
sample was stored at - 20°C or taken for affinity purification. 
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2.5.3 Affinity column purification  
2.5.3.1 Column preparation 
The columns used contained peptides coupled to glass beads and were supplied with 
the synthesised peptide. Before first time use, the column was equilibrated with 1 x PBS 
and washed with 5 x bead volumes of guanidinium chloride (6 M), HCl (10 mM), ethanol 
(100 %) and 1 x PBS. This intensive cleaning procedure was also used if the column 
started to cause problems, such as failure of the IgG to bind to the column or overloading 
of the column, which produce an unusually large flow-through UV reading. Columns were 
stored at 4°C in PBS-azide (0.02 % sodium azide / 1 x PBS) and capped at both ends to 
avoid drying and inhibit bacterial growth.   
 
2.5.3.2 Antibody purification  
Either after preparing the column or after storage, the column was equilibrated by 
washing with 3 x column volumes of 1 x PBS. The IgG was allowed to flow down the 
column three times, and the column rinsed with 10 bead volumes of 1 x PBS, 0.5 M NaCl 
in 1 x PBS and 1 x PBS again.  
 
2.5.3.3 Antibody elution   
Potassium thiocyanate (3.5 M) was used to elute the bound IgG by adding 1 ml at the 
time to the column, directly into the beads, for a total of 6 ml. The eluted antibody, had 
to be immediately de-salted by passing it through a G-25 column. 
 
2.5.3.4 Cleaning the affinity column 
Following the antibody elution, the affinity column was washed with 10 x bead volumes 
of HCl (10 mM), 1 x PBS and stored at 4°C in 0.02 % PBS-azide 
  
77 
 
2.5.4 G-25 desalting column: 
The 1.5 x 75 cm G-25 column was stored in 0.02 % PBS-azide and had to be equilibrated 
by allowing at least 2 column volumes of 10 mM sodium bicarbonate to flow through 
before use. The eluted antibody was loaded onto the column at a flow rate of 2 ml/min, 
and washed with 10 mM sodium bicarbonate until a peak in UV absorbance was visible, 
which corresponds to the antibody being eluted. The column separates the IgG from the 
salt, allowing the IgG to come out first and the salt after. 8 ml fractions were collected 
and UV spectroscopy was used to measure the IgG concentration. Fractions that had a 
considerable amount of antibody were pooled and aliquoted at 100 mg per aliquot. These 
were snap frozen in liquid nitrogen and lyophilised overnight. The lyophilised antibody 
was stored at -20ºC until further use. 
The G-25 column was left to run the salt off, and rinsed with 5 bead volumes of 10 mM 
sodium bicarbonate before flushing with two bead volumes of 0.02 % PBS-azide and 
stored in this solution.  
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2.6 Embryological techniques 
2.6.1 Embryo micro-injections 
Fertilized Xenopus laevis embryos were obtained from the EXRC and allowed to turn. 
The animal pole migrating to the top indicates the fertilisation of the eggs. Embryos were 
de-jellied in 2 % cysteine in 0.1 x MBS at pH 8.0. Once de-jellied, the embryos were 
washed thoroughly 6 times with 1 x MBS. 
Embryos were transferred into 3 % ficoll in 1 x MBS and aligned with the animal pole 
facing up on a grid. The liquid was partially removed to avoid the embryos moving. 
Injected embryos were left in ficoll for 3-4 hours after injection and transferred to 0.1 x 
MBS before gastrulation. 
Injections were usually of 4 nl and a maximum of 400 – 600 ng of nucleic acid (RNA or 
DNA) per embryo. Amounts were altered by altering the injection time.   
For gene editing, the embryos were injected as soon as possible after fertilisation to 
maximise chances of cutting the DNA before replication starts. The more intact DNA 
molecules, the more mosaic the embryo will be.  
Table 2. 31. Barth-HEPES Saline (10 X) MBS (Modified Barth’s Saline). 
MBS  
88 mM NaCl  
1 mM KCl  
2.4 mM NaHCO3   
10 mM HEPES  
0.82 mM MgSO4 x 7H2O 
0.33 mM Ca(NO3)2 x 4H2O  
0.41 mM CaCl2 x 2H2O  
5 µg/ml Penicillin  
5 µg/ml Streptomycin  
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2.7 VHH libraries 
2.7.1 General considerations  
The general process of VHH library production involves the generation of antigen protein, 
its purification, and immunisation of a camelid (in our case Llama glama), followed by 
the VHH library generation and screening. It was only in 1998 that it was established that 
dromedaries and llamas can be easily immunised (Lauwereys, et al., 1998), and that it 
is feasible to vaccinate an animal simultaneously with a mixture of several antigens to 
raise an immune response to each antigen, making the whole procedure more cost-
effective and ethically preferable  (Lauwereys et al., 1998; Van Der Linden et al., 2000).  
There have been many studies to optimise the VHH library generation process over the 
years, some key points are mentioned bellow. 
It was established that 20-30 ml of blood (Muyldermans, 2001) of an immunised llama 
contains sufficient VHH expressing B cells to clone a diverse set of the affinity-matured 
nanobodies with high recognition specificity for their cognate antigen; others suggest that 
a 100 ml sample is needed (Pardon, et al., 2014). Also, it has been found that llamas 
can be re-used for different VHH discovery projects by respecting a grace period of at 
least 6 months (Pardon, et al., 2014). According to Muyldermans (Muyldermans, 2001), 
the whole process from llama immunisation to the cloning, selection, expression and 
identification of recombinant VHH antibodies is routinely performed in less than 3 
months. Muyldermand also stresses the advantages of working with libraries from llamas 
immunised with one or two immunogens, as the complexity of the library and the ability 
to screen those correlates to the number of immunogens used.  
The VHH libraries used in this study were a kind gift from Sergei Sokol’s Lab (Mount 
Sinai Medical Centre, New York, USA), where two llamas were immunised; one with a 
protein extract from gastrula-neurula stage embryos and the other with a combination of 
36 proteins obtained from 12 laboratories worldwide. I was involved in the 
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characterisation of the gastrula-neurula stage embryo protein library, and the making of 
the 36 protein library. 
 
2.7.2 Llama PBMC prep on 400 ml blood samples 
Leucosep tubes (Greiner Bio-one, 227290) were prepared by adding 15 ml of 
mammalian lympholyte (Tebu-bio, CL5120) per tube and centrifuged for 1 minute at 1000 
xg. The blood was mixed with an equal volume of sterile PBS, and 30 ml was gently 
layered onto each leucosep tube using a 25 ml graduated pipette. The tubes were 
centrifuged at 1500 xg for 30 minutes with the slowest acceleration and no brake applied 
for the slow-down. The buffy layer was carefully removed into previously aliquoted 25 ml 
of PBS per 100 ml whole blood equivalent.  The buffy layer/PBS mix was centrifuged at 
1500 xg to pellet cells for 20 minutes, supernatant was discarded and PBS added to re-
suspend and pool into a single tube. 10 ml of PBS were used in total. Total cell count 
was taken by mixing 10 µl of the cells with 90 µl of 0.4 % trypan blue and counting cells 
with a haemocytometer. 
The cells were pelleted by centrifugation at 1500 xg for 20 minutes, and re-suspended 
in 10 % freeze medium (FCS + 10 % DMSO) at 5 x 107 cells per ml. Lymphocytes were 
stored at -80ºC until further use.  
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2.7.3 Library Construction 
To construct the VHH library, previously described methods were followed (Ladenson, 
Crimmins, Landt, & Ladenson, 2006; Ryckaert, Pardon, Steyaert, & Callewaert, 2010; 
Sherwood & Hayhurst, 2012). In summary, lymphocytes were isolated from the blood 
and the RNA extracted before synthesising the cDNA to use as template on the nested 
PCR reactions that amplify the VHH. From the cDNA library, reactions were tested on a 
small scale to optimise conditions, then up scaled to generate the bacterial library. From 
the bacterial library, the phage library was generated and panned against target 
proteins/antigens of interest. Once these VHH were isolated, they were verified and 
some characterised. 
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2.7.4 Primer design 
To generate a VHH library, the VHH specific region was amplified by nested PCR. 
Several different methods of VHH amplification have been published, mainly based on a 
two-step nested PCR of the VHH cDNA sequence from B lymphocytes. The first set of 
primers amplifies the region of the second constant heavy-chain domain (CH2) that is 
conserved among all IgG isotypes of camelids; they anneal to the template strand of 
leader-signal sequences of camelid VH and VHH genes and to the coding strand of CH2-
sequence of camelid IgG (for example primers CALL001 and CALL002); whereas the 
second pair of primers anneals in a well-conserved region of the leader signal sequence 
of all V elements of family III, by far the most abundant V family in camelids (such as 
primers SM017 and SM018) (Pardon, et al., 2014). A list of the most commonly used 
primers to isolate the VHH specific coding region from llama serum is shown in Table 2. 
32. 
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Table 2. 32. Most commonly used primers to isolate the VHH specific coding region from 
llama serum.  
Name given Sequence Paper 
CALL001 5’ GTC CTG GCT GCT CTT CTA CAA GG 3’ 
(Rothbauer et al., 2006) 
CALL002 5’ GGT ACG TGC TGT TGA ACT GTT CC 3’ 
SM017 
5’ CCA GCC GGC CAT GGC TCA GGT GCA GCT 
GGT GGA GTC TGG 3’ 
SM018 
5’ CCA GCC GGC CAT GGC TGA TGT GCA GCT 
GGT GGA GTC TGG 3’ 
A4short 
5’ CAT GCC ATG ACT CGC GGC CAC GCC GGC 
CAT GGC 3’ 
Reverse 
Primer 38 
5’ GGA CTA GTG CGG CCG CTG GAG ACG GTG 
ACC TGG GT 3’ 
VHH-Back: 
5’ GAT GTG CAG CTG CAG GAG TCT GGR GGA 
GG 3’ 
 (Pardon, et al., 2014) 
VHH-For: 
5’ CTA GTG CGG CCG CTG GAG ACG GTG ACC 
TGG GT 3’ (R. Zhang & Shen, 2012) 
 
PMCF 
5’ CTA GTG CGG CCG CTG AGG AGA CGG TGA 
CCT GGG T 3’  
MP57 5’ TTA TGC TTC CGG CTC GTA TG 3’ (Hassanzadeh-ghassabeh, 
Saerens, & Muyldermans, 
2011) 
GIII 5’ CCA CAG ACA GCC CTC ATA G 3’ 
SHFmu 
5’ TCG CGG CCC AGC CGG CCA TGG CGC AGG 
TSM ARC TGC AGG AGT CWG G 3’ 
 
(Unger et al., 2015) 
SHRmu 
5’ ATG GTG ATG ATG ATT GTG CGG CCG CGC 
TGG GGT CTT CGC TGT GGT GCG 3’ 
 
LHFmu 
5’ TCG CGG CCC AGC CGG CCA TGG CCG ATG 
TGC AGC TGC AGG MGT CWG GRG GAGG 3’ 
LHRmu 
5’ ATG GTG ATG ATG ATG TGC GGC CGC TGG 
TTG TGG TTT TGG TGT CTT GGG 3’ 
H1R 5’ GTC CTG GCT GCT CTT CTA CAA GG 3’ 
(Yang et al., 2014) 
CH2D 5’ GGT ACG TGC TGT TGA ACT GTT CC 3’ 
H2s 
5’ GCC ATG GCT SAK GTB CAG CTG STG GAG 
TCT GG  3’ 
H3d 5’ GCG GCT GAG GAG ACG GTG ACC WGG 3’ 
VH2SfiI 
5’ ATT ACT GGC CCA GCC GGC CGG CTG AKG 
TBC AGC TGG TGG AGT CTG GRG GAG GCT 3’ 
VH3NotI 
5’ ATT ATT AGT GCG GCC GCT GAG GAG ACG 
GTG ACC WGG GTC C 3’ 
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Figure 2. 3. Nested primers to isolate the heavy chain only variable region from llama’s 
total cDNA by PCR. 
The 1st set of primers (shown in black) isolates the VH specific region, followed by the 2nd set of 
primers (shown in blue), which targets the VHH (VHH) specific region. Adapted from (Tanha, 
Dubuc, Hirama, Narang, & MacKenzie, 2002). 
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2.8 Bacterial library construction 
The cDNA made by RT of RNA isolated from lymphocytes, was subjected to nested PCR 
to amplify the VHH specific region. Upon the first amplification, the amplicons were 
separated by agarose gel electrophoresis and the correct size bands (heavy-chain only 
600 bp and conventional 800 bp) gel extracted with a Qiagen gel extraction kit.  
Once extracted, the purified amplicons were subjected to the second PCR and checked 
by gel electrophoresis. Pecan126, the vector of choice to construct the VHH library, was 
digested with NotI and SfiI and also checked by gel electrophoresis. 
Digested vector and PCR product of large-scale, second nested PCR were gel extracted 
and purified using standard methods. Ligations were carried out using T4 DNA Ligase at 
22°C for 20 hours. About 6 µg vector and 1.5 µg of the insert were required for a library 
of 2 x 109 colony forming units (cfu) using current methods.  The ligated material was 
ethanol precipitated, and the pellets were dissolved in 60 μl H2O. A total of 5 μg of ligation 
material were used for transformation. 
Electroporation was by a Gene Pulser (Bio-Rad, Bechhofer lab): 60 μl of ligated material 
and 270 μl of electrocompetent HVB88 cells were mixed, placed into 2 mm-gap cuvettes 
(BioRad or Bulldog Bio) and received a 2.5 kV pulse for 5.6 to 5.8 ms.  The samples were 
added to 2 ml of warm (37°C) SOB + 2 % glucose in a round bottom 15 ml tube and 
incubated on a platform shaker at 37°C for 1 hour.  The cultures were centrifuged at 
3000 rpm for 10 minutes.  The pellets were re-suspended in 500 μl SOB, 2 % glucose 
and each suspension was plated onto two 15 cm 2xYT, 2 % glucose plates 
(supplemented with 50 µg/ml ampicillin and 35 µg/ml chloramphenicol).  The plates were 
incubated at 37°C overnight, with resulting colony counts in the 1000000s. 
All colonies were collected from 74 15 cm plates with a scraper by adding 4 ml of 2xYT, 
2 % glucose medium. A total of 180 ml of bacterial suspension was collected in four 50 
ml conical tubes. The suspension was centrifuged at 3500 xg for 15 minutes to reduce 
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the volume to 70 ml after discarding part of the supernatant. An equal volume (70 ml) of 
ice-cold 30 % glycerol in terrific broth was added to the bacterial suspension and mixed 
well.  108 aliquots of 1.3 ml each were frozen on dry ice and stored at -80°C until needed.  
 
2.8.1 Phage library construction  
Phagemid library was made according to Sherwood and Hayhurst, 2012.  430 μl of the 
thawed bacterial library stock (see above) was placed into 500 ml 2xYT, 2 % glucose, 
supplemented with ampicillin and chloramphenicol with OD600 at 0.05, and cultured until 
OD600 of 0.44 (approx. 2 hours at 37°C). The helper phage M13K07 was added at 20 
MOI (multiplicity of infection) and incubated at 37°C for 30 minutes. The solution was 
shaken at 200 rpm for 30 minutes before the addition of arabinose (2 mg/ml final 
concentration), IPTG (10 μM final concentration) and Kanamycin (70 μg/ml final 
concentration).  The culture was incubated at 30°C for 22 hours, transferred into 16 round 
bottom 30 ml tubes (for high-speed centrifugation) and centrifuged at 7650 xg for 1 hour 
at 4°C. 500 ml of supernatant was collected and 100 ml 20 % PEG8000, 2.5 M NaCl was 
added and stirred at 4°C overnight.  500 ml of the phage preparation was centrifuged in 
twelve 50 ml conical tubes at 4080 xg for 1 hour at 4°C.  The pellets were re-suspended 
in 3.3 ml of PBS, 3.3 ml of glycerol were added and mixed well.  Phage aliquots of 500 
µl each were made in 13 tubes and stored at -80°C until further use. 
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2.8.2 VHH selection of affinity binders by phage display 
Adsorption immunoassay plates (96 wells in this case) were coated with 200 μl of 10 
μg/ml antigen in 1 x PBS overnight at 4ºC in a humidified container. The following 
morning, the lysate from the plates was collected and stored at 4°C for future use. The 
empty microtiter wells were washed by immersing the plate in a large container of wash 
buffer (1 x PBS with 0.05 % Tween™20) and agitated to release any bubbles in the wells.  
The plate was removed from the container, inverted and the contents flicked out by 
tapping into a paper towel. This process was repeated 3 times. The wells were blocked 
by adding 200 μl of 1 x blocking buffer (2 % non-fat dry milk in 1 x PBS), and incubated 
for 1–2 hours at room temperature. In a separate, pre-blocked microcentrifuge tube, the 
recombinant phage antibody supernatant was diluted with an equal volume of 1 x 
blocking buffer and incubated for 15–30 minutes at room temperature. The blocked wells 
were washed three times with PBS as previously described. 200 μl of the diluted 
recombinant phage antibody supernatant was added to each antigen-coated well; the 
plate was sealed and incubated for 1 hour with shaking at room temperature and 30 
minutes static at room temperature. The recombinant phage antibody supernatant was 
removed and stored at 4ºC for future use. The plate was washed to remove unbound 
phage. In the first panning, 10 washes with PBS were followed by 10 washes with 
PBSTw. For the second and successive pannings 20 washes with PBS and 20 washes 
with PBSTw were used. 
To elute the bound phage, 100 μl of 100 μM triethylamine was added to each well, the 
plate was covered with a sealer and incubated for 10 minutes at room temperature. 
Meanwhile, 1 M Tris-HCl, pH 7.5 was aliquoted out at 250 μl per centrifuge tube. Once 
unbound, 5 wells of phage were collected into one tube containing Tris to neutralise the 
eluate and stored at 4°C until further use. 
To infect the bacteria with the phage and propagate the phage, 100 μl of HBV88 cells 
were used to inoculate 50 ml 2xYT and incubated with shaking at 37°C for 2-3 hours, 
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until the OD600 of 0.4 - 0.8 was reached. These exponential phase HBV88 cells were 
aliquoted into 10 ml, 375 µl of the neutralised eluate were added to each 10 ml and mixed 
3 times upside down before being incubated statically at 37°C for 30 minutes.  
Following 30 minutes of infection, 100 μl of the cell suspension was removed for titration 
(-1), and the rest pelleted by centrifugation at 3000 rpm for 10 minutes. Cells were re-
suspended, spread onto 2xYT medium plates (2xYT, 2 % glucose, 50 µg/ml ampicillin 
and 35 µg/ml chloramphenicol) and incubated overnight at 37ºC. 
The following day, the plates were scraped with 3 ml 2xYT into Falcon tubes. 200 μl of 
this solution was diluted into 5 ml of 2xYT, OD600 measured, and sufficient culture was 
added to 40 ml pre-warmed 2xYT supplemented with 2 % glucose, ampicillin and 
tetracycline to OD600 of 0.1. The solution was stirred for 1 hour at 37°C, and helper phage 
was added to an moi of 20. For the helper phage to bind, the solution was stirred gently 
and left static at room temperature for 30 minutes. IPTG to final 10 μM, arabinose to final 
2 mg/ml and kanamycin to final 50 μg/ml were added and the solution stirred at 30ºC for 
at least 8 hours.  
Panning was normally done for 3-4 rounds with mixed populations of VHH expressing 
clones. If successful enrichment was noted, the colonies from the subsequent, purified 
phage were used for single VHH isolation. Therefore, during this incubation, the VHH 
sequence was passed from the bacteria to the phage. Either the culture was centrifuged 
and the supernatant tested by ELISA or it was mixed with 100 µL blocking buffer and 
repeat processes above.  
Essentially the same process was followed to purify nanobodies recognising embryo 
cytoskeleton except that instead of target protein being immobilised on a plate, the 
insoluble cytoskeleton was used as an “affinity bead” and the bound nanobodies were 
collected by centrifugation between washing steps. 
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The presence of VHH encoding sequences in the isolated phage was confirmed by 
digestion of isolated DNA with NdeI, which released the VHH encoding sequence. 
Subsequently, the VHH itself was detected by western blotting against the his-tag 
encoded with the VHH using standard techniques (Robinson and Guille, 1999). To test 
whether the nanobodies raised against cytoskeleton recognised a single protein in 
embryos these were tested in a western blot against 20 µl of embryo extract using the 
same technique.  
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2.9 Suppliers 
All consumables employed in this project were obtained from the following suppliers:  
Abcam (http://www.abcam.com/) 
Addgene (https://www.addgene.org/) 
Alpha Laboratories (https://www.alphalabs.co.uk/) 
Bio-Rad (http://www.bio-rad.com/) 
Fisher Scientific (https://www.fishersci.co.uk/) 
GE Healthcare (http://www3.gehealthcare.co.uk/) 
Gene Tools (http://www.gene-tools.com/) 
Grainer Bio-One (https://www.gbo.com/en_GB.html) 
NEB (https://www.neb.com/) 
Promega (https://www.promega.co.uk/) 
Polyplus (https://www.polyplus-transfection.com) 
Qiagen (https://www.qiagen.com/gb/) 
Roche (https://www.roche.co.uk/) 
Sigma Aldrich (https://www.sigmaaldrich.com/united-kingdom.html) 
Takara (www.takarabio.com) 
Thermo Fisher (http://www.thermofisher.com/uk/en/home.html) 
VWR (https://uk.vwr.com/store/)  
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3 Creation and characterization of complex 
libraries 
3.1 Introduction 
Technological advances and the acceleration of research output over the past decades, 
has enhanced the need for species-specific reagents. Techniques that were established, 
such as the use of mRNA assays to study gene expression and protein function, were 
called into question by the results from new generation experiments, such as the 
revelation of significant discrepancies between the mRNA and protein levels in the early 
Xenopus embryo (Peshkin et al., 2015). Some laboratories attempted, and some 
succeeded, in raising antibodies against Xenopus-specific proteins. For example, Prof 
Elizabeth Jones from the University of Warwick generated a variety of antibodies against 
kidney, nervous system and epidermal proteins (Kyuno, Massé, & Jones, 2008; Naylor 
et al., 2009). Professor James Maller from the University of Colorado raised antibodies 
against proteins involved in the regulation of the cell cycle (Eckerdt, Yamamoto, 
Lewellyn, & Maller, 2011). Prof Hugh Woodland, also from the University of Warwick, 
produced antibodies to aid the study of how the primordial germ cells come about and 
how they differentiate from cells that will become other types of cells, such as skin, 
muscle, nervous system and so on (Nijjar & Woodland, 2013).  
In 2003, an antibody was raised in sheep against recombinant xNAP1L (Abu-daya et al., 
2005; Steer et al., 2003). The xNAP1L antibody became popular due to its cross-
reactivity with the human version of the gene and aided studies of Emery-Dreifuss 
muscular dystrophy disease (EDMD1). This meant that what appeared to be a 
reasonable amount of the antibody obtained by immunizing a sheep, was quickly used 
up (Abu-Daya et al., 2005; Faunes et al., 2009; Friedeberg et al., 2006; Glanz, Bunse, 
Wimbert, Balczun, & Kück, 2006; Gong et al., 2014; Malartre, Short, & Sharpe, 2006; 
Melcon et al., 2006; Park & Luger, 2006; Puffenberger et al., 2004; Shintomi et al., 2005; 
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Vardabasso, Manganaro, Lusic, Marcello, & Giacca, 2008; Zlatanova, Seebart, & 
Tomschik, 2007).  Most of these antibodies have been raised either in sheep or rabbit, 
producing a limited quantity and once that stock is finished the antibody has to be raised 
again and entirely re-characterised. Only a small quantity, mainly from E. Jones’s 
collection, have been generated as hybridomas, which allows production of a specific 
antibody almost indefinitely.   
One of the remarkable advantages that llama single-chain antibodies have over 
conventional antibodies, apart from the ease of storage, their size and stability, is that all 
their coding region is encoded in a single exon, and therefore can be cloned into a vector 
and stored as a conventional plasmid indefinitely. These single-chain antibodies 
sequences are isolated from lymphocytes and amplified, before being cloned into a 
phagemid vector for phage display. This technique, first described in 1985 (Smith, 1985), 
allows a connection of the protein to the genetic information that encodes them. Bacteria 
carrying the phagemid vector with the sequence of interest are infected with helper 
phage, this allows the phage to be produced that express the gene inserted in the 
phagemid. The phage then displays the protein on its coat, making the protein 
accessible, these can be selected by binding assays. The selected phage, in turn can 
re-infect fresh bacteria and transfer back the genetic material. The discovery of this 
selection process allowed the generation of large protein libraries that could be screened 
and amplified, a process called in vitro selection. There have been studies that report 
the successful isolation of multiple VHHs from libraries generated by immunizing llamas 
with multiple antigens (Conway, Sherwood, Collazo, Garza, & Hayhurst, 2010; Harmsen 
et al., 2013). Therefore, the potential to raise multiple single-chain antibodies in a single 
llama was something the Xenopus community became very interested in.  
The need for a reliable and sustainable source of Xenopus-specific antibodies 
encouraged the scientific community that employs Xenopus as a model organism to join 
efforts. Twelve leading laboratories provided 36 purified proteins to immunise a Llama 
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glama in a project supervised by Dr Sokol at the Mount Sinai Hospital, USA. A second 
Llama glama was immunised at the same time with a pool of proteins extracted from 
Xenopus laevis embryos at the gastrula-neurula stage. The basics of this project were 
to test the feasibility of isolating VHHs from llamas immunised with multiple antigens.  
The opportunity arose to collaborate with the Sokol laboratory. Upon the immunisation 
of the llamas, a library with the isolated VHH fragments for the gastrula-neurula stage 
embryos proteins was constructed, and we collaborated in the screening of this library. 
The blood from the llama immunised with the 36 purified proteins was collected, and we 
collaborated with the construction and further screening of this library.  
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3.2 Results 
3.2.1 Bacterial library construction 
Two llamas had previously been immunised, one with a cocktail of 36 purified proteins 
and the other with embryo lysate from mixed gastrula-neurula stage embryos (see 2.7.2). 
The llama’s blood was collected, lymphocytes were isolated and cDNA generated. The 
cDNA was used as a template to isolate the VHH specific region by nested PCR (see 
2.7.3). Appropriate amplicons were gel purified and checked by a second gel 
electrophoresis (see 2.7.2). The vector used to construct the library (pecan126) was 
digested with NcoI and SfiI, gel extracted and purified (MinElute Gel Extraction Kit, 
Qiagen).   
The digested pecan126 vector and amplicons from the nested PCR had their purity and 
concentration confirmed via gel electrophoresis before ligation (Figure 3.1 shows the 
library components for the 36 protein immunization). Pecan126 digestion #2 and a 
mixture of the PCR products were ligated to generate the VHH library (see 2.1.1.1).  
Ligation and electroporation into HBV88 cells yielded a library with an estimated total of 
108 colonies and with a transformation efficiency of 2x106/μg for the ligated material.  All 
colonies were collected from 74 15 cm plates with a scraper by adding glucose medium 
to each plate. 
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Figure 3. 1. Purity and concentration confirmation via gel electrophoresis of library 
elements before ligation. 
In order to prepare a phagemid library from the lymphocytes obtained from the llama immunized 
with 36 proteins, nested PCR was used to amplify the VHH encoding DNA. The vector pecan126 
was double digested with NcoI and SfiI and recovered in higher concentration in reaction # 2, thus 
this was used further. The large-scale nested PCR products were pooled, before ligating into the 
pecan126 vector.   
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3.2.2 Isolation and characterisation of individual VHHs 
VHH libraries can be screened for the presence of antigen-specific binders, either by 
panning or by direct colony screening (Riechmann & Muyldermans, 1999). The B-cells 
expressing antigen-specific VHH circulating in the blood of an immunised dromedary can 
quickly reach 1 % of the total B cell population. Therefore, the direct testing of 1000 
individual clones of the VHH library is expected to yield perhaps 10 antigen binders 
(Muyldermans, 2001). Colony screening with labelled antigen, as performed in the late 
1980s (Huse et al., 1989), or screening of the induced cultures by ELISA is indeed 
feasible for the VHH libraries (De Meyer, et al., 2014). However, retrieving the binders 
by panning is to be preferred to the screening of individual colonies, because the panning 
will also select for those binders with the highest affinities and those that express better 
in bacteria. VHHs can be selected through panning of phage particles on immobilised 
antigen (Pardon, et al., 2014). A pH shock eluted antigen bound phage particles and 
these were regrown through infection of bacteria (Hoogenboom et al., 1991; 
Muyldermans, 2001). Specific adsorption onto the solid surface of an ELISA plate is still 
the most common way to immobilise targets for selection by phage display (Pardon, et 
al., 2014) and this is what was used (see 2.8.2). 
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3.2.3 Screening libraries for the presence of VHHs 
It is recommended in the literature to try different capturing or immobilisation methods 
when screening libraries for VHHs (Pardon et al., 2014). For example to vary the antigen 
concentration, use different detergents or ligands, try different washing and incubation 
buffers or to use different elution methods.  
Two methods of immobilisation were tested in this part of the project. One method 
involved protein coated ELISA plates which allowed the selection of VHHs against 
individual antigens (see 2.8.2). After 3 rounds of panning, the VHHs were expressed, 
then DNA from colonies was prepared and analysed. The results obtained showed that 
after 3 selection rounds a considerable proportion of clones carry the correct size insert 
and express VHHs upon induction. An average of 70 % of the clones were positive in 
our hands, although Figure 3.2 A shows more. Colonies carrying the positive clones were 
picked from the master plate and used to express the VHHs in the bacterial periplasm 
as described in the methods section (see 2.3.2). The positive, expressed VHHs were 
tested via western blot (see 2.4.2) as VHHs made for this study are all his-tagged (Figure 
3.2 B and D) and all of these showed expression of the correct sized protein (VHH + his).   
The second method tested is aimed at situations when specific antigens are unavailable, 
and a more generic immunogen can be used. A total lysate of gastrula and neurula 
embryos was used to immunize a llama, resulting in a library containing a mixture of 
VHHs recognising all proteins present in the embryos at this developmental time point. 
To select for VHHs recognising cytoskeletal proteins, a mainly insoluble cytoskeleton 
preparation was used as the immobilized surface. VHHs were allowed to bind to the 
insoluble cytoskeleton, collected by centrifugation and unbound material was washed 
off, this process was repeated four times. To elute the bound phage, triethylamine was 
added to the cytoskeleton pellet, incubated and centrifuged. To test whether specific 
VHHs had been purified, a total embryo lysate was separated by SDS-PAGE and the 
VHH was in turn used as primary antibody in the western blot (see 2.4.2), followed by 
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the α-his antibody used for detection (Figure 3.2 C). These western blots displayed a 
uniform signal in all lanes at 30 kDa, which was found to be a false positive when further 
analysed. 
These multi-antigen libraries yielded a vast number of VHHs. While screening for VHH 
clones both at the DNA or protein level, many positive results were obtained among the 
hundreds tested (above). However, the complexity of these libraries made it very difficult 
to find a target protein-specific VHH. Multiple tests against Xenopus embryo lysates (see 
2.4.1) at a variety of developmental stages were carried out as western blots (over 30 in 
total), as well as ELISA tests (over 15) on purified proteins, all being negative (data not 
shown). These results together with the number of articles describing the use of a single 
antigen for immunization, contributed to the decision to immunise llamas with single 
antigens.  
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Figure 3. 2. Screening libraries for the presence of VHHs. 
The library made from the llama injected with 36 proteins, was used to prepare VHH DNA from 
separate colonies. DNA from these colonies was digested with NdeI producing a band migrating 
at 1.7 kb, which indicates the presence of VHH (A). Colonies that showed positive for VHH DNA 
were induced to produce periplasmic VHHs, which were then purified. These VHHs contain a his-
tag and were detected by western blotting with α-his antibody (B). A VHH raised against mixed 
gastrula-neurula protein extract was purified by affinity binding to Xenopus cytoskeletal proteins 
in collaboration with Keiji Itho (C). Its specificity was tested by western blotting against Xenopus 
embryo proteins: 1) total protein stage 11; 2) total protein stage 15; 3) cytoskeletal protein. 
Schematic representation of VHH detection by western blot (D). Periplasmically expressed VHHs 
were run on SDS-PAGE, transferred into a nitrocellulose membrane and incubated with α-his 
antibody followed by α-mouse IgG- HRP conjugated secondary antibody and chemiluminecence 
detection.   
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3.3 Llama immunisation with single antigens 
The libraries created in the USA by the Sokol lab produced libraries that were too 
complex for successful screening. In 2015, a scientific paper reported the use of a VHH 
to inhibit β-catenin-mediated Wnt signalling (Newnham et al., 2015). These VHHs were 
produced at the Centre for Dairy Research (CEDAR, University of Reading). Laura 
Newnham introduced us to the farm procedures and provided us with a sample from the 
published β-catenin VHH and its mutated control (used as proof of principle in chapter 
6).  
Two llamas were obtained in December 2015, held and maintained by CEDAR. These 
animals had a period of adaptation of 6 months. One of the dairy cows from the farm 
contracted tuberculosis (TB), thus the farm was unable to conduct experiments until all 
the animals were tested and showed results clear of TB. This period extended for 20 
months. In August 2017 the llamas, Sunny and Valentine, were immunised, one with a 
long peptide and the other with an octomeric MAP respectively (Table 5.1 and Table 
5.2).    
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3.3.1 Lymphocyte isolation  
Leucosep tubes were used to isolate the lymphocytes (see 2.7.2) and the resulting cells 
were counted in a haemocytometer.  The yields were within the expected range.  
  a. Sunny:  3.4x107 total lymphocytes (1 aliquot of 680 µl) 
  b. Valentine: 5.9x107 total lymphocytes (2 aliquots of 590 µl) 
The cells were pelleted by centrifugation and re-suspended in 10 % freeze medium at 5 
x 107 cells per ml. Eppendorf tubes containing the lymphocytes were stored at -80ºC until 
RNA can be made from them.   
 
3.3.2 Testing for an immune response in llama serum 
In order to discover whether the llamas had produced antibodies against Cdk1 and Ascl1, 
western blotting (see 2.4.2) was performed comparing the pre-immune and immune sera 
on extracts from embryos overexpressing Cdk1 or Ascl1. Additional proteins of the 
expected size were detected by the appropriate sera (Figure 3.3) strongly suggesting 
that there has been an immune response to the immunogens (Figure 5.2).  
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3.4 Discussion 
The construction and characterisation of the VHH libraries created by the Sokol 
laboratory in the USA provided us with the knowledge and starting materials needed to 
transfer those techniques to Portsmouth.  
VHHs from these libraries were selected by panning against embryonic cytoskeleton or 
immobilised proteins, and their DNA and expressed periplasmic proteins tested. While 
in Sokol’s lab, the worked focused on the library generated against the gastrula-neurula 
stage embryonic protein extract from which many VHH expressing clones were isolated. 
However, they all bind yolk proteins (Itoh & Sokol, 2014). The fact that all VHHs isolated 
and tested from this library recognise the same embryonic yolk protein highlights the 
need for pure proteins and single or a reduced number of immunogens per animal.  
Once in Portsmouth, the library from 36 purified proteins was created and screened 
against two of its immunogens, Liz1 and Ndel1. These antigens were supplied to the 
Sokol lab by Prof Anna Philpott and Prof Viki Allan, who kindly donated these proteins to 
us.  
We were able to isolate clones containing VHH sequences, confirmed by their size when 
digested with specific enzymes, and the proteins produced were positive on α-his 
western blots. However, these did not recognise any Xenopus proteins, despite having 
selected them against immobilized Xenopus proteins, suggesting two possibilities. First, 
that the selection method was ineffective, and second, that the immunogens had not 
been checked for purity. The immunogens could have carried contaminating bacterial 
proteins which would generate a far greater immune response than the proteins from 
Xenopus, which, as a vertebrate, is much more closely related to llama.  The level of 
complexity of this library will therefore be very extensive and most likely be dominated 
by the response to the bacterial proteins (Leenaars & Hendriksen, 2005). This made the 
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purity of the immunogen, in our experience, one of the most important points to consider 
when raising these types of antibodies.    
These two libraries can be compared, as it is likely that yolk proteins are either at higher 
concentrations or have greater immunogenicity levels than other proteins in the gastrula-
neurula lysate, supposedly a mixture of all proteins present in that developmental time 
point in the embryo. Yolk dominance stopped any antibody against the target proteins 
being isolated. This is similar to the lack of useful antibodies being present in the 36 
antigens library, which was most likely caused by E. coli contaminants dominating the 
immune response. The antigens used in this study were provided by 12 different 
laboratories, raised and purified in different ways (likely E. coli expressed) and were not 
checked inhouse before administration to the llama. Therefore, the fact that there were 
no Xenopus proteins detected when testing the complex, 36 protein library is not 
surprising. Based on this experience, I recommend that bacterially produced proteins are 
not used for llama immunization. By this time, the knowledge about the difficulties 
encountered when screening VHH libraries created with multiple antigens was coming 
to light. It was then that the decision to immunise llamas in the UK was made.  
Serum from the immunised llamas was collected and tested for its response which was 
positive. To complete this work which was delayed for 18 months by the TB infection, 
libraries will be made from the isolated lymphocytes and VHHs against Ascl1 and Cdk1 
selected. 
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4 Expression of Xenopus transcription 
factors to be used as antigens for 
immunisation and tools for VHH 
purification 
4.1 Introduction 
Understanding the genetic regulatory networks involved in development and diseases 
requires, among other things, antibodies to transcription factors (TFs) for both system-
wide and focused studies; this works well with the rapid and powerful gain and loss of 
function experiments possible in Xenopus (Grainger, 2012). The experience gained 
while working on the complex libraries described in Chapter 3, drove us to avoid bacterial 
expression and to look for highly purified proteins to use as antigens for llama 
immunization. In this chapter, we explore two methods of protein expression, a 
commercial in vitro kit and a cell culture method employing Human Embryonic Kidney 
cells. This was to understand how successful these approaches were likely to be on a 
larger scale, and to test the process of nanobody production and purification with a 
subset of these proteins.  
The first step in raising antibodies in any host is to obtain purified protein in sufficient 
quantities for the immunisation of the host; Muyldermans et al. (2001) suggested that 
around 100 µg are needed for VHH raising and purification in Llama glama. However, 
an updated protocol from UCB (Newnham et al., 2015) suggests 500 µg per injection, 
thus, at least 2.5 mg per immunogen for 5 injections. 
Antibodies are proteins that are produced by the body as an immune response to a 
specific antigen, which can be an alien protein (Janeway, 2001). Xenopus proteins, either 
expressed endogenously or in other organisms, can be used to immunise llamas, 
generate an immune response, and so antibodies specific to the injected protein can be 
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isolated from the llama’s serum. We have identified that obtaining purified proteins is the 
major bottleneck in the antibody production process. 
Expression systems are organisms or cell extracts in which a genetically engineered 
protein is produced. For protein expression, one of the most commonly used expression 
systems is bacterial cells. These are transformed with a plasmid containing the desired 
protein’s coding nucleotide sequence that can be fused to other proteins for selection, 
expression enhancement or as a supplement to aid the protein in folding, purification and 
visualisation. A concise review of the type of bacterial cells used to express proteins was 
given by Gomes et al. (Gomes, Byregowda, Veeregowda, & Balamurugan, 2016). The 
main disadvantage with proteins generated in this manner for us is the potential 
immunogenicity that any carry-over of bacterial proteins could have on a mammalian 
host, since they will be recognised strongly as non-self by mammals (Leenaars & 
Hendriksen, 2005).  
A different approach was considered, which consisted of the expression of proteins in 
vitro. Many companies offer kits which contain a biomolecular translation machinery 
extracted from cells, together with specially modified vectors and customised reagents 
to aid the cloning, transformation, transcription and later translation of the protein. This 
process is also called cell-free protein expression, as the proteins are produced in the 
absence of the cell itself. There have been multiple reviews of these processes in recent 
years (Carlson, Gan, Hodgman, & Jewet, 2014; Chong, 2008; Zemella, Thoring, 
Hoffmeister, & Kubick, 2015). 
As a cellular alternative, HEK293T cells, a kind gift from Simon Kolstoe, were used for 
transient transfection of recombinant proteins. This method, combined with the design 
and cloning of the protein sequence into the delivery vector via In-Fusion, has been well 
established by the Oxford Protein Production Facility (OPPF) and transferred to 
Portsmouth via Jonathan Chamberlain (Nettleship et al., 2015). The vectors used in this 
study derive from a single ancestor pTriEx2 (Novagen), which was modified to produce 
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pOPINE, the first vector of the pOPIN series. From the pOPINE vector, OPPF has 
developed a library of vectors for protein expression with multiple qualities such as inter-
host vectors, vectors with secretion signals and a wide variety of tags (Berrow et al., 
2007; Nettleship et al., 2008).  
Cdknx (also known as p27Xic-1) and Neurog2 proteins were chosen as targets for in 
vitro expression, due to their popularity within the community. These are two key 
developmental proteins involved in neural differentiation (Vernon & Philpott, 2003), cell 
cycle control and neurogenesis (Movassagh & Philpott, 2008; Nguyen et al., 2006; 
Vernon et al., 2006). Mechanisms by which these proteins regulate the cell cycle are 
widely studied with Xenopus oocytes and egg extract systems (Maller, 2012; Ryffel et 
al., 2003). In situ hybridization of the mRNA has led to the visualization of the mRNA 
expression in the embryo, however visualization of the protein has not been reported 
(Bao, Talmage, Role, & Gautier, 2000; Nishitani et al., 2015; Sabherwal et al., 2009; 
Schlosser et al., 2008; Vernon & Philpott, 2003).  
For the protein expression in HEK cells, multiple proteins were studied. These were also 
chosen by request from the community and the approach involved discarding targets 
that presented difficulties, and carrying on with the ones that worked. The idea was to 
test whether the approach could work, then to focus on troubleshooting.  
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4.2 Results 
Xenopus laevis being allotetraploid, carries duplicates of many of its genes (Session et 
al., 2016). They are referred as the S and L versions. Careful study of the target 
sequences was carried out prior to designing the experiments. Examples of these 
approaches are given through the thesis for a few of these targets.  
 
4.2.1 Neurog2 
Using Xenbase (James-Zorn, et al., 2013), the RNA-seq data of both Xenopus laevis L 
and Xenopus laevis S homeologues were compared to find out which gene pair had less 
mRNA expression from oocyte to pre-MBT embryo stages. By choosing the homeologue 
with less or no mRNA expression at this point, the maternal contribution to the later 
embryo was minimised. Early mRNA expression might make interpreting protein 
expression data from the antibody difficult, therefore misleading our judgment of antibody 
quality. This is due to maternally derived mRNAs having been able to express the protein 
in multiple sites of the embryo at different stages unrelated to mRNA expression at the 
tested stage (Wuhr, et al., 2014). The Xenopus laevis S Neurog2 homeologue has higher 
mRNA levels at the egg stage (Figure 4. 1); therefore the Xenopus laevis L sequence 
was chosen to work with. 
The mRNA RefSeq found in Xenbase was used to identify the coding sequence (CDS 
from nucleotides 357-1001), and its translation was checked against the Human genome 
to make sure it encoded the target protein using NCBI’s BLAST (Madden, 2002). To sub-
clone this sequence into the expression vector, NdeI and NotI would be used, so the 
sequence was checked for lack of those sites using the APE program 
(http://biologylabs.utah.edu/jorgensen/wayned/ape/). 
The primers used to amplify the target sequence needed to be designed so the enzyme 
sites used to cut the PCR fragment were in frame (NdeI and SalI), therefore resulting in 
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a maintained open reading frame when ligated into the expression vector. To design the 
forwards primer 20 bases from the Xenopus laevis L RefSeq sequence were selected 
starting at position 357, and the NdeI enzyme sequence was added at the 5’ end:  
5’ cat atg atg gtg ctg ctc aag tgc g 3’.  
For the reverse primer, 20 bases were selected from the Xenopus laevis L RefSeq 
sequence starting at nucleotide 1001. The sequence TGA was left out, as this is a stop 
codon and the ribosome needed to carry on reading past this site to make the protein as 
a GST fusion, which is the approach used in this kit. The primer was composed of the 
complementary sequence of these 20 base pairs plus the SalI sequence:  
5’ gtc gac aat gaa agc gct gct ggc ag 3’. 
 
4.2.2 Cdknx  
The process to generate an insert with the correct primers for Neurog2 was repeated 
with Cdknx (Figure 4. 2). In this case, both homeologues were expressed identically at 
early stages, but there is no information in Xenbase other than the genomic sequence 
and the RNA-seq data for the S homeologue. We therefore chose to work with cdknx L. 
From Xenbase’s Ref-seq, we identified CDS nucleotides 23-652 as the coding sequence. 
The sequence’s translation was corroborated as previously described and primers were 
generated in the same manner:   
Cdknx forwards (NdeI):  5’ cat atg atg gct gct ttc cac atc gc 3’ 
Cdknx reverse (SalI):   5’ gtc gac tcg aat ctt ttt cct ggg gg 3’ 
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Figure 4. 1. Neurog2 Xenopus laevis L (green) and Xenopus laevis S (purple) RNA-seq 
profiles by development stages. 
Note in Xenopus laevis S there is expression in the oocyte, egg and gastrula stages, dropping 
considerably after MBT, which indicates maternally-derived expression. 
 
Figure 4. 2. RNA-seq profile for Xenopus laevis cdknx by developmental stages. 
RNA-seq data indicates expression in the blastula and gastrula stages probably reflecting some 
maternal imput, sequences are available only for the L version of this gene. 
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4.2.3 In vitro protein expression of neurog2 and cdknx ORFs 
Target proteins were chosen from a list of genes suggested by the community. To 
express Cdknx and Neurog2, a commercial, coupled in vitro transcription-translation 
system was tested (see 2.1.9, 2.4.3). The reaction was based on HeLa cells lysate and 
reported to yield 100 µg/ml of protein per reaction (reactions being of 25 µl each). Cdknx 
(630 bp; 210 AAs; 25.2 kDa) and neurog2 (645 bp; 215 AAs; 25.2 kDa) ORFs were sub-
cloned into pT7CFE1-cGST-HA-his (Figure 4. 3 and Figure 4. 4), a plasmid supplied with 
the kit. This allowed the expression of the protein as a GST fusion containing HA and 
his-tags for ease of purification and detection of the produced protein.  
Plasmids containing the complete coding region for the proteins were sourced from the 
EXRC plasmid collection and the target sequence amplified by PCR. These single bands 
were cloned into pCR2.1-TOPO and colonies were screened. Two preps for each gene 
were sent for sequencing to corroborate the results; one neurog2 clone showed the 
correct sequence but cdknx did not. A new cdknx template was obtained. PCR 
amplification products (see 2.1.9.2) were ligated into 2 vectors, pGemTeasy and Topo 
pCR4.0, since this was a time-sensitive project and the efficiency of cloning into different 
vectors varies (see 2.1.3, 2.1.4). DNA from three out of 16 colonies had the correct size 
insert and sequence. Cdknx in pGemTeasy, neurog2 in pCR2.1 and the commercial 
destination vector pT7CFE1-CGST-HA-his were double digested with NdeI and SalI and 
the appropriate ligation performed (see 2.1.9.4). The successful insertions were 
assessed by double digestion (see 2.1.1) of mini preps with SalI and NdelI. Two out of 
33 final clones had the correct insert, confirmed by sequencing before use. 
 
 
 
  
111 
 
Figure 4. 3. Protein expression via the human in vitro transcription – translation kit based 
on HeLa cell extracts (Pierce 1-Step Human Coupled IVT Kit – DNA). 
Target sequences were amplified by PCR with primers containing SalI and NdeI sites, sub-cloned 
into pGemTeasy and digested with the mentioned enzymes. These fragments were cloned into 
the pre-linearized pT7CF1-CGST-HA-his vector. Proteins were expressed following 
manufacturer’s instructions and purified by his-trap chromatography columns. 
 
 
 
  
112 
 
 
Figure 4. 4. pT7CFE1-CGST-HA-his vector map. 
Target sequences were cloned into the pre-digested vector at the NdeI and SalI sites, to obtain 
GST-HA-6his tagged proteins. 
 
  
  
113 
 
4.2.3.1 In vitro Cdknx and Neurog2 protein expression   
Proteins were expressed in vitro using the 1-step human high yield mini IVT kit following 
the manufacturer’s instructions. Expressed proteins were analysed via Coomassie blue 
stained SDS-PAGE (Figure 4.5 A; see 2.4.2.1). The SDS-PAGE confirmed that the gel 
had run nicely, but that insufficient exogenous protein was expressed to be detected 
against the endogenous HeLa proteins from the lysate. 
The produced proteins were purified by affinity chromatography using his-trap columns 
(see 2.4.5.1) and analysed by western blot (Figure 4. 5 B; see 2.4.2). The targets were 
identified as a single band very close to the expected band of 51 kDa (arrowed), showing 
that they have been expressed. The yield was quantified using the bicinchoninic acid 
assay (BCA assay) following the manufacturers’ instructions and showed that only 0.005 
mg of each protein was produced (1/5 of the maximum reported yield). The reaction cost 
(£400 per reaction), and the lower than expected yield showed this approach was not a 
time or cost effective production method, since it had already been optimised by the 
manufacturer but did not allow us to make close to the 2.5 mg needed to immunize a 
llama. Therefore, alternative methods of protein production had to be considered. 
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Figure 4. 5. Cdknx and Neurog2 proteins expressed in vitro via the high yield IVT kit. 
Proteins were expressed in HeLa lysate, purified by Ni column and eluted in 3 steps (1-3 above). 
The proteins were separated by SDS-PAGE and visualized by western blot using α-his antibody. 
A constant band can be observed at 49 kDa in elution 1 and 2 for both proteins, this is very close 
to the expected size of 51 kDa of the GST fusion protein. The third elution from the NI column for 
both protein is close to null, insinuating that all (or most) of the protein was eluted in steps 1 and 
2. 
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4.2.4 HEK cell expression of target proteins 
Protein expression via mammalian cell lines allows the production of proteins with 
relatively low background immunogenicity from contaminants when it comes to their use 
as antigens in mammals, compared to proteins produced in non-mammal mediums. 
There are a variety of cell lines that can be used as a “machinery” to express proteins, 
such as Lung carcinoma (A549),  Glioblastoma (GAMG), Embryonic kidney cells 
(HEK293T) and Cervical carcinoma (Hela) among others (Bandaranayake & Almo, 2014; 
Geiger, Wehner, Schaab, Cox, & Mann, 2012). 
The Oxford Protein Production Facility (OPPF, (“OPPF-UK: Home,” n.d.)) has developed 
a standardised method which allows optimisation for producing a wide range of proteins 
based on Human Embryonic Kidney cells (HEK cells) and other platforms (see 2.4.4). 
They have developed a system which exploits the In-fusion cloning system provided by 
Takara (www.takarabio.com) and developed an innovative plasmid collection (the pOPIN 
vectors) with unique enzyme combinations that allow the cloning of the insert of interest 
with high success rates and can be used for expression in multiple systems. pOPIN 
destination vectors were successfully transformed, grown, digested and gel purified 
(MinElute Gel Extraction Kit, Qiagen) for subsequent cloning. 
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4.2.4.1 Isolation and cloning of target sequences 
Vector plasmids were a gift from Ray Owens (OPPF) through Addgene (pOPINE 
(Plasmid #26043); pOPINF (Plasmid #26042); pOPINM (Plasmid #26044); pOPINJ 
(Plasmid #26045)). The following plasmids were a direct donation from Ray Owens: 
pOPINTTGneo, pOPINE-StrepII, pOPINGM, pOPINFS, pOPINE-Flag3. (Berrow et al., 
2007). In Table 4. 1 are the cloning sites and product tags for each vector according to 
OPPF. 
Plasmids were digested (see 2.1.1) according to the linearization sites recommended by 
OPPF (https://www.oppf.rc-harwell.ac.uk/OPPF/protocols/cloning.jsp) 
Table 4. 1. OPPF vectors used to express proteins in HEK cells, their recommended 
cloning sites and expected products.  
Taken from https://www.oppf.rc-harwell.ac.uk/OPPF/protocols/cloning.jsp or given by Ray Owens 
(personal communications). 
Vector Cloning sites Product  
pOPINE  NcoI - PmeI POI-KHIS6 
pOPINF  KpnI - HindIII HIS6-3C-POI 
pOPINM  KpnI - HindIII HIS6-MBP-3C-POI 
pOPINJ  KpnI - HindIII HIS6-GST-3C-POI 
pOPINTTGneo KpnI - PmeI SS[RPTPmu]-POI-KHIS6 
pOPINE-StrepII NcoI - PmeI HIS6- StrepII -3C-POI 
pOPINGM KpnI - PmeI SS[MBP]-POI-KHIS6 
pOPINFS KpnI - NheI HIS6-3C-POI-StrepII 
pOPINE-Flag3 NcoI - PmeI HIS6- Flag3-3C-POI 
 
The inserts of interest were obtained by PCR amplification (see 2.1.6) of the target 
sequences from plasmid templates (supplied by the EXRC) with specific primers. These 
primers contained a region homologous to the pOPIN destination vector of choice to 
enable the In-Fusion reaction (see 2.1.10.7). A full table with the primers used in this 
study can be seen in Appendix I. Fli1, gata2, hairyI and neurog2 sequences were 
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targeted by PCR. The fli1 expected sequence was not amplified; the amplicon produced 
was considerably larger than expected, and an alternative donor plasmid was used as 
template (Figure 4. 6 A) providing with the correct size amplicon. gata2, hairyI and 
neurog2 were amplified from sequenced plasmids and the products contained a mixture 
of bands of different sizes. Gata2 exhibited a smear suggesting two possible reasons; 
contamination of the template, or insufficient extension time, giving products of slightly 
different sizes. The extension time for gata2 amplification was increased from 1.15 
minutes to 2 minutes due to its length; this allowed the positive amplification of the gene. 
The gata2 amplicon was gel purified using Quiaquick gel extraction kit.  HairyI and 
neurog2 were subjected to PCR (see 2.1.6) with a temperature gradient for the annealing 
step to find the optimal temperature to favour the amplification of a single amplicon. 
HairyI with pOPINE and pOPINF primers were successfully amplified while neurog2 was 
not. An alternative PCR master mix was also tested with a wider temperature gradient 
range with no success.  PCR reactions for lisI, cdknx, ndelI, deltaI, talI, mytI, neuroD-
short, ndelI-short, fliI-short, gata2-short, hairyI-short and ncor2 with pOPINE and 
pOPINF specific primers were set up at this point (data not shown). Optimization was 
required to amplify gata2-Short, myt1, and talI. The optimisation of these PCR reactions 
yielded correct amplicons for the following inserts:  
 deltaI-pOPINE 
 cdknx-pOPINE 
 ncor2  -pOPINE 
 gata2-pOPINE 
 gata2-pOPINF 
 neuroD-Short-pOPINE 
 neuroD-Short-pOPINF 
 fliI-Short-pOPINE 
 fliI-Short-pOPINF 
 hairyI-Short-pOPINE 
 hairyI-Short-pOPINF 
 mytI-pOPINE 
 mytI-pOPINF
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These PCR products were treated with DpnI (see 2.1.10.5) which cut any carry through 
plasmid and then subjected to a Cloning Enhancer treatment (see 2.1.10.6) as detailed 
in the In Fusion protocol. Transfection of these constructs into HEK cells is detailed later 
in this chapter. 
Upon receiving a different vector, pOPINTTGneo (a kind gift from Ray Owens), more 
primers were designed (Appendix I), and PCR amplification of the insert sequences was 
attempted. J-line Xenopus cDNA was generated (see 2.1.8) and used as starting 
material for some of the reactions (Table 4. 2) since no amplification was obtained from 
plasmids containing the inserts. PCR optimisation was attempted for the cdkI, fliI and talI 
clones without success (data not shown). Positive amplicons were cloned into 
pOPINTTGneo, sequenced and used for transfection (see 2.4.4). The unsuccessful 
cloning procedures were not investigated, as we used a drop-out strategy in which we 
carried on working with the targets that worked, the rest were left behind. 
For cdkI, a different set of primers was designed, aiming to reduce the difference in 
annealing temperature between the primers, and so aid amplification. These primers 
were tested in 2 different donor plasmids; both gave good amplification with the correct 
size bands, 303 bp for the N-terminal and C-terminal regions, and 906 bp for the full-
length version (Figure 4. 6 B). 
  
  
119 
 
 
Figure 4. 6. PCR amplification of inserts to clone into pOPIN vectors by in-fusion. 
Inserts for cloning into the pOPIN vectors were prepared using standard conditions (methods) 
and separated by gel electrophoresis. fliI (1362 bp) 2nd amplification with pOPINE (1) and 
pOPINF (2) primers (A). cdkI PCR product to be cloned into pOPINTTGneo vector successfully 
amplified as C-terminal, N-terminal and full-length coding region (B). 
 
 
  
  
120 
 
Table 4. 2. PCR amplification of target genes to be cloned into pOPINTTGneo vector, 
stating template used, primer, amplicon size and success in amplification and sub-cloning.  
Template PCR primers Expected size 
PCR 
successfully 
Cloned  and 
sequenced 
Plasmid DNA 
gata2-
pOPINTTGneo 
380 bp Yes Yes 
Plasmid DNA 
ncor2-
pOPINTTGneo 
351 bp Yes Yes 
Plasmid DNA 
talI-N-
pOPINTTGneo 
422 bp No  
cDNA 
talI-N-
pOPINTTGneo 
422 bp Yes No 
Plasmid DNA 
neurog2-C-
pOPINTTGneo 
435 bp No  
cDNA 
neurog2-C-
pOPINTTGneo 
435 bp Yes No 
Plasmid DNA 
neuroD-
pOPINTTGneo 
320 bp Yes No 
Plasmid DNA 
neuroD-C-
pOPINTTGneo 
323 bp Yes No 
Plasmid DNA 
talI-C-
pOPINTTGneo 
290 bp No  
cDNA 
talI-C-
pOPINTTGneo 
290 bp No  
Plasmid DNA 
fliI-C-
pOPINTTGneo 
320 bp No  
cDNA 
fliI-C-
pOPINTTGneo 
320 bp No  
Plasmid DNA 
cdkI-N-
pOPINTTGneo 
303 bp No  
Plasmid DNA 
cdkI-C-
pOPINTTGneo 
303 bp No  
Plasmid DNA 
cdkI-FL-
pOPINTTGneo 
906 bp No  
Plasmid DNA 
cdknx-N-
pOPINTTGneo 
306 bp  Yes  Yes 
Plasmid DNA 
cdknx-FL-
pOPINTTGneo 
627 bp Yes Yes 
ddH2O Negative control    
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4.2.4.2 In-Fusion cloning of Xenopus proteins into pOPIN vectors for 
protein expression 
The In-Fusion reactions were set up and incubated at 50ºC for 15 seconds (see 
2.1.10.7). These reactions were then frozen at -20ºC until transformed. 
Transformation of cloning reactions into Dh5α cells (see 2.1.5) produced well-formed 
colonies (~100-150 per plate). DNA from the positive colonies was prepared and 
sequenced (Table 4. 3), where the sequences corresponded to the proteins of interest 
(Table 4. 3) large quantities of DNA were prepared, and they were transfected into HEK 
cells.  
Table 4. 3. Sub-cloning successes for Xenopus proteins. 
Vector deltaI gata2 cdknx ncor2 mytI 
hairyI-
Short 
fliI-Short 
neuroD-
Short 
pOPINF 
No 
colonies 
OK 
No 
colonies 
No 
colonies 
Empty 
vector 
OK OK OK 
pOPINE 
No 
colonies 
OK OK OK 
Empty 
vector 
OK 
Miss-
matches 
OK 
pOPINJ 
Empty 
vector 
Empty 
vector 
No 
colonies 
No 
colonies 
Empty 
vector 
Empty 
vector 
Empty 
vector 
Empty 
vector 
 
For mytI, primers were designed to amplify a shorter 1065 bp region of the 3369 bp full-
length mytI to go into pOPINE and pOPINF. After some optimisation of the PCR, this 
shorter version of mytI was successfully sub-cloned into pOPINE.  
CdkI C-terminal, cdkI full-length, gata2 full-length, ncor2 and neurog2 C-terminal were 
successfully sub-cloned into pOPINTTGneo vector. Correct clones were isolated and 
sequenced for gata2, ncor2 and neurog2. 
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4.2.5 A new approach, the use of vectors with secretion signals to allow 
the proteins to exit the nucleus and cell  
Four new vectors were subsequently obtained from OPPF, a gift from Ray Owens 
(pOPINE-StrepII, pOPINE-Flag3, pOPINGM and pOPINFS). 
These vectors were chosen as they all have a secretion signal, and they have different 
tags which might aid solubilization and secretion of the proteins. After growth of stab 
cultures and DNA preparation, the vectors were linearised; gel-extracted and purified 
(see 2.1). The vector’s purification was assessed by running 2 µl of each gel extracted 
plasmid on an agarose gel (data not shown). This confirmed the quality and quantity of 
the purified, digested vectors before ligation. 
As for the other vectors, PCR was performed on gata2, hairyI and cdkI templates with 
primers containing a homology region both to the template and vector. The vector’s 
homology was slightly adjusted to match the suggested tag on the In-Fusion protocol. A 
full list of primers used can be found in Appendix I. Following the In-fusion protocol, 
amplicons were subjected to a cloning-enhancer treatment before the In-fusion reaction 
into the destination vector (Figure 4. 7; see 2.1.10.4, 2.1.10.6, 2.1.10.7). 
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Figure 4. 7. Cloning enhancer treated PCR amplification of gata2, hairyI and cdkI to go into 
pOPIN vectors. 
The amplicons were all a single band of the expected sizes (+ or - 4 bp depending on primers 
used). For gata2-C-term the expected size was 380 bp, for hairyI-C-terminal 372 bp, cdkI-FL 905 
bp and hairyI-FL 801 bp. 
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4.2.5.1 Transfection of pOPIN plasmids encoding Xenopus proteins into 
HEK293T cells 
HEK293T cells were cultured as previously described (Nettleship et al., 2015). A 24 well 
culture plate was seeded with 3 different cell concentrations and left to grow overnight 
(see 2.4.4.1). The wells with the healthier looking cells were chosen to be transfected 
using JetPrime reagent (Polyplus) using the manufacturer’s instructions (see 2.4.4.2).  
All the vectors in the pOPIN collection have either a C-terminal or N-terminal his-tag. 
This facilitates western blot detection of expressed products and their purification. 
Transfected proteins were run on a 10 % SDS-PAGE, transferred onto a nitrocellulose 
membrane and analysed by western blot (see 2.4.2). Two types of antibody were used 
to detect the expressed proteins, an α-his HRP conjugated antibody (Abcam, ab1187), 
and a primary α-his antibody used with a secondary HRP conjugated antibody (Santa 
Cruz Biotechnology, G-18).  The α-his HRP conjugated antibody exhibited non-specific 
binding giving constant bands in the region of ~45 kDa (arrowed in Figure 4. 8). The 
Primary α-his with secondary HRP conjugated, also exhibited a background band, 
however only on the cell lysate and at about ~90 kDa (arrowed in Figure 4. 8). Since this 
is very distinct from the size of the desired targets, we decided to use α-his primary with 
a separate HRP-labelled secondary for all subsequent western blot studies. 
From these experiments, we observed that pE-neuroD-short and pE-hairyI-short were 
expressed, however, they were found in the cell lysate and not the media. The vectors 
sequences were examined carefully, and despite these vectors being supplied as 
secretory, no signal sequence was present. The presence of a secretion signal in the 
expression vector allows proteins to be transported from the cell out to the media 
(Nettleship et al., 2015). This makes the expression and purification more efficient. 
Therefore, a different set of vectors was sourced.  
Following the faint expression of NeuroD present in Figure 4. 8 and the successful 
expression of HairyI shown both in Figure 4. 8 and Figure 4. 9, large quantities of 
  
125 
 
pOPINE-neuroD-short and pOPINE-hairyI-short DNA were prepared. Medium scale 
transfections were carried out as previously described (see 2.4.4.3). The expressed 
proteins were assayed by western blot of their his-tag to test expression. The lysate, the 
media, and the re-suspended cell pellet were analysed and successfully expressed (data 
not shown).  
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Figure 4. 8. Small-scale HEK cell transfected proteins media and cell lysate. 
Media and lysate from each transfection were separated by 10 % SDS-PAGE and transferred 
into a membrane. The membrane was incubated with α-his HRP conjugated antibody. HairyI-
short and neuroD-short were expressed in vector pOPINE, predominantly in the cell lysate. No 
secretion into the media was observed. 
 
Figure 4. 9. Small-scale HEK cell transfected proteins media and cell lysate. 
Media and lysate from each transfection were separated by 10 % SDS-PAGE and transferred 
into a membrane. The membrane was incubated with α-his primary antibody, and HRP 
conjugated secondary antibody. HairyI-short was expressed in vector pOPINE, predominantly in 
the cell lysate. No secretion into the media was observed. Bands were visible in the Rara2 and 
FliI lanes, however these proteins run very low on the gel, not correlating to their actual size 
(arrowed in Figure).   
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4.2.5.1.1 Purification of medium scale transfected HairyI and NeuroD 
proteins 
Cells from the pE-hairyI-Short and pE-neuroD-Short medium scale transfections (see 
2.4.4.3) were lysed by mPER which contains a mild, non-denaturing detergent that 
dissolves cell membranes to extract and solubilize total protein from most cellular 
compartments (see 2.4.4.5.2), purified with his SpinTrap columns (see 2.4.5.1) and 
loaded into a 10 % SDS-PAGE. HairyI was highly expressed but the subcellular nature 
and insolubility of hairyI decreased the efficiency of the mPER treatment. For NeuroD, 
only a small quantity of expressed protein was observed (Figure 4. 10), therefore only 
HairyI was taken further.  
HairyI expression plasmid was transfected into four T175 flasks (see 2.4.4.3), following 
4 days of incubation the cells were harvested, and intracellular proteins were extracted 
using the mPER method (see 2.4.4.5.2). Despite the potential of this method, the 
proteins were still in the cell pellets after the extraction (Figure 4. 10).  
A summary table of transfections can be found in Appendix I. 
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Figure 4. 10. Intracellular protein extraction via mPER treatment of four T175 flasks of 
HEK293T cells transfected with the pE-hairyI-short construct. 
HEK293T cells were transfected with pE-hairyI plasmid, cells were collected, treated with mPER 
and analysed by Coomassie stain. The successfully expressed short version of hairyI is present 
very strongly in the cell pellet compared with the mPER lysate, suggesting the insolubility of the 
protein. Two bands can be prominently detected, one at the expected size of 14.8 kDa and one 
slightly lower. These could be two different isoforms of the same protein.  
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4.2.5.1.2 HairyI storage and integrity check after storing and other 
transfections 
Due to external factors, the successfully expressed HairyI protein had to be stored for 
over two months. To maximise the chances of recovering the protein after storage, 
multiple transfected samples were pooled into one volume and purified through an his-
trap column (Figure 4. 11; see 2.4.5.1). Fractions 5, 6 and 7 were found to have HairyI 
protein, they were collected and pooled again into a single volume. The pure protein was 
then split into two equal quantities, one mixed with its same volume of 20 % glycerol and 
the other left in its native form, and stored at -80ºC.  
Following storage, the proteins were thawed and tested on a western blot (Figure 4.12 
A; see 2.4.2). The integrity of the protein was unaffected by the storage, more so, the 
signal levels between the protein stored with glycerol and the protein stored in its native 
state were the same, suggesting both storing methods worked well.  
Both batches were pooled and dialysed against solution A from the AKTA start overnight 
at 4ºC, to remove glycerol that could affect further purification (see 2.5.2). The cleaned 
proteins were purified on an AKTA start with an his-trap FF Crude (1 ml) column (Figure 
4.12 B and C; see 2.4.5.2). Fractions 10 and 11 of elution 1 and fractions 3-6 of elution 
2 were collected and analysed on a 14 % SDS-PAGE (Figure 4.13) together with the 
load material. The protein was detected before and after dialysis, and fractions 3 and 5 
of the second elution.  
Meanwhile, large-scale transfections in 4x roller bottles containing a total of 1L of 
cultured cells were set with hairyI and gata2 (see 2.4.4.4). Upon culturing cells for 5 days, 
the media was extracted and the cell pellets lysed by the mPER method (see 2.4.4.5.2) 
and purified with a his-trap FF-crude column on an AKTA start (see 2.4.5.2). Fractions 
were collected and analysed via western blot (see 2.4.2). The expressed proteins were 
present only in the cell pellets. The sequences were re-checked to corroborate the 
correct arrangement and in frame location of the insert and signal sequence, which were 
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correct. Two theories arose. One was the probability of the proteins being secreted and 
degraded quickly thus; they were not present in the media at the end of the transfection 
course. The other suggested that the proteins were not efficiently secreted from the cell. 
A small-scale transfection was carried out and a time course was taken in which the 
medium was analysed to assess the secretion of the transfected proteins (see 2.4.4.2). 
The medium from the time course and the pelleted cells were analyzed by western blot 
and Coomassie staining (Figure 4.14 A and B). Gata2 was clearly present in the cell 
pellet in both analyses. The constant band present at ~28 kDa in the western blot gave 
doubts as there was no sign of the protein on the Coomassie-stained gel. A separate 
western was run to confirm these results (Figure 4.14 C), where there was a clear 
expression in the cell pellet, however, no proteins in the media at any time point. The 
first western false positives for the media might have been sample leakage when loading 
the gel. 
These results show that the proteins were not secreted at any point from the cell. 
Transcription factors are often DNA binding proteins which are found mainly in the 
nucleus. The strong protein-DNA interactions might be one of the causes they were not 
successfully secreted. 
The vector sequences were checked to corroborate that the secretion signal was 
present, were it came to our attention that this was missing from the plasmids we used, 
despite their original description.  
A new vector was tested, pOPINTTGneo, which contained a secretion signal. Small-
scale transfections of Gata2, Ncor2 and Neurog2 were carried out to test the transfection 
efficiencies of the pOPINTTGneo vector. Neurog2 was detected when the cell pellet was 
analysed in a western blot (showed in Figure 4.15), however this was unsuccessfully up-
scaled and purified. 
Large-scale transfected cells with the gata2-pOPINTTGneo, was solubilized by 
sonication and 8 M urea treatment (see 2.4.4.4, 2.4.4.6), and purified through an his-trap 
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column in the AKTA start (Figure 4.16; see 2.4.5.2), where the pellet gave a signal with 
the α-his antibody, while all the fractions from and around the elution’s peaks were 
negative (data not shown). The flow-through was clear, suggesting that the protein 
possibly became stuck in the column. The column material was boiled in SDS-PAGE 
loading buffer and tested on a Coomassie stained gel, where no appropriately sized 
bands were detected (Figure 4.16). 
By this point, the cost of protein production via HEK cell expression had become very 
high due to the complications that arose due to the proteins being insoluble and the 
production time-frame was greatly underestimated, thus commercial companies were 
contacted to either synthesise or express proteins. 
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Figure 4. 11. Purification via his-trap column of HairyI expressed protein.  
Fractions 5, 6 and 7 were collected, pooled and stored at -80ºC. Western blot of his-tag protein 
eluted in 9 fractions after being purified with the FF-crude his-trap column (A). UV absorbance 
was detected between fractions 4 and 6, indicating the elution of the protein, confirmed by the 
western blot (B). 
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Figure 4. 12. HairyI integrity and purification after storage. 
The stored proteins were thawed and tested on a western blot (A), both batches were then pooled 
to make a total volume of 3 ml, which was dialysed into solution A to separate the protein from 
the glycerol purified through a his-trap column in the AKTA start. The UV peak corresponding to 
the protein elution (B, C enlarged) was very low. 
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Figure 4. 13. Further purification of HairyI analysed by western blot. 
HairyI sample before and after dialysis, together with a number of fractions collected from the 
AKTA start purification. HairyI is present before and after dialysis, however, it was eluted in the 
second 0-100 % imidazole gradient, most prominently on fraction 5. 
 
 
 
 
  
135 
 
 
Figure 4. 14. Gata2 transfection. 
The stability of the protein produced by the transfection of HEK293T cells with Gata2 in 
pOPINTTGneo, was tested by taking a time course of the media to assess protein secretion from 
the cells to the media and its potential degradation. Analysis by Coomassie stain (A) and western 
blot (B), shows the presence prominent band at around the expected size of 20 kDa. Western 
blots are more sensitive than Coomassie stained gels, therefore the band is visible in all the 
samples, however there is no visible protein in the Coomassie stained gel. A repeat western (C), 
demonstrates that the band present in the first western was an artefact from over-filled wells, as 
no protein was visible on the time course media. Gata2 was present in the pelleted cells, however 
it was not secreted to the media in any of the tested time periods. 
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Figure 4. 15. Neurog2 protein transfected with pOPINTTGneo. 
Small-scale transfection of Neurog2 by HEK293T cell transfection using the pOPINTTGneo 
vector. A selection of DNA preparations were used to maximize the chances of expression, where 
4/5 DNA preparations produced a band at the expected protein size of 17 kDa (arrowed). The cell 
pellet containing expressed Gata2 was loaded as positive control (arrowed). Despite multiple 
attempts to up-scale and solubilize Neurog2, this was unsuccessful, and due to time restrictions, 
not pursued. 
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Figure 4. 16. Western blot to visualize Gata2 expressed protein before and after 
purification. 
Gata2 protein made by HEK293T cell transfection, was collected and solubilized with 8 M urea 
before loading into an his-trap column for purification. Samples were taken before loading the 
column, in 1 ml elution volumes and the flow through was also tested. Column samples were 
boiled in SDS loading buffer, to extract any bound protein. These samples were tested both by 
western blot and Coomassie stained SDS-PAGE. The Gata2 protein is present at the expected 
size (20 kDa) in the pre-loaded sample, but not in any elution or even the flow-through or column 
itself. A separate column, used to purify HairyI was also tested, without success. These findings 
suggested the loss of the protein either by precipitation or degradation. This was not pursued.  
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4.2.6 Commercially synthesised and expressed proteins 
Although proteins were expressed successfully via transfection into HEK cells, these 
showed a high level of insolubility and proved innefficient and costly to purify. 
Commercial companies were contacted to express 25 potential targets in a mammalian 
system. These targets were mainly early Xenopus transcription factors. Four out of eight 
companies were not willing to try to express these in mammalian systems due to the 
difficulty in the purification process for nuclear proteins. The remaining companies would 
carry out the expression and purification, at high price, however, they could not assure 
us there was going to be a product at the end of the procedure (Table 4. 4). A list of the 
suggested targets can be found in Appendix III. 
Table 4. 4. Companies contacted to express the given targets and their responses. 
Thermo Scientific Synthesis of 9/25 proteins (£700-£4000 small scale) 
Bio Basic Yes - (> £ 7000 per mg) 
Neo Biolabs Yes (> £ 5000 small scale) 
Biorbyt No 
Lonza  No 
Abm No 
GeneScript No 
Evotec Yes (>£16000 each w/ IMAC, cleavage, sub IMAC, SEC) 
 
Due to the unfeasibility of using mammalian systems to produce an antigen in-house or 
commercially, we explored the option of synthesising peptides. Two companies were 
considered, Alta Bioscience and Thermo Scientific.  
Alta Bioscience provides the option of synthesising peptides as octameric multi antigenic 
peptides (MAPs). MAPs are an effective method of raising antibodies using synthetic 
peptides. They consist of eight identical peptide chains which are synthesised joined to 
a common polylysine core. The molecular weight of these peptides, (10 kDa-15 kDa) is 
sufficient for them to be highly immunogenic without the need to couple to a carrier 
protein. This technique gives very high titers and works for any epitope except the 
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extreme C-terminus of a protein, according to Alta Bioscience and in the experience of 
our colleagues (A. Thorne, F. Myers and C. Crane-Robinson, personal communications). 
Sequences of 3 proteins were sent to Alta Bioscience. Their analysis identified the most 
immunogenic section of the protein. These suggested sequences were checked against 
the Xenopus genome to avoid generating antibodies that recognise multiple Xenopus 
proteins. For CDKI a 42 AA 8-branched sequence was suggested (Figure 4.17) and for 
MytI a 33 AA 8-branched MAP was also suggested (Figure 4.18). 
The third antigen supplied by Alta Bioscience, Kash5 (Figure 4.19), was generated and 
used as directed by a collaborator. This study aimed to validate the use of octameric 
MAPs to raise antibodies in sheep and test it as an alternative route to antibody 
generation in llamas. The development of this antibody is described in the “Kash5 
antibody” section of this thesis (Chapter 5). 
Thermo Scientific provided us with a different approach, the option of generating long 
peptides of up to 120 AAs long. These peptides are long enough to provide an immune 
response without the need to couple them to a carrier protein. Out of the 26 targets that 
were sent for analysis, only peptides to 9 were suggested as shown in Table 4.5. This 
was due to the extensive analysis needed to identify suitable peptide sequences for the 
other proteins. The purity of the peptides produced decreases with the peptide length. 
Also, the quantity obtained is about 1/5 of that obtained with the Alta Bioscience. Despite 
these disadvantages, we obtained two antigens from Thermo Scientific, asclI, and rarα2, 
so that we could directly compare the MAPs and linear peptides as antigens. The five 
sequences suggested by both companies were checked by BLAST to confirm no cross-
reactivity with other Xenopus proteins. 
  
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 4
. 
1
7
. 
C
d
k
1
 o
c
to
m
e
ri
c
 M
A
P
 s
e
q
u
e
n
c
e
 s
u
g
g
e
s
te
d
 b
y
 A
lt
a
 B
io
s
c
ie
n
c
e
. 
C
d
k
1
 c
o
d
in
g
 r
e
g
io
n
 (
d
a
rk
 p
in
k
) 
w
it
h
 s
tr
u
c
tu
re
s
 p
re
d
ic
te
d
 b
y
 p
s
ip
re
d
 (
lig
h
t 
g
re
e
n
) 
a
n
d
 P
h
y
re
2
 (
d
a
rk
 g
re
e
n
).
 T
h
e
 s
e
q
u
e
n
c
e
 s
u
g
g
e
s
te
d
 b
y
 A
lt
a
 b
io
s
c
ie
n
c
e
 
h
ig
h
lig
h
te
d
 i
n
 o
ra
n
g
e
. 
  
141 
 
 
M
y
t1
 c
o
d
in
g
 r
e
g
io
n
 (
d
a
rk
 p
in
k
) 
w
it
h
 s
tr
u
c
tu
re
s
 p
re
d
ic
te
d
 b
y
 p
s
ip
re
d
 (
lig
h
t 
g
re
e
n
) 
a
n
d
 P
h
y
re
2
 (
d
a
rk
 g
re
e
n
).
 T
h
e
 s
e
q
u
e
n
c
e
 s
u
g
g
e
s
te
d
 b
y
 A
lt
a
 
b
io
s
c
ie
n
c
e
 h
ig
h
lig
h
te
d
 i
n
 o
ra
n
g
e
. 
 F
ig
u
re
 4
. 
1
8
. 
M
y
t1
 o
c
to
m
e
ri
c
 M
A
P
 s
e
q
u
e
n
c
e
 s
u
g
g
e
s
te
d
 b
y
 A
lt
a
 B
io
s
c
ie
n
c
e
. 
  
142 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 4
. 
1
9
. 
K
a
s
h
5
 o
c
to
m
e
ri
c
 M
A
P
 s
e
q
u
e
n
c
e
 s
u
g
g
e
s
te
d
 b
y
 A
lt
a
 B
io
s
c
ie
n
c
e
. 
K
a
s
h
5
 c
o
d
in
g
 r
e
g
io
n
 (
g
re
y
) 
w
it
h
 s
tr
u
c
tu
re
s
 p
re
d
ic
te
d
 b
y
 p
s
ip
re
d
 (
lig
h
t 
g
re
e
n
) 
a
n
d
 P
h
y
re
2
 (
d
a
rk
 g
re
e
n
).
 T
h
e
 s
e
q
u
e
n
c
e
 s
u
g
g
e
s
te
d
 b
y
 A
lt
a
 b
io
s
c
ie
n
c
e
 
h
ig
h
lig
h
te
d
 i
n
 o
ra
n
g
e
. 
  
143 
 
Table 4. 5. Thermo Scientific proposed peptide sequences for 9/26 proteins that were sent 
for analysis. The amount and purity are estimates from the company, corresponding to the 
length and nature of the sequence.  
Peptide 
Name 
Sequence 
Peptide 
Length 
Amount Purity 
ASCLI 
AAVARRNERE RNRVKLVNLG FATLREHVPN 
GAANKKMSKV ETLRSAVEYI RALQQLLDEH 
DAVSAAFQSG  
70 1-4mg >90 % 
NEUROG2 
SGETVLKIKK TRRVKANNRE RNRMHNLNSA 
LDSLREVLPS LPEDAKLTKI ETLRFAYNYI 
WALSETLRLG DPVHRSAST 
79 1-4mg >90 % 
NGN3 
VKQRRNRRVK ANDRERNRMH NLNSALDALR 
SILPTFPDDA KLTKIETLRF AHNYIWALSE 
TLRMADQSLL 
70 1-4mg >90 % 
RARA2 
MYENVDVSPT HYHMMDFYSH NRQCLWPEKR 
INPYGTPLGT QHWSSSNH 
48 1-4mg >90 % 
TRA2B 
HIGNRANPDP NCCLGVFGLS LYTTERDLRE 
VFSKYGPLSD VSIVYDQQSR RSRGFSFVYF 
ENVDDAKEAK ERANGMELDG RRLRVDFSIT 
KRPHTPTPGI 
100 1-4mg >80 % 
CDKNX 
MAAFHIALQE EMISAPAVLP RLSAGTGRGA 
CRNLFGPIDH DEMRSELKRQ LKEIQASDCQ 
RWNFDFETGT PLKGIFCWEP VESKDMPSFY 
SQNRSIAANT 
100 1-4mg >80 % 
ETV2 
DKKPLPTASS GPIQLWQFLL ELLQDSSCQK 
LISWTGNGWE FKLSDPNEVA RRWGRRKNKP 
RMNYEKLSRG LRYYYHKNII HKTGGQRYVY 
RFVCDLQDLL SRPTQTSQPP TKTQRSRIQ 
119 1-4mg >80 % 
DAZL 
MSGKEESSNY AATAEEEAVN QGFVLPEGEI 
MPNTVFVGGI DITMDEIEIR DFFTRFGNVK 
EVKIITDRTG VSKGYGFISF SDEVDVQKIV 
KSQISFHGKK LKLGPAIRKI CTYVQPRPVV  
120 1-4mg >80 % 
PPP2R5A 
EIEEILDVIE PTQFKKIQEP LFKQISKCVS 
SSHFQVAERA LYFWNNEYIL SLIEENIDKI 
LPIMFGSLYK ISKEHWNPTI VALVYNVLKT 
LMEMNGKLFD ELTGSYKAER QREKKKELER 
120 1-4mg >80 % 
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4.3 Discussion 
The expression of these proteins in bacteria was not considered, to minimize the 
background on downstream analysis that was not an option. 
The in vitro transcription of Neurog2 and Cdknx via cell-free extracts was successful, 
showing that this is definitely a powerful tool to express DNA binding and insoluble 
proteins. The size of the proteins detected in the western correlated to the size of the 
fusion formed by the expressed protein and the MBT tag. However, the low yield 
produced by this method could have been investigated, but due to the expense and time 
restrictions, this process was left aside. The price of this method has decreased 
significantly since 2012, becoming more accessible. 
Protein production via HEK cells was an established method at our facility, where the 
expression of high quantities of soluble material easily purified was routinely done. A 
table with all the transfection plasmids created and the transfection results can be found 
in Appendix 1. Transfections were carried out in 6 or 12 well plates at first, and once a 
plasmid was found to express the desired protein, it was transfected into T175 flasks or 
roller bottles.  
We worked with either full length or short versions of CdkI, DeltaI, FliI, Gata2, HairyI, 
MytI, NeuroD, Neurog2, RARα2, Ncor2, TalI and Cdknx. A variety of nine vectors were 
tried, all derived from the original pOPINE vector. Protein expression was achieved for 
CDKI (pOPINE-StrepII-FL; pOPINE-Flag3-FL), Neurog2 (pOPINTTGneo-C-term), 
Gata2 (pOPINTTGneo-C-term; pOPINE-StrepII-C-term) and HairyI (pOPINE-C-term; 
pOPINE-StrepII-C-term; pOPINE-Flag3-C-term; pOPINFS-C-term). 
All the target proteins we worked with were found to be insoluble and the inconvenience 
that this caused was underestimated until the commercial companies themselves 
refused, or overpriced the non-guaranteed expression of these proteins in mammalian 
hosts.  
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The decision to use peptides was taken, and even from the target sequences we 
supplied to various commercial companies, there were some that not even peptides were 
suggested to us, because of the complexity of their structures. Alta Bioscience supplied 
us with 3 octomeric MAPs, for MytI, CDKI and Kash5. ThermoFisher provided with 
pricing for 9 peptides, from which we asked them to synthesise AsclI and Rarα2. 
CdkI and AsclI were later used to immunize llamas, to generate VHHs; and Kash5 was 
used to immunize a sheep, to provide a conventional antibody. The success of these 
approaches is described in Chapter 5. 
From my wealth of experience, if I was to do this again or if somebody else was trying to 
do it, what I would recommend for the raising of Xenopus-specific antibodies against 
transcription factors, is to avoid bacterial expressed proteins (due to the potential carry 
over contamination), avoid in vitro expression (as the cost of producing sufficient antigen 
to immunize a large mammal is excessive), and also to avoid HEK cell expression (as 
the purification of the proteins is nearly impossible). Therefore the investment of time 
and effort to design a suitable peptide is recommended.   
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5 Host immunisation and antibody screen 
5.1 Introduction 
This chapter explores two methods used to obtain antibodies. Kash5 is used in the most 
conventional of the ways, as an immunogen in sheep. This immunization generates the 
most widely used antibodies, conventional light and heavy chain Abs. Ascl1 and Cdk1 
were used to immunize 2 llamas and generate single chain antibodies.  
Since VHHs were first discovered, their uses have been broadened considerably, going 
beyond the conventional applications of antibodies. VHHs are produced as coding region 
libraries which allow them to be selected, provided in unlimited quantities and engineered 
to have a range of properties, such as enhanced tissue penetration and lower 
immunogenicity (Lauwereys et al., 1998; Muyldermans, 2001). They have become key 
players in multiple applications, including fundamental research, diagnostics, and 
therapeutics (De Meyer et al., 2014; Ma, Sun, Kang, & Wan, 2014). 
A brief review of the potential that VHHs offer is given in the main introduction (Arias et 
al., 2014; Hagihara & Saerens, 2014; Kim, Hussack, Kandalaft, & Tanha, 2014; 
Siontorou, 2013). More importantly, if VHHs as tools are introduced into the Xenopus 
community, backed up by published findings, they are expected to have significant 
impact on the type, ease, cost and time-scales of experiments, hence improving the 
usefulness of Xenopus as a model.  
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5.2 Results 
5.2.1 VHH Libraries 
VHHs were generated via the immunization of two camelids (Llama glama) with an 
antigen each. After 6-weeks the serum was extracted and a cDNA library was generated 
from the lymphocytes which hold sequences encoding all the expressed antibodies 
present in the llama’s serum (see 2.7). These single-chain antibodies can either be 
screened directly or alternatively a series of selection rounds (panning) can be run. In 
panning, the proteins encoded by the library are bound to the target protein, and then 
washed off, eventually purifying E. coli containing a phagemid encoding the specific, high 
affinity VHH (Figure 5.1). Commercially synthesised peptides were used as immunogens 
for this study as the in-house protein expression did generate proteins, however these 
were insoluble and could not be purified (Chapter 4).   
Two types of antigens were used, a long peptide (50 AAs) synthesised by Thermo Fisher 
for AsclI, and an octomeric MAP (42 AAs) made by Alta Bioscience from CdkI. AsclI is a 
transcription factor that plays a key role in neuronal differentiation and since it was first 
described in Xenopus in 1993 (Ferreiro, Skoglund, Bailey, Dorsky, & Harris, 1993) 
became a popular target when studying mesoderm induction and neural differentiation 
among other developmental processes (Min et al., 2016; K. M. Taylor & LaBonne, 2007; 
Wylie, Hardwick, Papkovskaia, Thiele, & Philpott, 2015).  
CdkI in the other hand, is a protein involved in the control of the eukaryotic cell cycle. 
This protein is one of the most studied in Xenopus, with over 800 papers associated with 
its activity and pathways in frog development (taken from Xenbase). It was first described 
in Xenopus 1975 (Drury & Schorderet-Slatkine, 1975) when describing the maturation 
promoting factor (MPF) in Xenopus laevis oocytes. Since then is been associated with 
spindle formation, mitogenic signalling and protein phosphorylation between others 
(Lohka & Maller, 1985; J L Maller, 1986). Both these proteins have been extensively 
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studied and antibodies against them are high on the priority list for the Xenopus 
community.  
Llama immunization followed procedures first established and recommended by Dr 
Laura Newnham (UCB). In summary, two llamas were acquired by the EXRC and kept 
under contract at “The centre for dairy research” (part of the University of Reading). The 
contract included the EXRC’s right to use the llamas for research purposes, and the 
centre for dairy research, to house, look after and follow the immunizations procedures 
when instructed. Immunizations followed the recommended timings and concentrations 
(Table 5.1 and Table 5.2). Three bleeds were collected, one before the immunization 
course started (pre-immune), one after 3 immunization were carried out (1st bleed) and 
the third, after 5 doses of the antigen were given.  
The bleeds were composed of 300 ml of blood and 5 ml of serum from each llama. The 
first bleed was treated by centrifugation to isolate the plasma by standard methods.   
The serum was used as primary antibody on western blot (see 2.4.2) with α-llama IgG 
goat-HRP conjugated as secondary antibody (Figure 5.2), and the immune response of 
the animals was confirmed with bands of the expected size present in the immune serum 
but not in the pre-immune.  
Following immunization, the llamas can be “re-used” and there is no need for them to be 
culled. There is a recommended resting period of 6 months between immunizations, 
which allows the immunogen to leave the blood stream, and the llama to recover from 
the treatment. At the end of their use llamas are employed as guard animals by farmers 
(The centre for dairy research, personal communications), making their use ethically 
preferable to animals normally killed like rabbits and sheep.   
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Figure 5. 1. Schematic representation of the processes involved in the generation of VHHs. 
Two llamas were immunized with an antigen each and after 6 weeks 100 ml of the blood was 
collected. A series of processes take the raw llama blood, isolates the lymphocytes, from these 
white blood cells the mRNA is extracted, and a pool of all the VHH specific cDNA is generated by 
a nested PCR. The VHH specific regions were cloned into a phagemid vector which produced the 
bacterial libraries. These libraries could be infected with helper-phage and screened directly or 
undergo selection rounds to isolate the high affinity binders to the chosen target, a process called 
panning. The identified VHHs are finally expressed and characterized. 
 
 
Immunogen Llama glama 
Collect blood 
mRNA isolation and 
RT-PCR 
Isolate lymphocytes 
PCR with nested 
primers 
Ligation to phage 
display vector 
Transform in E. coli 
and generate library 
Screen 1000 colonies  
Identify clone with 
antigen-specific VHHs 
Express as soluble 
VHHs 
VHH phage display 
Panning 
Coat 
Bind Rinse 
Elute 
Express as soluble 
VHHs 
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Figure 5. 2. Immunization response assessment by western blot analysis of post-injected 
llama serum, compared to pre-immune. 
Two llamas were immunised with one antigen each. Sunny (llama #1) was injected with the Ascl1 
long peptide generated by ThermoFisher, while Valentine (llama #2) was injected with the Cdk1 
octomeric MAP provided by Alta Bioscience. Immunization procedures followed previously 
stablished protocols outlined in Tables 5.1 and 5.2. Total protein extracts from embryos injected 
with cdk1 and ascl1 to over-express such proteins, were separated in a 10 % SDS-PAGE and 
detected by using a 1/250 dilution of the llama serum in blocking buffer. The llama proteins were 
visualized with 1/2000 dilution of HRP goat α-llama antibody in blocking buffer. Ascl1 displays a 
protein of the correct size (~22 kDa), while in the Cdk1 western blot two distinct bands are 
observed, one of the correct size (~33 kDa) and the other lower (~18 kDa). The nature of the 
second band would be clarified once the library is created and screened. 
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Table 5. 1. Immunization schedule for Sunny. A 100 ml pre-bleed was taken before starting 
the course of injections. Following three doses of 0.5 mg Ascl1 protein mixed with the adjuvant 
GERBU, a first bleed was taken and the llama immunized twice more the same antigen. A second, 
final bleed was then taken. 
 
  
 Schedule 
Day 
No 
Date Notes Action 
0 07th August 2017   
100 ml Pre-bleed - Whole blood in sodium 
heparin + 1 ml serum 
1 08th August 2017   Dose A 0.5 mg Ascl1 protein + GERBU LQ 
28 
05th September 
2017 
  Dose B 0.5 mg Ascl1 protein + GERBU LQ 
56 
03rd October 
2017 
  Dose C 0.5 mg Ascl1 protein + GERBU LQ 
66 13th October 2017 
Decision point:  are 
further doses are 
required? 
Test (or final) bleed - 400 ml whole blood in 
sodium heparin + 1 ml serum 
84 31st October 2017   Dose D 0.5 mg Ascl1 protein + GERBU LQ 
112 
28th November 
2017 
  Dose E 0.5 mg Ascl1 protein + GERBU LQ 
122 
08th December 
2017 
  
Final bleed - 500 ml whole blood in sodium 
heparin + 1 ml serum 
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Table 5. 2. Immunization schedule for Valentine. A 100 ml pre-bleed was taken before starting 
the course of injections. Following three doses of 0.5 mg Cdk1 protein mixed with the adjuvant 
GERBU, a first bleed was taken and the llama immunized twice more the same antigen. A second, 
final bleed was then taken. 
 
 
  
 Schedule 
Day 
No 
Date Notes Action 
0 07th August 2017   
100 ml Pre-bleed - whole blood in sodium 
heparin + 1 ml serum 
1 08th August 2017   Dose A 0.5 mg Cdk1 protein + GERBU LQ 
28 
05th September 
2017 
  Dose B 0.5 mg Cdk1 protein + GERBU LQ 
56 
03rd October 
2017 
  Dose C 0.5 mg Cdk1 protein + GERBU LQ 
66 
13th October 
2017 
Decision point:  are 
further doses are 
required? 
Test (or Final) Bleed – 400 ml whole blood 
in sodium heparin + 1 ml serum 
84 
31st October 
2017 
  Dose D 0.5 mg Cdk1 protein + GERBU LQ 
112 
28th November 
2017 
  Dose E 0.5 mg Cdk1 protein + GERBU LQ 
122 
08th December 
2017 
  
Final Bleed - 500 ml whole blood in sodium 
heparin + 1 ml serum 
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5.2.2 Kash5 antibody raising and characterization 
The tight link between this reaserch and the community through the EXRC encouraged 
the immunization of sheep with an octomeric map which provides comparison terms for 
the raising and testing of antibodies agains VHHs. 
The coiled-coiled domain-containing protein 155 (CCDC155), more commonly known as 
Kash5, is a nuclear protein that is involved in the connection between the nuclear lamina 
and the cytoskeleton (Houben, Ramaekers, Snoeckx, & Broers, 2007). Kash5 is required 
for homolog pairing during meiotic prophase (Zeng et al., 2018) and an antibody against 
this would be a useful tool for cell biologists studying a variety of cell processes.  
This protein was not straight forward to work with bioinformatically as it is not annotated 
in the Xenopus genome. The protein sequence was previously identified and provided 
to us by Prof Viki Allan. The Xenopus tropicalis sequence was the starting point, and the 
sequence identity when compared to Xenopus laevis is surprisingly low (Figure 5.4). 
There is however likely to be sufficient identity with Xenopus laevis for the epitope to be 
recognised in both species. A search of the most recent version (9.1) of the Xenopus 
tropicalis genome, made possible the identification of the gene. It is situated in 
chromosome 7, scaffold_707 between bases 104521509 and 104540066, and consists 
of 16 exons. This annotation has been submitted to Xenbase (Figure 5.3) 
The antigen was generated by Alta Bioscience as an octameric MAP (Figure 5.3) of a 
section of the Xenopus tropicalis version of the protein. The 20 AAs long sequence was 
compared to that of Xenopus laevis and found to be very similar, only 2 amino acids 
different (Figure 5.4). All tests for this antibody were carried out using Xenopus laevis 
animals, unless otherwise stated.  
Two milligrams of octameric Kash5 antigen were shipped to “Origen Antibodies Limited” 
to immunize one sheep under their standard protocol. In synthesis, this protocol involved 
taking a pre-immune bleed, followed by the immunization with 0.5 mg of the Kash5 
antigen. After a period of 4 weeks, a bleed was taken and the sheep immunized again 
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with a second dose of 0.5 mg of the antigen. This was done 3 times with an outcome of 
one pre-immune and 3 immune-bleeds with accumulated dosages of the antigen. 
The serum was tested by western blot on egg extracts and embryo extracts. As positive 
control, an MBP tagged Xenopus Kash5 protein was used, a kind gift from Prof Victoria 
Allan (University of Manchester).  
The Kash5 protein is 59.159 kDa in weight and the MBP tag 42.5 kDa, the fused protein 
is ~90 kDa in weight. 
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Comparison of Xtr KASH5 vs Xla 
PREDICTED: lymphoid-restricted membrane protein-like [Xenopus laevis]  
Sequence ID: XP_018083668.1 Length: 572 Number of Matches: 1 
 
 
Query  1    YKLQGTCWNPE--SEEGQLSDSKNATQGCLNGVPNSTSEEQLLDTAFEACDTEGRGEVTV  58   
            YK  GT  NPE  SE+G LSDS NAT+ CL   PNS+SEEQLLDTAF+ACDTEG+GEVTV  
Sbjct  2    YKHLGTFLNPEEPSEDGLLSDSANATEDCLGDFPNSSSEEQLLDTAFQACDTEGKGEVTV  61   
 
Query  59   FQIIDYLKSVTDQPCDGDRLQHLCKMLDPEEQGRSLDLPTFRKVMSEWIASCCSDSDITE  118  
            +QIIDYLKSVTDQ CDGDRLQHLCKMLDPE+QGRSLDLPTFR++MSEWIASCC+D  +TE  
Sbjct  62   YQIIDYLKSVTDQTCDGDRLQHLCKMLDPEDQGRSLDLPTFRRLMSEWIASCCNDRYVTE  121   
 
Query  119  TVENIKSEKGSSLPCG-VLEREAEHEGYGG-DVNKFMGEHADFISKIRDLSFANKKLMDQ  176  
             VE+IKSE GS LPC  V E  AEHEGYGG DVNKF+GEHA F+SKIRDL+FANKKLMDQ  
Sbjct  122  KVEDIKSESGSYLPCANVFEHGAEHEGYGGGDVNKFLGEHAYFVSKIRDLNFANKKLMDQ  181   
 
Query  177  KMKLQKSLETADETNSHLLEEISEVKSKLKISQQAVNHSRSLSNELEDLKAYTKTLEDKI  236  
            K+KLQKSLETADETNSHL+EEISEVKSKLKISQQAV+HSRSLSNELEDLKAYTK+LEDKI  
Sbjct  182  KIKLQKSLETADETNSHLIEEISEVKSKLKISQQAVSHSRSLSNELEDLKAYTKSLEDKI  241   
 
Query  237  AAFGSQKEELEKDNLSLCNQRQMLQEEMYNLLIDKENLKGNIDSLSAEKDNMGLQICEYE  296 
             +AFGSQKEELEKDNLSL NQR+MLQEE+YNLLI+K+ LKGNIDSL+AEK  MG QI EY+  
Sbjct  242  SAFGSQKEELEKDNLSLSNQREMLQEEIYNLLIEKDKLKGNIDSLTAEKGKMGHQISEYK  301   
 
Query  297  SLISQKEMLLEEEKVKSQQLRSIVDEHRLQVQVLQREKRLLHEQLLQPNKENMPLNQSVS  356  
             LISQKEMLLE+  V+S +L+SI++EHRLQVQVL+REKRLLHEQLLQPNK+NM L+QSVS  
Sbjct  302  RLISQKEMLLEDRNVQSHRLQSILEEHRLQVQVLKREKRLLHEQLLQPNKDNMFLHQSVS  361   
 
Query  357  VKQLPLPVQSVHRELEEIQEKIR-VKSELLSPICGIPQASGSNVLCPIQDTDMTSDDAWA  415  
            VKQLPLPVQSVHRELEEIQE+ +  K+ELLSPICGI QA+GS++LCPIQD DMTSDDAWA  
Sbjct  362  VKQLPLPVQSVHRELEEIQEQKKCFKTELLSPICGISQATGSHMLCPIQDADMTSDDAWA  421   
 
Query  416  VTELLLVQLKQGTEALIRSVHEMTSSDQSVSYLYEQSGHFLLELNYLLELKNVWERQWGR  475  
            +TELLLVQLKQGTEALI SVHEM SSD SVSYLYE+S HFL ELNYLLELKN+WERQ G   
Sbjct  422  ITELLLVQLKQGTEALITSVHEMASSDHSVSYLYEKSSHFLQELNYLLELKNIWERQSGS  481   
 
Query  476  LGRAVQLYTGKEAKEPDSEELPATEWLCTDTLHTSIVPCIQLQNKSSLWLTLILLGTLMF  535  
            L  A+QLYTGKE ++PD+ E PAT+W+CTD L T  VP +QLQNKSS+WLT++LLGTLMF  
Sbjct  482  LSGALQLYTGKETRKPDTHEFPATKWICTDMLDTPTVPYMQLQNKSSIWLTVLLLGTLMF  541   
 
Query  536  CPAWAGEHIWTVLKAEIWPHLDLHYHSPPPV  566  
            CPAWAGEHIWTVLK E+WPHLDLHY SPPPV  
Sbjct  542  CPAWAGEHIWTVLKGELWPHLDLHYPSPPPV  572 
 
Figure 5. 4. Xenopus tropicalis Kash5 protein sequence aligned to Xenopus laevis Kash5 
protein sequence. 
These orthologues have regions with considerable differences between species, however, the 
region selected to generate the octomeric MAP (20 AAs shown in yellow) is more conserved with 
only two amino acids difference (shown in green) and 15 amino acids of consecutive alignment, 
which is sufficient for the antibody to recognize the site. These sequences and alignments were 
provided by Prof Viki Allan. 
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Upon the end of the immunization course, the three bleeds and the pre-immune sample 
were tested via western blot against the purified Kash5/MBP protein and wild-type 
Xenopus laevis embryo extracts (Figure 5.5; see 2.4.2).  
Embryos were collected at stage 6, 11 and 21 and kept at -80ºC until treated. Proteins 
were extracted as previously described (see 2.4.1).  The SDS-PAGE used to 
characterize these antibodies were 10 %, unless otherwise stated. Two different protein 
ladders were used, since the preliminary results had unclear sizing and the second 
marker was used as size confirmation.   
Two concentrations of the purified protein were run, together with 3 different quantities 
of the mixed embryo extract. The serum was used at a 1/1000 dilution in blocking buffer 
(5 % milk in TBSTw), followed by 1/2000 Donkey α-sheep HRP conjugated secondary. 
All three bleeds showed specific binding to the purified kash5/MBP protein which runs at 
the expected size corresponding to the Kash5/MBP fusion (59.159 kDa + 42.5 kDa). 
Also, stronger bands around the 55-60 kDa can be seen, corresponding the expected 
size of endogenous kash5 protein. However, these western blots using crude serum 
show considerable background (Figure 5.5), thus the antibodies were purified. 
The sheep’s pre-immune serum was treated with caprylic acid and dialyzed, as 
previously described (see 2.5.1, 2.5.2). Alta Bioscience provides pre-packed columns of 
the antigen peptides covalently bound to controlled pore glass, (Peptide-CPG) for use 
as affinity columns to purify antibodies raised by the MAP version of the same peptide. 
Serum from Kash5 injected sheep was treated with caprylic acid, dialysed and affinity 
purified through the supplied column before being desalted in a G-25 column (see 2.5). 
The purification yield for bleed 1 was 4.48 mg, bleed 2 was 10.32 mg and bleed 3 was 
1.12 mg. These were aliquoted into 0.1 or 0.2 mg lots and lyophilised before storing at -
20ºC until needed. An aliquot of each bleed was re-suspended in PBS and stored at 4ºC 
to be tested by western blot (Figure 5.6). The purified serum was tested at 1 µg/ml. 
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To test the purified antibody a 10 % SDS-PAGE was prepared and run with kash5/MBP 
positive control, embryo extract and egg extract were also included. The egg extract was 
included as kash5 is a key protein in the early egg/embryo development as it associated 
with chromosome pairing and synapsis among other key developmental processes 
(Zeng et al., 2018). 
The background in the western blot was reduced considerably after purification. Even 
the pre-immune control was much clearer after the caprylic acid and dialysis treatment 
(Figure 5.6).  
 
  
159 
 
 
 
 
Figure 5. 5. Western blot to test the immune response of the sheep against the Kash5 
octomeric MAP immunisations. 
Two size ladders were used in these western blots to confirm the size marks from the SeeBlue 
plus2 ladder, which were not clear in previous runs. Proteins of two sizes have been arrowed in 
green for the Precision plus protein marker. The Kash5 protein is 59 kDa in weight and fused to 
the MBP tag is 90 kDa. The four gels were run and treated under the same conditions, the only 
variable being the primary antibody used. Pre-immune bleed (A); first bleed (B); second bleed 
(C); third bleed (D). The positive control, an MBP-Kash5 protein, was clearly detected at ~95 kDa 
on the 50 ng well as a duplex (orange), which is possibly due to proteolysis that may occur and 
change the protein mass. Protein from embryos at stage 6, 11 and 21 were isolated and run at 
0.5, 1 and 2 embryos per lane. Despite the high background levels, there were two prominent 
bands absent in the pre-immune at 20 kDa and 55 kDa (blue arrows). To further assess the 
antibody, this was purified.  
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Figure 5. 6. Western blot to test purified kash5 antibody. 
The Kash5 protein is 59 kDa in weight and fused to the MBP tag is 90 kDa. The four gels were 
run and treated under the same conditions, the only variable being the primary antibody used. 
pre-immune bleed (A); first bleed (B); second bleed (C); third bleed (D). The positive control, an 
MBP-Kash5 protein, was clearly detected at ~95 kDa in the 3 bleeds (orange), being negative on 
the pre-immune. Protein from embryos at stage 6, 11 and 21 were isolated and run at 0.5 and 1 
embryos per lane. Egg extracts were included at 1 µl and 3 µl per lane. The high background 
levels observed before purification of the antibody were minimized, even on the pre-immune that 
was only treated with caprylic acid and dialyzed gave a clearer signal. The previously seen bands 
at 20 kDa and 60 kDa were present on bleed 1 and bleed 3 (blue arrows). The high molecular 
weight bands could be aggregated proteins producing background. 
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Figure 5. 7. Western blot to optimize purified kash5 antibody staining.  
The Kash5 protein is 59 kDa in weight and fused to the MBP tag is 90 kDa. The four gels were 
run and treated under the same conditions, the only variable being the primary antibody used. 
pre-immune bleed (A); first bleed (B); second bleed (C); third bleed (D). The positive control, an 
MBP-Kash5 protein, was clearly detected at ~95 kDa in the 3 bleeds (orange), being negative on 
the pre-immune. Different denaturation of the protein extracts were tested, altering the 
temperature and length of incubation, with no clear difference between them. Protein from 
embryos at stage 6, 11 and 21 were isolated and run at one embryo per lane and egg extracts at 
1 µl per lane. The previously detected band at 60 kDa was particularly prominent on bleed one, 
while undetected with bleed 3. The band at 20 kDa was present mainly on bleed 3, and there was 
an extra band detected at about 40 kDa present on bleed 1 and bleed 3. To further test this 
antibody, embryos with over-expressed Kash5 need to be considered.  
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Following transfer, the membrane was incubated with 1/1000 dilution of purified serum 
in blocking buffer, followed by 1/2000 donkey α-sheep HRP conjugated secondary also 
in blocking buffer. Bleed 1 shows the strongest bands. Bleed 2 gave no visible bands 
with the embryo or egg extracts, and bleed 3 gave very faint bands.  
The proteins did not penetrate the SDS-PAGE very well, thus a variety of denaturing 
methods were used improve protein displacement through the gel. At this stage, the 
loading dye also was adjusted and instead of using a DTT based loading dye, we used 
a mercaptoethanol based loading dye.  Bleed 2 and 3 did not show the expected 
response (Figure 5.7). 
By comparing at the amount of antibody collected in bleed 2 (10.32 mg) and bleed 3 
(1.12 mg), with the lack of detection on the western blot, the assumption was made that 
the affinity column had failed to purify the antibody from the second and third bleeds. 
The purification of antibodies from these bleeds was repeated and obtained 3.2 mg and 
1.76 mg respectively.  
To aid the identification of the correct bands on western blot, and confirm the specificity 
of the antibodies, embryos were micro-injected with kash5 mRNA to overexpress the 
protein and give a stronger kash5 signal compared to WT were tested (see 2.6). 
To generate the mRNA, total RNA was extracted from embryos as previously described 
(see 2.1.7) and cDNA synthesized following standard protocols (see 2.1.8). kash5 was 
targeted with gene specific primers (Table 2.4 and Table 2.5). Multiple primers for 
Xenopus laevis and Xenopus tropicalis were tested to optimize amplification of kash5 
from wild type cDNA with no luck. The ODC housekeeping gene was used as control to 
test the integrity of the cDNA with positive amplifications in all reactions (data not shown). 
The kash5 sequence is A-rich and repetitive, thus PCR was not possible, despite 
optimization.  
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Kash5 was then synthetized by Genewiz (https://www.genewiz.com/) straight into a 
pCS2+ vector, from which mRNA was translated and injected into embryos. No 
overexpression was visible when tested with the Kash5 antibody (Figure 5.8).  
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Figure 5. 8. Kash5 overexpression to confirm the specificity of Kash5 antibody. 
Kash5 mRNA injection into one-cell stage Xenopus laevis embryos, allowed to reach st16 and 
total protein extracted from them. Un-injected embryos of the same stage were used as control. 
The 1st bleed of Kash5 antibody was used to detect endogenous Kash5, and visualized with his-
antibody. A single band can be seen just below the 50 kDa marker, however this do not correlate 
to the previously detected  band or Kash5 expected size of 59.1 kDa. The stability of this antibody 
came into question, therefore further experiments have to be considered to stablish if the loss of 
recognition of the 60 kDa was due to the antibody losing its affinity for the target.  
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5.3 Discussion 
Kash5 is one of many key proteins required in early development, it forms part of the 
linker of nucleoskeleton and cytoskeleton during mitotic cell division (Zeng et al., 2018). 
Work carried out with this protein was particularly challenging due to the lack of 
information available about it in Xenopus. Kash5 has not been mapped to the Xenopus 
genome and its expression together with EST or mRNA data is not available (to our 
knowledge). The information used to work with was provided by Prof Viki Allan, which 
allowed us to elucidate and propose new data for the community, currently being 
assessed by Xenbase.  
The kash5 mRNA sequence is very repetitive and with multiple sections of consecutive 
4 and 5 of the same nucleotide. The translated sequence also displayed repetitive amino 
acid motifs. These characteristics made Kash5 challenging to clone. Multiple attempts to 
isolate the kash5 sequence from genomic DNA were unsuccessful. Therefore the 
production of an octomeric MAP by Alta Bioscience was considered. 
Compared to llamas, the sheep immunization was a straight-forwards process. Sheep 
immunization for antibody generation is relatively common and the procedures are widely 
available and easily accessible.  
The response of the sheep to the antigen was clear from the un-purified, first bleed 
identifying the positive control, an MBP-tagged Kash5, and extra band of the expected 
size compared to the pre-immune. The detection of high molecular weight proteins, 
suggested that the embryo lysate was not completely denatured. To reduce background, 
the antibodies were purified, and the embryo proteins were tested with different 
denaturing approaches. The purification of the antibody was successful recognizing a 
clear band of the expected size with reduced background.  
We used Kash5 in this study, because it was part of the agreement with the EXRC to try 
this protein, however there are several features of Kash5 which made it not the ideal 
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protein for these analysis, mainly its sequence repetitive nature. If we would have had 
the chance to choose, we would have chosen a well characterized protein, with known 
sequence and function. Also, we would have used the same protein to immunize the 
llama and the sheep, as this would have provided with a direct comparison of the benefits 
and drawbacks of both methods. 
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6 The use of a β-catenin VHH as proof of 
principle  
6.1 Introduction 
6.1.1 β-catenin’s importance in development 
Vertebrate development is dictated by numerous pathways and processes by which the 
fertilised egg develops into an adult (Horner & Wolfner, 2008). Early development is 
influenced by a combination of the genetic background and the maternal signal carried 
by the egg (Tadros & Lipshitz, 2009). Finding the localization and functions of these 
maternal proteins combined with understanding the regulation of the transcription, 
mRNA turnover and later translation of new proteins are key to developmental biology 
studies. 
One of the best studied, key pathways in development is that of Wnt signalling. Since 
the elucidation of the first members of this family in 1982 (Nusse & Varmus, 1982), there 
have been over 25 000 research papers published (taken from a PubMed search, April 
2018) focused on different aspects of the Wnt signalling members, mechanisms and 
function. Wnt signalling occurs in all phyla (Loh, van Amerongen, & Nusse, 2016) and is 
well conserved. Nusse and Varmus (Nusse & Varmus, 2012) present a fantastic review 
of the Wnt pathway and its historical development, in which they highlight β-catenin as 
one of the key players in such processes. β-catenin is a protein that is maternally 
inherited and is key to many developmental processes in the early embryo such as the 
neurogenic niche for midbrain dopamine neurons (Tang, Miyamoto, & Huang, 2009) and 
cell fate (Huang & Niehrs, 2014) among others. β-catenin is localized in 3 distinct cellular 
compartments: the plasma membrane, the cytoplasm and nucleus (MacDonald, Tamai, 
& He, 2009), and its study requires a diverse set of approaches, as for example 
conventional antibodies might bind the cytoplasmic protein, but cannot penetrate the 
nuclear envelope to bind the nuclear proteins under normal conditions (Marschall, 
  
168 
 
Frenzel, Schirrmann, Schüngel, & Dübel, 2011). β-catenin is an excellent example of a 
“dual-function” protein, as it is involved in cell-cell adhesion and as later discovered, in 
signalling as a transcription factor. 
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6.1.2 β-catenin in Xenopus 
β-catenin was first described in 1989, when cDNA studies in human HeLa and avian 
fibroblasts linked β-catenin with cell adhesion properties (Ozawa, Baribault, & Kemler, 
1989). It wasn’t until 1991 that the same molecule was associated with cell to cell 
adhesion in Xenopus (McCrea & Gumbiner, 1991). Through the 1990s there were many 
studies around β-catenin and its effects on early development, such as the elucidation 
of its expression patterns (DeMarais & Moon, 1992). Its involvement in axis induction 
was first postulated using antibody injections (McCrea, Brieher, & Gumbiner, 1993), and 
confirmed by maternal knockdowns (Heasman et al., 1994). It was also implicated in 
mesoderm induction (Schohl & Fagotto, 2003), cell migration and histogenesis (Broders 
& Thiery, 1995) among others. In 1997, a revolutionary methodology was published 
called “Morpholino” oligos, which allowed the knockdown of gene expression 
(Summerton & Weller, 1997). These were morpholino ring based “oligonucleotide” 
fragments which bind to the endogenous RNA and block translation and splicing. These 
worked well in Xenopus; Heasman et al showed it working with β-catenin (Heasman et 
al., 2000). Gene function studies bloomed with this approach, although careful controls 
are needed (Eisen & Smith, 2008; Tandon, Showell, Christine, & Conlon, 2012) and 
some off-target effects appear difficult to avoid (Gentsch et al., 2018).  
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6.1.3 Loss of function experiments  
Morpholino injections became the popular way of inhibiting gene function, particularly in 
Xenopus and zebrafish. The injection of an antisense RNA created a phenotype 
representative of the embryo state when such protein is depleted, or knocked-down. 
More so, the phenotype, can sometimes be rescued by the injection of the sense RNA, 
that, given time, restores the embryo to its original healthy state. Some of the first 
overexpression and knockdown β-catenin studies by sense and antisense RNA 
injections were performed by Janet Heasman in 1994 (Heasman et al., 1994) in which 
she found that knocking down β-catenin inhibits dorsal mesoderm induction in the early 
embryo. The key function that β-catenin has in the Wnt signalling pathway is highlighted 
when the gene is knocked-down and a variety of distinct phenotypes arise (Figure 6. 1). 
Some embryos develop without dorsal structures, including the notochord, somites, and 
neural tube, embryos also lack heads and tails (Heasman et al., 2000). Figure 6. 1 
illustrates phenotypes that occur when β-catenin is depleted from the embryo at 4-cell 
stage and 8-cell stage. These results demonstrate a dorsal signalling pathway 
dependent on nuclearly localised β-catenin. However, they also raise some new 
questions, such as why the depletion of β-catenin affects both the dorso-ventral and 
anterior-posterior axes, suggesting that β-catenin could be involved in other pathways 
(Heasman et al., 2000).  
The study of β-catenin and the Wnt signalling pathway have been the focus of many 
developmental biology laboratories were Xenopus serves as a model organism. This, 
combined with the possibility of acquiring a β-catenin VHH, made this gene a perfect 
candidate for proof of principle studies for understanding how having a VHH to a frog 
protein could be exploited.  
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Figure 6. 1. Phenotype caused by the depletion of β-catenin in the early Xenopus embryo. 
Control un-injected embryos (A); injections into two dorsal at the 4-cell stage (B); injection into 
two dorsal animal cells at the 8-cell stage (C); injection into two dorsal vegetal cells at the 8-cell 
stage (D); injection into two dorsal animal and two dorsal vegetal cells at the 8-cell stage embryo 
(E). Injection into two dorsal cells at the four-cell stage caused complete ventralisation in all cases 
(Heasman et al., 2000). 
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6.1.4 A VHH against β-catenin 
An unpredicted meeting with previous users of the Reading facility for VHH production, 
made it possible for us to obtain a tested and published human β-catenin VHH 
(Newnham et al., 2015). This VHH is commercially sensitive and can be used only under 
certain restrictions. A brief description of the procedures carried out by Laura Newnham 
to obtain, isolate and characterize the β-catenin VHH are describe below. 
The β-catenin VHH was obtained by the immunization of 2 llamas with full-length, 
recombinant, human β-catenin protein. A phage library was synthesised and 2 x 108 
clones screened. Seventy eight percent of the clones contained in-frame VHH domains 
and each VHH subfamily was present as proposed by Harmsen et al (Harmsen et al., 
2000). 
The immune phage library was screened against biotinylated β-catenin by panning and 
monoclonal identification of positive clones was carried out by enzyme-linked 
immunosorbant assay (ELISA), in which 43 to 100 % were positive. Over 50 different 
variable region sequences that bound β-catenin were identified; 31 could be grouped 
into 12 distinct families, with 19 being significantly different from any family. 
The functional inhibition of β-catenin activity was tested by a luciferase-based Wnt 
signalling HEK293T reporter bioassay, in which 4 active intracellular antibodies inhibited 
β-catenin’s function. LL3 was chosen for further work as it did not display toxicity to the 
cell as did other active VHHs. In some cases, the penetration of the VHH into the cells 
caused the cell culture to perish or reduce growth. Three amino acids were mutated in 
the LL3 sequence to serve as negative control (Figure 6. 2 A). To assess the efficiency 
of the negative control, an ELISA assay was performed by capturing biotinylated β-
catenin on to streptavidin coated plates, adding VHH-scFc constructs and revealed with 
α-mouse Fc-HRP. As a negative control in this binding assay, an empty vector was used. 
Results show that as the concentration of the VHH-scFc increases, so does the binding 
to the immobilised β-catenin; however, the mutated VHH-scFc does not bind (Figure 6. 
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2 B).  The transfection efficiency of the LL3VHH expression clone and its mutated form 
was tested by analysing post-transfection cell lysis via western blot. A single band of the 
correct size was observed in the LL3 and LL3.CDRAAA, while no band was present in 
cells transfected with an empty vector (Figure 6. 2 C). The relative activity of intracellular 
antibodies LL3 and LL3.CDRAAA in a transfected HEK293T assay was analysed, with 
differences between the inhibition potential of the LL3 compared to LL3.CDRAAA and 
empty vector (Figure 6. 2 D).  
LL3-scFc and LL3.CDRAAA-scFc coated beads were used for immunoprecipitation of 
cellular β-catenin from HEK293T bioassay cellular lysate, and specifically-bound 
proteins were eluted. The un-transfected cell lysate was included as a positive control 
for the detection of endogenous β-catenin and negative control for the VHH. Western 
blots for (A) β-catenin, detecting endogenous β-catenin and LL3, while negative for the 
mutated LL3; (B) VHH-scFc, positive for LL3 and its mutated form, while no detected in 
the cell lysate (Figure 6.3). 
This human β-catenin VHH was received from Laura Newnham, UCB; propagated and 
sequenced upon receipt (Figure 6. 4 and Figure 6.5).  
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Figure 6. 2. β-catenin VHH and mutated control. 
The relative expression and binding capacities of the β-catenin VHH and its mutated vertion were 
analysed against a vector control.  LL3VHH and its mutated, non-binding form (A). ELISA test to 
assess the binding capacity of the negative control (B).  Testing the transfection efficiency of the 
LL3VHH and it is mutated by analysing post-transfection cell lysis via western blot (C). The 
relative activity of intracellular antibodies LL3 and LL3.CDRAAA in the transfected HEK293T 
assay was analysed, by the inhibition of a wnt reporter gene with clear differences between the 
inhibition potential of the LL3 compared to LL3.CDRAAA and empty vector (D) (Newnham et al., 
2015) . 
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Figure 6. 3. Binding capacities test of LL3-scFc and LL3.CDRAAA-scFc by immuno-
precipitation of cellular β-catenin from HEK293T cells. 
LL3-scFc and LL3.CDRAAA-scFc coated beads were used for immunoprecipitation of cellular β-
catenin from HEK293T bioassay cellular lysate, and specifically bound protein was eluted. The 
un-transfected cell lysate was included as a positive control for the detection of endogenous β-
catenin and negative control for the VHH. Western blots for β-catenin, detected endogenous β-
catenin and LL3, while negative for the mutated LL3 (A); VHH-scFc, positive for the LL3 and its 
mutated form, while no detected in the cell lysate (B (Newnham et al., 2015).  
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Figure 6. 4. Native β-catenin VHH and control mutated form containing vector map. 
Vector map received from Laura Newnham, containing the human β-catenin VHH and control. 
The full vector sequence cannot be publicised for confidentiality reasons. 
 
 
 
 
 
 
 
 
 
 
Figure 6. 5. Sequence alignments of native β-catenin VHH and control mutated form. 
Human β-catenin VHH sequence upon propagation, sequences were identical except the eight 
nucleotide changes that correspond to the amino acid changes deliberately made in the mutant 
protein.  
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6.2 Results 
6.2.1 Sub-cloning β-catenin and mutated β-catenin VHH into a vector for 
expression in Xenopus  
One of the advantages of VHHs, is that all of the coding region is encoded into a single 
exon, allowing the easy manipulation of the sequence. This way, the sequence can be 
sub-cloned into an expression vector which would allow it to be transcribed into RNA and 
this RNA later injected into embryos, which translate the protein from the inserted RNA 
(see 2.6).  
RNA transcription and later translation of the target protein requires sections of the vector 
to be specific. In this case, the pCS2+ vector’s backbone includes an SP6 promoter, 
which drives the transcription reaction; an SV40 late polyadenylation site and two 
polylinkers, between which the target sequence is inserted.  
Primers were designed to amplify the β-catenin VHH sequence and add a 5’ BamHI site 
and a 3’ EcoRI site. Amplification of β-catenin and mutated β-catenin VHH were 
performed by PCR (Figure 6. 6 A; see 2.1.6) and purified on an agarose gel for ligation 
into pGemTeasy (see 2.1.4). DNA from single colonies was prepared and subjected to 
digestion with EcoRI to release the insert (see 2.1.1). Positive clones were sequenced 
(Figure 6. 6 B). Two clones containing β-catenin VHH and two clones containing mutated 
β-catenin VHH were double digested with BamHI and EcoRI, gel purified and then ligated 
into the pre-digested pCS2+ vector (see 2.1.3). Five colonies from each of the inserts 
were prepared and double digested with BamHI and EcoRI to release the insert; positive 
colonies were sent for sequencing (Figure 6. 6 C). Two β-catenin and three mutated β-
catenin VHH sequences were correct. These clones were stored for further use. 
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Figure 6. 6. Cloning of native β-catenin VHH and control mutated form into pCS2+. 
Primers were designed to amplify the β-catenin VHH sequence and add a 5’ BamHI site and a 3’ 
EcoRI site. Amplification of β-catenin and mutated β-catenin VHH were performed by PCR (A), 
heated to 68ºC and loaded onto an agarose gel. The fragments were gel purified and ligated into 
pGemTeasy. DNA was extracted from single colonies, prepared and digested with EcoRI to 
release the insert (B).  Positive clones were sequenced and double digested with EcoRI and 
BamHI before T4 DNA ligate into a pre-digested pCS2+ vector. The final plasmids were double 
digested with EcoRI and BamHI to release the sequence (C), and the five positive clones 
(arrowed) were sent for sequencing. 
  
  
179 
 
6.2.2 Can β-catenin VHH block gene activity in the frog?                  
Loss of function 
The ability to block gene activity in the early embryo allows the elucidation of the 
importance of such genes in development. However, traditional methods have been 
challenged by recent developments in technology, such as single-cell sequencing and 
the ever-growing “omics” data pool (Blighe et al., 2018; Getwan & Lienkamp, 2017; 
Packer & Trapnell, 2018), therefore new avenues need to be investigated. 
Native β-catenin-VHH and mutated β-catenin-VHH were transcribed from the carrier 
pCS2+ vector with SP6 and the RNA analysed by agarose gel electrophoresis; four 
reactions were performed for each Figure 6.7 A).  One-cell Xenopus embryos were 
microinjected with 200 pg, 500 pg and one ng of the RNA. These were allowed to develop 
to organogenesis (St 26) and analysed; 61 % of the defective embryos were expressing 
the native form of β-catenin-VHH. However, 37 % of embryos microinjected with RNA 
encoding the mutated β-catenin-VHH were also defective. The control, un-injected 
embryos were mostly normal, with only 2 % showing defects (Figure 6. 8).  
These findings started us questioning whether the mutated β-catenin-VHH acts as a true 
non-binding negative control in Xenopus. 
Previous research has suggested that targeted microinjections of β-catenin either into 
the dorsal or the ventral part of the 4-cell Xenopus embryo gave rise to different 
phenotypes (Itoh & Sokol, 1999) since the developmental pathways affected were 
different. Microinjection of two ventro-vegetal (VV) blastomeres or two dorso-vegetal 
(DV) blastomeres at the 4-cell stage embryo (Figure 6.7 B) with 200 pg per injection of 
native β-catenin-VHH made the majority of the embryos dissociate (Figure 6.7 C). 
Injections with the mutated control β-catenin-VHH caused numerous premature deaths 
and some similar phenotypes to that of the produced by the native version. Again, the 
effect observed by the microinjection of the mutated, control β-catenin-VHH were similar 
to those observed with the binding, non-mutated form rather than to the un-injected 
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control. Therefore, a further control experiment was designed to normalise the 
expression of the mutated control to that of the binding protein (Figure 6. 9). Injections 
were performed in batches of 25 embryos, and repeated 4 times to obtain this data. 
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Figure 6. 7. β-catenin loss of function experiments in Xenopus laevis embryos. 
Mutated and native β-catenin-VHH mRNA were synthesised (A) and microinjected into one-cell 
Xenopus embryos which were allowed to develop to stage 26 and screened. A considerable 
proportion of the embryos injected with the mutated, non-binding form of β-catenin-VHH also 
displayed abnormalities, while non-injected controls behaved as expected. Microinjection of two 
ventro-vegetal (VV) blastomears or two dorso-vegetal (DV) blastomears at the 4-cell stage 
embryo (C) with 200 pg per injection. Again, the effects observed from the microinjection of the 
mutated, control β-catenin-VHH were similar to those observed with the binding, non-mutated 
form rather than to the un-injected control. Injections were performed in batches of 25 embryos, 
and repeated 4 times to obtain this data.  
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Figure 6. 8. β-catenin-VHH RNA micro-injection into one-cell Xenopus laevis embryos. 
One-cell Xenopus embryos were microinjected with 200 pg, 500 pg and 1 ng of native β-catenin-
VHH and mutated, non-binding form RNA. These were allowed to develop to tailbud stage (st 26) 
and analysed. Embryos expressing the native form of β-catenin-VHH had defects, however, 
embryos microinjected with RNA encoding the mutated β-catenin-VHH were also defective. The 
control, un-injected embryos were mostly normal. 
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Figure 6. 9. β-catenin-VHH RNA micro-injection into four-cell Xenopus laevis embryos. 
Xenopus laevis embryos microinjected with control mutated β-catenin and native β-catenin. 200 
pg were injected into each of the two ventro-vegetal (VV) blastomeres or two dorso-vegetal (DV) 
blastomeres. Embryos injected with native β-catenin displayed cell dissociation and early death, 
as well as a considerable proportion of the embryos injected with the mutated non-binding form 
of β-catenin. Non-injected control embryos developed as expected. 
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6.2.3 Resourcing a true negative control - GFPVHH 
The ability of the mutated β-catenin VHH to interfere in Xenopus development made 
validating the use of these VHHs as a way of blocking gene activity by RNA injection 
very difficult. The difference in severity and penetrance of native and mutant forms of β-
catenin VHH makes it highly likely that the VHH can act as a functional blocking reagent 
but the effect of the mutant VHH suggests that it too can bind β-catenin.  
A different VHH with no relation to β-catenin and no molecular effect in the wild-type 
early Xenopus embryo would serve as a true negative control. We chose the pOPINE-
GFP-VHH (Addgene #05162; (Kubala, Kovtun, Alexandrov, & Collins, 2010)) which was 
propagated and sequenced upon receipt (see 2.1.5). PCR primers were designed to 
amplify the nucleotide sequence encoding the VHH, and add specific restriction enzyme 
sites at the 3’ and 5’ ends Figure 6.10 A). The amplicons produced by PCR (Figure 6.10 
B) were TA sub-cloned into pGemTeasy, single colonies DNA prepared, digested to 
release the insert and positive clone sequenced (Figure 6.10 C; see 2.1.1, 2.1.4, 2.1.6). 
Only 1/22 tested colonies had an inserted sequence, far less than for other PCR products 
cloned this way previously. The target sequence was then separated from the backbone 
by double-digest and T4 DNA ligated into a pre-digested pCS2+ plasmid (see 2.1.3). The 
ligation was repeated multiple times, with different optimisation procedures such as time, 
concentration, temperature and cells used to transform with no positive outcome. To 
solve this cloning issue, primers for the In-fusion cloning kit were designed and will be 
tested as further development to this project (see 2.1.10). 
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Figure 6. 10. A true negative control, pOPINE-GFP-VHH, Addgene #05162A. 
PCR primers were designed to amplify the nucleotide sequence encoding the pOPINE-GFP-VHH 
and add specific restriction sites at the 3’, and 5’ ends (A). The amplicons produced by PCR (B) 
were TA sub-cloned into pGemTeasy, single colonies DNA prepared, digested to release the 
insert and positive clone sequenced (1/22 – C). The target sequence was then separated from 
the backbone by double-digest and T4 DNA ligated into a pre-digested pCS2+ plasmid. The 
ligation was repeated multiple times, with different optimisation procedures such as time, 
concentration, temperature and cells used to transform with no positive outcome (D). To solve 
this cloning issue, primers for the In-fusion cloning kit were designed and will be tested. 
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6.2.4 Expression of β-catenin VHH as periplasmic protein and its use as 
Antibody 
One of the multiple advantages that heavy-chain-only antibodies have is that they can 
be sub-cloned into a vector and be expressed as periplasmic protein in bacterial cultures 
such as E. coli BL21 cells. The vector used in this study, pecan126, was a gift from Serge 
Muylderman (Figure 6. 11, unpublished vector), which allows the translation of the 
encoded protein and adds a his-tag to its C-terminal. It contains the lacZ gene sequence, 
allowing easy identification of vectors carrying the insert by blue-white test, and the pelB 
sequence that allows the secretion of the protein into the bacterial periplasm. 
Control, mutated β-catenin-VHH and native β-catenin-VHH were amplified by PCR with 
specific primers and sub-cloned into pGemTeasy (data not shown; see 2.1.4, 2.1.6). 
Positive, sequenced clones were double digested with EcoRI and NotI (see 2.1.1), and 
ligated into a pre-digested pecan126 vector (see 2.1.3). Single colonies were DNA 
prepared and screened by double digestion with the same enzymes (Figure 6. 12 B). As 
the vector sequence was unknown, we designed primers from the insert into the vector 
(Figure 6. 12 A), these sequences later allowed the design of primers from the vector 
into the inserted sequence. 
The pecan126 vector containing the mutated, control and native forms of β-catenin-VHH 
sequence, were transformed into E. coli BL21 cells and plated on ampicillin selective 
plates (see 2.1.5, 2.3.1.1). In synthesis, single colonies were used to inoculate ampicillin 
supplemented 2xYT media and left to grow overnight at 37ºC. This overnight culture was 
used as a starter culture for large scale 2xYT medium and incubated until the OD600 was 
approximately 0.3-0.5. IPTG was added to a concentration of 1 mM and the culture 
incubated at 30ºC overnight to induce protein production. After the incubation period, 
cells were centrifuged, supernatant removed and the pellet collected. The cells were re-
suspended in TES buffer and kept on ice for one hour. This incubation induces the 
release of proteins from the cell, followed by an osmotic shock to boost the proteins into 
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the media and incubated further. The protein was collected by centrifuging the cells and 
collecting the supernatant, then periplasmic proteins were stabilised by the addition of 
salt and stored at 4ºC for up to 1 month, or -20ºC for the longer term (see 2.3.2).  
Periplasmic expression of the mutated control and binding forms of β-catenin-VHH was 
tested by an α-his-tag western blot (Figure 6. 13 A; see 2.4.2). Six colonies were chosen 
for expression from each sequence, and all 12 successfully expressed the his-tagged 
periplasmic protein. Large-scale preparation of one colony each was prepared and 
tested by western blot and Coomassie staining (Figure 6. 13 B). In the α-his-tag western 
blot, a single band can be observed of 18 kDa, corresponding to the expected size of the 
protein. While on the Coomassie stain, multiple bands are observed, but no significant 
background. Suggesting the protein is clean enough to use for staining in either western 
blot or immunohistochemistry.  
The periplasmic produced VHHs were used as antibodies to detect endogenous proteins 
in Xenopus laevis embryo extracts via western blot. Whole embryo protein extractions 
(see 2.4.1) were taken from embryos from a developmental course (st 2, st 6, st 10, st 
15, st 21/22, st 33/34, st 37 and st 43) and separated through an SDS-PAGE. These 
were transferred to a membrane and one blotted with the native β-catenin-VHH, and the 
other with the mutated form of β-catenin-VHH (Figure 6.14). These were detected by 
using α-llama-HRP antibody and revealed a constant band at around 55 kDa which did 
not correlate to the size of β-catenin (93.8 kDa). This band could correlate to the 
endogenous β-catenin that might run at a different size, or to the mecp2 protein which 
the his antibody can sometimes bind to. The need for a true negative control became 
imminent. 
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Figure 6. 11. pecan126 vector map. 
The pecan126 vector allows the expression of the periplasmic protein in bacterial cultures such 
as E. coli BL21 cell. It contains a lacZ gene sequence, allowing easy identification of vectors 
carrying the insert by blue-white test, and the pelB sequence which allows the secretion of the 
protein into the bacterial periplasm. When the protein is translated, this vector allows the insertion 
of a his-tag to the protein’s C-terminal. A kind gift from Serge Muylderman (unpublished vector). 
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Figure 6. 12. Sequencing and cloning of native and control β-catenin-VHH into the 
pecan126 vector. 
Native β-catenin and control VHH sequences were amplified by PCR and sub-cloned into 
pGemTeasy (data not shown). Positive, sequenced clones were double digested with EcoRI and 
NotI, and ligated into a pre-digested pecan126 vector. Single colonies were DNA prepared and 
screened by double digestion with the same enzymes (B). As the vector sequence was unknown, 
we designed primers from the insert into the vector (A), these sequences later allowed the design 
of primers from the vector into the inserted sequence. 
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Figure 6. 13. Periplasmic expression of the mutated control and native forms of β-catenin-
VHH. 
Six colonies from each construct were grown, and all 12 successfully expressed the his-tagged 
periplasmic protein. An α-his-tag western blot (A) illustrates two of the expressed clones that were 
up-scaled to large-scale preparation and tested by western blot and Coomassie staining (Figure 
6. 13 B). In the α-his-tag western blot, a single band can be observed of 18 kDa, corresponding 
to the expected size of the protein. While on the Coomassie stain, multiple bands are observed, 
but no significant background. Suggesting the protein is clean enough to use for staining in either 
western blot or immunohistochemistry. 
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Figure 6. 14. Detection of Xenopus laevis endogenous β-catenin by antibody staining. 
Proteins from wild-type embryos at stages 2-43 were extracted and separated by SDS-PAGE. 
These proteins were transferred into a membrane that was subjected to either non-binding control 
β-catenin or the native, binding form. An α-his antibody was used to locate the bound VHH and 
visualised by HRP detection. The continuous band detected at ~55 kDa does not correlate to the 
size of β-catenin (93.8 kDa). This band could correlate to mecp2 (467 AAs, 56 kDa) protein which 
the his antibody can sometimes bind to. The need for a true negative control became imminent. 
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6.2.5 Can single chain antibodies be used for in vivo labelling of β-catenin 
in Xenopus laevis?  
Another advantage of single chain antibodies, is that they can be used to label proteins 
in vivo, as their reduced size and high specify allow them to penetrate and bind proteins 
within the cell. To investigate the possibility of using VHHs as in vivo imaging agents in 
Xenopus, the β-catenin VHH and its mutated form were designed as fusions with 
fluorescent proteins. 
Fluorescent proteins were first described in jellyfish in the 1950s (Davenport & Nicol, 
1955). However it was not until much later that these proteins were cloned into an 
expression vector for the preparation of non-fluorescent apoGFP (Prasher, Eckenrode, 
Ward, Prendergast, & Cormier, 1992). Since then, GFP has been used extensively in 
Xenopus and other species to label many specific aspects of the anatomy (A. Gautier & 
Tebo, 2018; Kuroda, Wessely, & De Robertis, 2004; Mishin, Belousov, Solntsev, & 
Lukyanov, 2015; Preston, Aras, & Zaidi, 2018; Takagi et al., 2013). The main 
disadvantage with using GFP in Xenopus is that the yolk from the embryo auto fluoresces 
at the same wavelength that GFP is detectable, thus producing background in the 
imaging. New fluorescent proteins became available at the end of the 1990s, the Red 
fluorescent proteins (DsRed) (Matz et al., 1999). This protein was isolated from non-
bioluminescent reef corals and led to the discovery of many new fluorescent proteins 
and chromoproteins. In 2001, it was published that proteins tagged with DsRed were 
often found to aggregate within the cell (Lauf, Lopez, & Falk, 2001) and by 2004 a whole 
range of monomeric units derived from the original DsRed were published (Figure 6.15  
(Shaner et al., 2004)). The protein of choice in this study is on the red spectrum, katushka 
RFP, which was discovered in 2007 by Andrey Zaraisky and colleagues (Shcherbo et 
al., 2007), and released by Evrogen together with a  fluorescent protein colour palette 
which covers the entire visible range from blue to far-red (Day & Davidson, 2009). Upon 
encountering drawbacks in the cloning and experience with the fluorescent signal 
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emitted by katushka RFP as a fusion protein (personal comments from A. Abu-Daya and 
M. J. Guille), a different derivate from DsRed, mCherry (Figure 6.15), was used in parallel 
(Shaner et al., 2004).  This approach enhanced the chances of success, and if both 
worked would allow a direct comparison of expression between these proteins.  
  
194 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 15. DsRed, one of six fluorescent proteins isolated by Matz and colleagues from 
non-bioluminescent reef corals in 1999 (Matz et al., 1999) and its derivate. 
Matz and colleagues used mRNA microinjection assays in Xenopus embryos and expression in 
mammalian cell culture to demostrate these proteins’ usefulness for in vivo labelling. However, 
proteins tagged with DsRed were often found to aggregate within the cells (Lauf et al., 2001) and 
efforts were made to generate derivatives of the DsRed protein that would have less or no side 
effect when fusing to a recombinant protein. Shaner et al., published in 2004 a variety of enhanced 
derivatives from DsRed with absorbance at different wavelengths and less or no effect when fused 
to another protein. GenBank accession numbers are given under the name of each (Shaner et 
al., 2004). 
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6.2.5.1 Cloning β-catenin VHH with KatushkaRFP in pCS2+  
To create a KatushkaRFP-VHH fusion in pCS2+ (Figure 6.16 A), Katushka was extracted 
from a donor vector (Love et al., 2011) by amplification with primers containing an added 
sequence corresponding to EcoRI and SfiI (Figure 6.16 B; see 2.1.6). The amplicons 
obtained were cloned into pGemTeasy (see 2.1.4) and digested with EcoRI and SfiI (see 
2.1.1). Bands of the expected size were sliced from the agarose gel and purified 
(MinElute Gel Extraction Kit, Qiagen). These bands were ligated into a pre-digested 
pCS2+-VHH vector containing the mutated and non-mutated forms of β-catenin-VHH 
(see 2.1.3). Single colonies were analysed by EcoRI-SfiI digestion of extracted DNA, but 
no positive clones were observed (Figure 6.16 C). The same DNA fragments were tested 
by amplification of the insert region when bands were observed for some of the clones 
(Figure 6.16 D). The clones showing bands upon amplification by PCR were sequenced, 
and for ¾ of the sequenced clones, the VHH sequence was intact. However there was 
no KatushkaRFP sequence (Figure 6.16 D). 
As result, a different approach was taken (Figure 6.17 A), in which the VHH encoding 
sequences and the katushkaRFP sequence were amplified by PCR (Figure 6.17 B; see 
2.1.6), co-ligated into pGemTeasy (Figure 6.17 C; see 2.1.4) and, once the VHH-
katuskaRFP sequence was linked, excised from the pGemTeasy vector (see 2.1.1) and 
ligated into a pre-digested pCS2+ vector (see 2.1.3). Single colonies were tested by 
EcoRI digest, designed to yield two products, the backbone of 4110 bp and the whole 
VHH-katushkaRFP cassette of 1209 bp. Upon analysing the EcoRI digested DNA, a 
band of only 700 bp could be seen (Figure 6.17 D), suggesting that only one insert was 
cloned into the vector.  
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Figure 6. 16. KatushkaRFP-VHH fusion in pCS2+.  
Cloning design (A) where the amplified katushkaRFP (B) was cloned into pGemTeasy, digested 
and purified before ligation into pre-digested pCS2+-VHH vectors. Single colonies were analysed, 
by preping the DNA from bacterial colonies and digesting them to release the insert, with no visible 
positive clones (C). These colonies were further analysed by amplification and plasmids 
displaying bands indicating the present of the insert (D) were sequenced. These plasmids 
contained the VHH sequence, but the KatushkaRFP was not present (E).  
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Figure 6. 17. An alternative approach to clone KatushkaRFP-VHH. 
Cloning design (A) were the VHH encoding sequences, and the katushkaRFP sequence was 
amplified (B), ligated into pGemTeasy (C), digested and ligated into a pre-digested pCS2+ vector. 
Single colonies were tested by EcoRI digest, with only a 700 bp band could be seen (D), 
suggesting that only one insert was incorporated to the backbone. 
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6.2.5.2 Cloning VHH with mCherry in pCS2+ 
The strategy to clone the mCherry sequence fused to the native and mutated β-catenin-
VHHs into a pCS2+ vector (Figure 6. 18) involved the amplification of such sequences 
with specific primers, and separately TA cloned them into pGemTeasy. The VHH 
encoding pGemTeasy vectors were digested (see 2.1.1), gel purified (MinElute Gel 
Extraction Kit, Qiagen) and T4 DNA ligated into a pre-linearized mCherry-pGemTeasy 
vector (see 2.1.3). Once the native and mutated β-catenin-VHH-mCherry cassette 
sequence was confirmed in pGemTeasy, it was digested out and clone into a linearised 
pCS2+ vector.  
The outcome of this cloning strategy was similar to that of the katushkaRFP cloning. Only 
the mCherry or the VHH sequences were present at the end of the cloning in the 
destination vector. To optimise this cloning, primers for the In-fusion cloning kit were 
designed and will be tested (see 2.1.10).  
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Figure 6. 18. Strategy to clone mCherry fused to native and mutated β-catenin-VHH into 
the pCS2+ vector.  
The VHHs and mCherry sequences were amplified with specific primers, and separately TA 
cloned into pGemTeasy. The VHH sequences were digested and purified before T4 DNA cloned 
into a pre-linearized mCherry-pGemTeasy vector. Once the entire cassette sequence was 
confirmed in pGemTeasy, it was digested out and clone into a linearised pCS2+ vector. 
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6.3 Discussion 
The possibility to work with a tested and published VHH as a proof of principle provided 
a wide variety of opportunities that were not achievable with the libraries generated in 
USA (discussed in chapter 3).  
The differences between the human and Xenopus laevis β-catenin sequences is 
minimal, with high chances of VHHs raised against the human form cross-reacting with 
the Xenopus protein. These strictly controlled and commercially sensitive VHHs were 
sequenced and confirmed upon receipt. The cloning into pCS2+ and mRNA expression 
was successful and created a phenotype when injected. Such phenotypes can be directly 
linked to previously published β-catenin knock-downs and Wnt signalling pathways 
disruptions (as previously discussed in the Introduction). 
The mutated version of β-catenin-VHH caused a higher than expected proportion of the 
embryos to develop abnormally compared to the un-injected. This suggests that this 
does bind to the endogenous β-catenin with lesser affinity than the native β-catenin-VHH. 
To find a true-negative control, the GFPVHH was sourced from Addgene. The 
propagation of the original clone was successful, but all attempts to clone this sequence 
into an expression vector were unsuccessful, for unknown reasons. An In-Fusion 
reaction will be tried as an alternative cloning strategy.  
The expression of the native and mutated forms of β-catenin provided a high, 
reproducible yield of relatively pure protein. These proteins were used as antibodies and 
did recognise an endogenous Xenopus protein. However, the size it runs did not 
correlate to the β-catenin protein and is almost certainly Mscp2.  
The potential use of these VHHs as visualisation agents were not tested as the cloning 
of the VHHs with the KatushkaRFP and mCherry proteins were unsuccessful. However, 
strategies for further work have been established. 
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7 HA-tagging of the endogenous Gata2 
locus in Xenopus laevis 
7.1 Introduction 
7.1.1 General Introduction 
Protein detection via antibody binding is a powerful tool used broadly in science. 
Nevertheless, it has its limitations. For example, proteins that are closely related (such 
as H2AZ1and H2AZ2 or H3.1 and H3.3) are sometimes difficult to differentiate and 
identify (Wen et al., 2014). The specificity barrier, poor accessibility of the protein to the 
antibody’s binding site or cross-reactivity of the antibody can decrease the use of 
conventional antibodies. Additionally, antibodies may not be the best approach when 
studying poorly characterised proteins (because exposed regions cannot be identified) 
or proteins with low immunogenicity. To follow these proteins, a different approach has 
to be taken; epitope tagging. This technique is particularly useful when discriminating 
between individual members of closely related proteins families or the identification of in 
vitro-mutagenized variants in the context of the endogenous wild-type protein (Fritze & 
Anderson, 2000).   
Epitope tagging refers to fusing a short amino acid sequence recognised by a pre-
existing antibody with a known epitope (Brizzard, 2008). It was first developed as a 
method of visualising proteins, and the main advantage that this procedure offers is that 
the time and expense associated with generating and characterising antibodies against 
multiple proteins are obviated (Fritze & Anderson, 2000; Munro & Pelham, 1987). From 
the first tag ever reported, the Evans Blue T-1824 (Rawson, 1943), many different tags 
with a variety of properties have been used, usually with commercially available 
antibodies against them. A significant discovery was made when fluorescent tags were 
reported that allow the visualisation of proteins in tissue culture without the need of a 
secondary antibody (Tsien, 1998), and this has revolutionised many aspects of cell 
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biology (Ellenberg, Lippincott-Schwartz, & Presley, 1999). The tag chosen in this study 
is the HA tag, first described in 1983 (Niman et al., 1983), a sequence from the influenza 
virus hemagglutinin epitope (YPYDVPDYA). A table of the commonly used protein tags 
(Li, 2010) is given in Table 7.1 and a graphic representation of the relative popularity of 
individual affinity tags according to a data search of PubMed Central (May 2018) in 
Figure 7.1. 
Table 7. 1. Commonly used protein tags (Li, 2010; Maue, 2007). 
Affinity Tag Sequence or size (aa) 
Protein A IgG-binding domain (aas) 
his tag HHHHHH (aas) 
FLAG DYKDDDDK (aas) 
HA YPYDVPDYA (aas) 
c-myc EQKLISEEDL (aas) 
V5 GKPIPNPLLGLDST (aas) 
StrepII WSHPQFEK (aas) 
SBP MDEKTTGWRGGHVVEGLAGELEQLRARLEH HPQGQREP 
(aas) 
S-peptide KETAAAKFERQHMDS (aas) 
CBD TNPGVSAWQVNTAYTAGQLVTYNGKTYKCL 
QPHTSLAGWEPSNVPALWQLQ (aas) 
GST 220 (aas) 
MBP 396 (aas) 
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Figure 7. 1. Graphic representation of the relative popularity of individual affinity tags 
according to a data search of PubMed Central (May 2018). 
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A variety of approaches were used over the years to achieve the epitope tag labelling of 
proteins. Scientific studies evolved considerably from the first transgenic mouse, in which 
simian virus 40 (SV40) containing an origin of DNA replication and a gene product 
(thymidine kinase (TK)) was inserted into the mouse genome in 1980 by Gordon et al. 
(Gordon et al., 1980), to the numerous transgenic or mutant Xenopus lines today 
available (EXRC, 2016). The advances in technology and the elucidation of the Xenopus 
laevis genome have made it possible to perform the latest of gene editing techniques.  
Although an artificial change to the genome was first reported in 1927 (Muller, 1927) 
when it was shown that the rate of mutagenesis could be enhanced with radiation or 
chemical treatment, the first targeted genomic changes were produced much later in 
1979 (Scherer & Davis, 1979). Scherer and Davis proposed a system by which foreign 
sequences or deletions, constructed in vitro, could be introduced into a chromosome and 
be used to replace the wild-type chromosomal copy. In the early 1980s mouse embryonic 
stem cells (ES cells) became hugely popular due to the realisation that they could be 
used as a vehicle for introducing targeted genetic modifications into the germline by 
homologous recombination (reviewed by Solter, 2006), producing gene knock-out 
(complete loss of function). The development of programmable site-specific nucleases, 
including zinc-finger nucleases (ZFNs) (Young & Harland, 2012), transcription activator-
like effector nucleases (TALENs) (Lei et al., 2012), meganucleases (MNs) (Pan, Chen, 
Loeber, Henningfeld, & Pieler, 2006), and most recently, the clustered, regularly 
interspaced, short palindromic repeats (CRISPR) associated proteins (including cas9) 
(Nakayama et al., 2013) have greatly enabled and accelerated genome editing (Guha & 
Edgell, 2017).   
The CRISPR/cas9 technology was used in this study to tag a protein endogenously. This 
aimed to allow researchers to visualise and identify the protein by altering the genetic 
background of the frog whilst affecting the protein’s structure and function minimally. This 
approach was first described in 2016 (Armstrong et al., 2016) where a knock-in line was 
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generated by homology-directed repair (HDR) in the tardbp and fus genes in zebrafish 
(Danio rerio), genes associated with amyotrophic lateral sclerosis (ALS). In summary, 
sgRNAs were designed to bind to the target sequence, guiding cas9 to make a double 
strand break and allowing the insertion of a donor single-stranded DNA molecule 
containing defined point mutations within the gRNA target site allowing the mimicking of 
human diseases, such as ALS. 
The Xenopus embryo genome can be manipulated by gene editing (Lei et al., 2012; 
Nakayama et al., 2013; Pan et al., 2006; Young & Harland, 2012), thus allowing 
researchers to insert, mutate or delete genes. One of the qualities of Xenopus laevis as 
a model organism is, that being allo-tetraploid, one copy of a particular gene can be 
manipulated without affecting the animal’s survival since the copy that remains generally 
allows the healthy development of the embryo.  One advantage of having this copy 
number, is that the genes can be manipulated without compromising their function, as 
long as the animal is heterozygous for that gene. This is most useful in cell biology and 
basic function studies. A disadvantage to this system is that it challenges the feasibility 
of producing true disease models, as the analysis of function in disease would be 
shadowed by the extra copy of the gene in question. 
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7.1.2 Epitope tagging history and pitfalls 
The beginnings of epitope tagging the endogenous locus are found in the birth of 
biotechnology in the last century, which revolutionised biological sciences. These 
discoveries range from the discovery of zymotechnology and industrial fermentation 
(Bud & Cantley, 1994) in early 1900, and the manipulation of an individual’s genetic 
structure to gene therapy (first attempted in 1980 by Martin Cline (Ermak, 2015)). 
Particularly relevant to this approach are the accidental discovery of the underlying 
biology underpinning the ground-breaking technology CRISPR/CAS by Francisco Mojica 
in 1993 (Mojica et al., 2005). The knowledge of this bacterial “immune system” grew until 
the early 2000s when the sgRNA (Makarova, Grishin, Shabalina, Wolf, & Koonin, 2006) 
and CRISPR/Cas9 (Josiane E. Garneau, 2010) systems were adequately described. 
Since 2013, the method developed from this biology has grown incredibly in popularity 
and can be applied to epitope tagging. Gene therapy human trials using this genome-
editing technique have occurred since 2016 (Reardon, 2016), and with this, new variants 
of this approach are emerging.  
Tagging the endogenous locus requires the insertion of a foreign sequence in the 
genome, providing a way of identifying and isolating proteins, but also jeopardising the 
ability of the altered protein to function in vivo. The alterations to the mRNA sequence 
can produce changes at the protein level such as the disruption of the functional domains 
or blockage of protein interaction surfaces, making the tagged gene non-functional. 
Furthermore, the expression level and stability of the protein might deviate from the 
endogenous expression level, making the expression levels of the tag non-physiological 
(Kanca, Bellen, & Schnorrer, 2017; Kolodziej & Young, 1991). Hence, functionality of the 
tagged proteins has to be tested. 
The aim in this section of the project was to add an HA-tag directly, in frame, at the end 
of the gata2 gene using CRISPR-cas9 so that the expression of the gata2 gene can be 
followed in fixed sections and whole mount using an anti HA antibody. 
  
207 
 
7.1.3 GATA Binding Protein 2  
In vertebrates, Gata binding protein 2, commonly known as Gata2, forms part of the gata 
family, six transcription factors involved in many aspects of embryonic development but 
associated primarily with hematopoietic development (de Pater et al., 2013). It binds as 
a multiprotein complex to regulatory elements (SCL/LYL1/LMO2/GATA2), and it also 
interacts with Runx1 (Wilson et al., 2010). There is a particularly prominent expression 
in early blood progenitors, as well as in megakaryocytes and mast cell lineages. 
Furthermore, it is crucial for the proliferation and maintenance of hematopoietic stem 
cells/early progenitor cells (Vicente, Conchillo, García-Sánchez, & Odero, 2012). Gata2 
germline deficiency results in embryonic lethality in mouse embryos and anaemic 
phenotype in Gata-/- stem cells (Tsai et al., 1994). In Xenopus, gata2 is expressed as a 
maternal transcript in the early embryo and abundantly from stage 11 onwards (Zon et 
al., 1991). As well as regulating the proliferation and maintenance of hematopoietic stem 
and progenitor cells (Moriguchi & Yamamoto, 2014), gata2 is involved in the Wnt 
signalling pathway by inhibiting the cannonical route and permiting progenitors to exit 
the cell cycle and commit to a hematopoietic fate. Gata2 has been associated with 
several human dissorders such as Early-Onset Coronary Artery Disease (Connelly et al., 
2006), Chronic Myeloid Leukemia (S.-J. Zhang et al., 2008), Immunodeficiency 21 (Hsu 
et al., 2011), Primary Lymphedema with Myelodysplasia (Ostergaard et al., 2011) and 
Predisposition to Myelodysplastic Syndrome and Acute Myeloid Leukemia (Hahn et al., 
2011). 
The most common gata2 mutations in humans occur within the highly conserved C-
terminal coding region. Hsu et al. (2011) stated that the 480-amino acid Gata2 protein 
contains two zinc finger domains and a nuclear localisation signal in its C-terminal half. 
The mutations can be divided into two main groups, those that allow the transcription of 
the mRNA into a non-functional protein (missense changes and deletions) or mutations 
which cause nonsense-mediated decay (NMD) of the mRNA (full gene deletions, 
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frameshift or early stop mutations) (Hsu et al., 2013). However, on fewer occasions 
mutations within the conserved noncoding and intronic regions have also been reported 
in patients, suggesting haploinsufficiency as the mechanism of Gata2 deficient disease 
(Hsu et al., 2013). 
The identification and visualisation of Gata2 in the early Xenopus embryo are of vital 
importance to validate and expand the knowledge obtained in Xenopus and mouse 
models.  
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7.1.4 Description of the target region 
In this study, the 3’ end of the Xenopus gata2 gene was targeted (Figure 7. 2). Gata2 
has been extensively studied in the Xenopus embryo as one of the major players in 
hematopoiesis (Walmsley et al., 1994) and other vital developmental processes (Zon et 
al., 1991). Antibodies against this Xenopus protein have not been reported (according to 
Xenbase) despite numerous attempts to produce them by a variety of labs.   
Gata2 is a developmentally essential protein, and it has been shown that on some 
occasions tagging can induce changes in protein surface expression or function, as well 
as its cellular localisation (Brothers, Janovick, & Conn, 2003). Xenopus laevis is 
allotetraploid, thus having four copies of many genes (Session et al., 2016) such as gata2 
which allows the modification of one pair and the frog can still develop with the “healthy” 
copy of gata2.  N-terminal endogenous tagging is not recommended as proteins tagged 
this way are prone to be overexpressed (Lafontaine & Tollervey, 1996) or mis-localised 
due to interference with the signal sequence (Gauss, Trautwein, Sommer, & Spang, 
2005), although this is not true when looking at transcription factors.  
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Figure 7. 2. Xenopus laevis gata2 gene (long chromosome), where the target site, situated 
at the 3' end of the coding sequence, has been highlighted by an arrow. 
sgRNA were designed around the target site to guide cas9 protein to make a double strand break 
and allow the insertion of the single-stranded oligonucleotide containing the HA tag.  
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7.1.5 Experimental design 
The aim of this chapter was to insert an in-frame HA tag at the end of Gata2 by CRISPR 
cas9 and homologous recombination, this will enable it to be followed through 
development. 
To generate an HA-tag knock-in, it was first necessary to find a sgRNA that cuts the 
target site well. The efficiency with which the genome gets edited by CRISPR/cas9 
depends on multiple variables, including the distance from the desired mutation point to 
the PAM site (Ward, 2015) and the guide sequence (Doench et al., 2016). In our hands, 
we saw that the sgRNA design has significant implications for the successful production 
of insertions and deletions (indels) in Xenopus embryos. The ease of production and 
manipulation of Xenopus laevis eggs allows making multiple injections at one point in 
time, providing the opportunity to test multiple sgRNAs in one set of injections and having 
sibling embryos. It has been established that starting with three different sgRNAs gives 
a good working sgRNA most of the time (M. Guille personal comments).  
Upon micro-injection (see 2.6.1) with cas9 protein and each sgRNA, the embryos were 
left to develop to stage 12-16 and tested by T7 endonuclease assay to assess the cutting 
efficiency (see 7.1.6), which detects indels resulting from CRISPR-mediated non 
homologous end joining (NHEJ). The best cutting sgRNA was chosen and co-injected with 
cas9 and the ssDNA containing the HA tag insertion. Embryos were left to develop to 
stage 41 when tail-snips were taken, DNA was prepared and the presence of insert 
tested by PCR (see 2.1.6). Most of the injected embryos did not survive to this stage. 
The sgRNAs were designed to affect only the gata2 L gene, having some sequence 
differences to the gata2 S gene.  It is known that the alteration of gata2 is lethal (de Pater 
et al., 2013), thus if the embryos were affected in both alloalleles, these would not grow 
past gastrulation. Only unaffected or heterozygous embryos, with the insertion not 
causing significant disruptions to the protein, would make it past this stage.  
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The insert positive tadpoles were kept and grown to adults. Once they were identifiable 
by their markings, they were photographed and toe-clipped. This second test was 
performed to identify the individual frogs that have the insertion in frame with the Gata2 
protein. 
In this case, the vast natural selection via gata2 functionality and the ease of testing 
tadpoles in large numbers keeps the need for tanks low. As the proportion of embryos 
that, in our case, grew to adulthood was 0.4 %.   
A flowchart of the methodology and graphic description of what happens in the embryo 
can be found in Figure 7. 3 and Figure 7. 4.                             
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Figure 7. 3. CRISPR/cas9 experimental design. 
From this experiment it was possible to design an effective strategy for this approach. A target 
region was selected according to previous knowledge about the protein of interest and multiple 
sgRNAs were designed to target this region. After the selection of the best cutting sgRNA, the 
ssDNA was designed to contain the sgRNA sequence (mutated to alter the nucleotide sequence, 
but not the amino acid sequence), complementary regions to the genome at both sides, and the 
inserted tag. The sgRNA, ssDNA and cas9 proteins were co-injected into one-cell embryos. 
Tadpoles were grown to stage 42 and tail clipped. Pools of the five tadpoles were tested, the 
positive pools then isolated and individual PCRs performed. The positive tadpoles were kept and 
grown to adulthood. As adults, the frogs were photographed, and toe clipped, DNA was prepared, 
and PCR was performed to identify the individuals with in-frame insertions.   
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Figure 7. 4. CRISPR/cas9 injection into the Xenopus laevis fertilised embryo. 
Cas9 protein, sgRNA, and ssDNA for insertion were injected into one-cell embryos and allowed 
to develop. The sgRNA guides cas9 to make a double strand break in a specific site in the 
genome, allowing the ssDNA containing homology arms at either side of the cut to bind and be 
incorporated the genome by the cell’s repair mechanisms; it cannot be re-cut since the ssDNA 
contains silent mutations in the sgRNA sequence (orange). The rate at which cas9 cuts differs 
from the rate to which the ssDNA gets “repaired” or incorporated into the genome, inducing 
mosaicism. Mosaic embryos have some cells with incorporated ssDNA, some cut by cas9 but 
without the ssDNA (probably displaying a variety of indels), and some not cut.  
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7.1.6 T7 endonuclease assay 
A simple method has been developed to test if the cas9/sgRNA micro-injections 
successfully altered the target gene in co-injected embryos. In summary, an amplification 
of the target site from genomic DNA extracted from injected and control embryos are 
denatured and allowed to reanneal. Once annealed, T7 endonuclease is introduced into 
the mix and further incubated (Figure 7.5). The reaction products are then visualised via 
gel electrophoresis; homoduplexes are not cut by the enzyme and heteroduplexes are, 
a difference readily detected by gel electrophoresis.  
 
 
 
 
 
 
 
 
 
 
 
 
  
216 
 
 
 
 
 
 
 
Figure 7. 5. T7 endonuclease assay. 
Genomic DNA extracted from injected and control, un-injected embryos, was subjected to PCR 
with primers designed to amplify a 322bp fragment surrounding the target site. The amplified DNA 
was denatured and re-annealed allowing the native DNA to form heteroduplexes with indels when 
cutting with a T7 endonuclease to detect mismatches. Upon running the samples through an 
agarose gel, differences in size were seen between the wild-type DNA and the manipulated DNA. 
Higher proportions of cut fragments reflect more indels in the target site (Nakayama et al., 2013). 
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7.1.7 Cas9 RNA and protein 
CRISPR/cas9 technology requires the co-injection of the cas9 enzyme with the sgRNA 
that targets it to the site to be cut. A variety of methods have been reported to work 
(Figure 7. 6). The injection of cas9 and the sgRNA both as DNA, the injection of cas9 
and sgRNA both as RNA, and more recently, the injection of sgRNA as RNA and cas9 
as the stable protein (Thurtle-Schmidt & Lo, 2018). DNA injection is inefficient in 
embryos, and at the start of this project, the cas9 protein was not readily available. 
Therefore we generated cas9 RNA.  
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Figure 7. 6. CRISPR/cas9 injection methods. 
sgRNA and cas9 have been reported to work when injected in different formats, DNA, RNA and 
protein (Thurtle-Schmidt & Lo, 2018). sgRNA and cas9 protein can be injected into the embryo 
as circular DNA plasmids (A), as RNA (B) or a combination of sgRNA as RNA and cas9 as a 
protein (C).  
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7.2 Results 
7.2.1 gata2 3’ region sgRNA design  
Three sgRNAs were designed to anneal to a particular sequence in the genome, in this 
case, the end of the gata2 gene. There was no precise target site on the 3’ UTR as the 
NHEJ would repair the sequence and introduce the tag in frame. The cas9 was guided 
to make a double-stranded cut 3 bp away from the PAM site. The sequence of sgRNA 
that anneals to the target sequence are 20-25 bp long (uppercase), to the 5’ of this a 
promoter sequence was added (T7 in this case) to enable RNA synthesis. To the 3’ is 
an overlap to the remainder of the sgRNA encoding the external sequence that allows 
cas9 to bind (lowercase) (Figure 7. 7 and Figure 7. 8). 
The sgRNAs were synthesised as described in Nakayama et al. 2014. In summary, the 
designed sgRNAs were annealed to a standard single-stranded sequence and extended 
with Taq polymerase to make a double-stranded DNA (dsDNA) template which was then 
transcribed with T7 RNA polymerase and visualised by agarose gel electrophoresis 
(Figure 7. 9) (Takuya et al., 2014). 
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Figure 7. 7. sgRNA design to the 3' UTR of Xenopus laevis gata2. 
Sequences were comprised of the T7 promoter sequence, the target specific sequence, and an 
overlap sequence with a second oligonucleotide including the cas9 binding region. 
 
 
 
Figure 7. 8. sgRNA sequences are targeting the gata2 C-terminus region. 
Three sgRNAs were designed (orange, pink and blue) to target the 3’ end of gata2 (dark red) or 
the 3’UTR (grey). Testing primers (purple), used in the T7 endonuclease assay were designed to 
amplify the target region (yellow). This region was also the target sequence subsequently used 
in CRISPRscan,  
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Figure 7. 9. sgRNA synthesis. 
The specific sgRNA encoding oligonucleotides were annealed to the universal ssOligonucleotide 
and extended with Taq polymerase to produce a dsDNA molecule (A) which was transcribed into 
RNA using T7 RNA polymerase (B). Two transcription reactions were performed for each sgRNA. 
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7.2.2 sgRNA efficiency determination by T7 endonuclease assay 
To test the efficiency of the sgRNAs designed to guide cas9 to the 3’ end of gata2 (see 
2.2), the region surrounding the cut site was amplified by PCR (Figure 7. 8; see 2.1.6) 
and subjected to digestion by the T7 endonuclease. One-cell Xenopus laevis embryos 
were co-injected with sgRNA and cas9 protein (NEB) (see 2.6.1). Three sgRNAs were 
tested, and cas9 was also injected on its own as a negative control.  
Pools of 10 embryos were collected at stage 16, DNA was prepared, amplified and tested 
with T7 endonuclease (Figure 7. 10) as described in chapter 2. Amplicons subjected to 
T7 endonuclease were visualised by agarose gel electrophoresis, but only one band of 
correct size for un-cut DNA was present. The absence of a second band corresponds to 
the absence of cutting site. Thus no genetic modification was achieved in the samples, 
the cas9 control behaved as expected. Single embryos were tested, and faint bands 
were observed when using sgRNA#3 (data not shown), suggesting that the assay was 
working. The incision rate was low, and not visible in a pool of 10 embryos (Figure 7. 
10).   
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Figure 7. 10. None of the first 3 sgRNAs produced indels in injected embryos.  
One-cell Xenopus laevis embryos were co-injected with sgRNA and cas9 RNA. Three sgRNAs 
were tested, and cas9 was also injected on its own as a negative control. Embryos were grown 
to stage 16, gDNA was prepared and the target region amplified by PCR. The amplicons were 
denatured, reannealed and incubated with a T7 endonuclease to revealed mismatches. The 
products were separated by agarose gel electrophoresis and visualised by ethidium bromide 
staining under UV light. No miss-maches were observed with any of the sgRNAs. 
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7.2.3 Can Cas9 protein cutting efficiency compare with Cas9 mRNA 
injection? 
The cas9 containing plasmid (a kind gift from Dr Marko Horb) was transformed and 
prepared upon receipt (see 2.1.5). The plasmid was linearised and transcribed with SP6 
(Figure 7. 11 A and B; see 2.1.11). The use of cas9 mRNA worked well for the whole 
group before cas9 protein was available (data not shown). However the drawback of this 
method was the risks in RNA synthesis consistency. RNA has limited stability and we 
observed differences in performance from batch to batch. The accelerated growth of 
CRISPR/cas9’s popularity allowed this inconvenience to be overcome by sourcing 
commercially available cas9 protein (NEB). Cas9 protein is stable at -20ºC and does not 
degrade as readily as RNA, moreover, the commercial quality assurance allowed the 
reproducibility of results in a more cost-effective manner. Nonetheless, we needed to 
compare the efficiency of the mRNA and protein directly. 
A duplicate experiment was carried out where the commercial protein was tested 
alongside cas9 RNA injection (see 2.6). The cas9 RNA was co-injected with three 
different sgRNAs; embryos were incubated until they reached stage 16, DNA was 
extracted from them and tested by T7 endonuclease assay (see 7.1.6). This showed that 
the cas9 RNA used in the previous experiment worked well and so the problem was with 
the guide RNA design (Figure 7. 11 C). 
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Figure 7. 11. Cas9 mRNA preparation and test Vs cas9 protein (NEB). 
The cas9 containing a plasmid (a kind gift from Dr Marko Horb) was transformed into DH5α cells 
and prepared upon receipt (A). The plasmid was linearized with NotI, cleaned by chromatography 
and transcribed with SP6 polymerase (B). Two reactions were performed producing good quality 
RNA. Reaction #1 showed a higher band which corresponded to leftover DNA that was not 
successfully eliminated despite the treatment with DNAaseI. To test the comparative efficiency of 
this cas9 mRNA with the protein commertially available, a test experiment was performed (C). 
One-cell Xenopus embryos were injected with a control sgRNA (known to work), control cas9 
mRNA (a gift from Dr Abu-Daya) and, the cas9 mRNA described here (A and B) and commercially 
available cas9 protein. There was no difference in the efficiency between the control cas9 mRNA, 
the cas9 mRNA made for these experiments and the commercial Cas9 protein (C).  
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7.2.4 New sgRNA design and production 
It was therefore decided that a further sgRNA was needed to cut the gata2 target region. 
Due to the increasing popularity of CRISPR/cas9 as a genetic engineering tool, and thus 
the investments aimed at making this research model more efficient and of widespread 
use, new tools or variants on this approach are regularly published. One of these 
advances was the development of an online predictive sgRNA-scoring algorithm that 
allowed the identification of potential sgRNAs that might be used. CRISPRscan was 
designed using data from Xenopus considering the molecular features that influence 
sgRNA stability, activity, and loading into cas9 in vivo (Moreno-Mateos et al., 2015). A 
fourth sgRNA (sgRNA #4) was thus designed utilising CRISPRscan (Figure 7. 12).  
At this point, it is interesting to note that sgRNA #3, designed by hand, and sgRNA #4, 
designed in silico, cover the same sequence. However, sgRNA #4 was 3 bp shorter and 
had its second nucleotide changed from a T to a G (Figure 7. 13).   
sgRNA #3 injected embryos previously showed very faint bands when subjected to T7 
endonuclease assay (data not shown). Therefore, sgRNA#3 was transcribed as a new, 
fresh batch when sgRNA#4 was made to minimize the differences between them during 
subsequent testing. 
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Figure 7. 12. CRISPRscan sgRNA suggestions for gata2 3' end target sequence. 
The 197 bp target sequence, composed of the 3’ end of the gata2 ORF and the beginning of the 
3’UTR of gata2 was submitted to CRISPRscan as a template. Four sgRNAs were suggested. The 
first suggested sequence in the list was chosen.   
 
Figure 7. 13 Sequence comparison of sgRNA #3 designed by hand against sgRNA #4 
designed by CRISPRscan. 
Note the sequences cover the same region. However, CRISPRscan alters one base pair (from T 
to G) and is slightly shorter. The differences are shown in red above. 
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7.2.5 Can sgRNA #4 successfully guide cas9 to the cut site? 
DNA from one-cell embryos micro-injected with cas9 protein and sgRNA #4 was 
extracted (Qiagen DNeasy Blood & Tissue Kit), amplified with target-specific primers 
(see 2.1.6) and subjected to T7 endonuclease assay as previously described (see 7.1.6). 
Embryos were injected with cas9 protein on its own as a negative control.  
The sgRNA#3 and sgRNA#4 exhibit consistent cutting. However, sgRNA#4 was chosen 
to work with since the stronger lower band on the gel suggests a more efficient indel 
formation at the target DNA (Figure 7. 14). 
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Figure 7. 14. T7 endonuclease assay of embryos co-injected with cas9 protein and sgRNA 
#3 and sgRNA#4. 
Embryos were co-injected at the one-cell stage with the gRNA shown and Ca9 protein, and 
allowed to grow to stage 16. Embryos were collected, DNA extracted, and the target region was 
amplified and reannealed. T7 endonuclease was added to the amplified target sequence and 
incubated before running on a 1 % agarose gel. Cas9 protein was injected on its own as a 
negative control. Both sgRNA #3 and sgRNA #4 cut the amplified sequence, sgRNA#4 doing so 
in a significantly more efficient manner. Each lane represents a single embryo.  
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7.2.6 Identifying the mutations made by sgRNA #4 and cas9  
To assess the efficiency and specificity of the mutagenesis by CRISP/cas9, the target 
PCR products were sub-cloned into pGemTeasy and sequenced (see 2.1.4, 2.1.6). 
Eighty-one percent of the sequences obtained showed deletions around the desired cut 
site. It also showed some random insertions in 6 % of the sequenced clones. All observed 
changes are shown in Figure 7. 15, while Figure 7. 16 shows the deletions in more detail. 
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Figure 7. 15. Target site amplicons were sub-cloned into pGemTeasy and sequenced. 
One-cell Xenopus laevis embryos were microinjected with cas9 protein and sgRNA#4. Embryos 
were allowed to develop to stage 16, DNA extracted from them and PCR amplified with specific 
primers. The PCR products were sub-cloned into pGemTeasy and sequenced. Deletions and 
random insertions were observed around the targeted cut site (enlarged in Figure 7.16). The large 
insertion on the 5th sequence was identified by BLAST against the Xenopus genome as a section 
of the gata2 gene outside the target region.  
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Figure 7. 16. Gata2 target site amplicons cloned into pGemTeasy. 
Three distinct populations can be observed after the co-injection with cas9 and sgRNA; one with 
5 deletions, one with 11 bp deletions and one with 12 bp deletions. In only one of the sequences 
were 2 inserted nucleotides observed. There are 3/16 uncut sequences.  
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7.2.7 Design of the insertion sequence for HA-tagging of gata2 
Once the sgRNA to be used had been identified, a single-stranded oligonucleotide 
(ssOligonucleotide) was designed to insert an HA epitope tag into the 3’ UTR of gata2 in 
Xenopus laevis. The design consisted of 20 base complementary sequence at the 3’ and 
5’ ends of the oligonucleotide, to guide the correct targeting of the ssOligonucleotide. 
The sequence corresponding to sgRNA sequence in the ssOligonucleotide was mutated, 
so the nucleotide sequence changed, but the amino acid sequence was the same. These 
nucleotide changes allowed the sgRNA to make an incision on the wild-type DNA, but 
once the oligonucleotide was inserted, the sgRNA would not recognise the mutated 
sequence as a target any longer. Following the sgRNA sequence, an HA tag sequence 
was designed in frame with the gata2 ORF. Straight after the HA tag, a new stop codon 
was inserted, followed by a BamHI site created for the identification of embryos with the 
successful insert (Figure 7.17). 
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7.2.8 Can an HA tag be inserted into the endogenous gata2 C-terminus? 
Embryos were co-injected with cas9 protein, sgRNA#4 and the HA tag-containing DNA 
(see 2.6.1). Three amounts of the insert DNA were tested: 50 pg, 100 pg and 200 pg. 
The majority of embryos (~90 %) injected with 200 pg of the insertion DNA did not 
develop after gastrulation and were mostly deformed. When injected with 100 pg and 50 
pg of insert DNA, embryos had a higher rate of successful gastrulation (~20 %), 
developing less frequent deformities. Most of the deaths occurred between stages 8 and 
12, correlating with the onset expression of gata2 in the embryo (Figure 7. 18). Therefore, 
injections were performed with 50 pg and 100 pg of insert DNA thereafter. From over 
6000 injected embryos, only 168 grew to the tail-bud stage from which 27 tested positive 
for the insertion (16 %). Tadpoles were tested by PCR of the extracted genomic DNA 
(Qiagen DNeasy Blood & Tissue Kit) and in some cases cloned into pGemTeasy for 
sequencing (see 2.1.4, 2.1.6). The sequences showed a variety of in-frame and out-of-
frame insertions. The tadpoles at these stages (between stage 30 and 42) could not be 
kept separately, due to welfare and practical considerations, for long enough to be able 
to extract the DNA, PCR, sub-clone and sequence. Thus they were mixed and left to 
grow to adults. Only 15 frogs developed to adulthood, which could then be identified by 
photographing the patterns on their backs allowing for the subsequent identification of 
the in-frame mutation-containing animals.  
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Figure 7. 18. Xenopus laevis gata2 RNA-Seq expression data. 
Expression of gata2 starts at stage 8-9, with the highest steady-state RNA levels at stage 12. 
Over 90 % of embryos co-injected with sgRNA and cas9 did not survive past gastrulation (stages 
10.5-12). This could be due to different reasons. It is good practice to account for the possibility 
of DNA toxicity and its effects on the embryos. Therefore control embryos were injected with either 
the sgRNA or the ssOligonucleotide alone. These embryos developed normally, as did the un-
injected controls. When co-injecting cas9 and sgRNA, without the ssOligonucleotide, embryos 
exhibit a higher rate of mortality compared to uninjected controls. This may indicate that the 
incisions made by the activity of cas9 can produce off-target lethal effects and that the gata2 
protein is mutated and becomes non-functional.  
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7.2.9 Detecting and characterizing HA sequence insertions at the gata2 
locus 
Embryos injected with sgRNA, Cas9 protein and the HA tag insertion sequence were 
allowed to develop to stage 16-20, tail snipped, DNA extracted (Qiagen DNeasy Blood 
& Tissue Kit) and tested for the insertion of the HA tag. Testing was done by PCR (see 
2.1.6) and amplicon digestion with BamHI (see 2.1.1), a site designed following the HA 
tag on the insertion DNA (highlighted in orange in Figure 7.19). 
Amplicons produced by amplification of the insertion site and surrounding genomic DNA 
subjected to BamHI digestion were expected to yield three products.  An un-cut fragment 
corresponding to the wild-type, non-mutated DNA, and two smaller fragment 
corresponding to the digested inserted DNA fragment. This approach was unsuccessful 
(data not shown). This may be due to the mosaicism between cells from which the DNA 
was extracted and suspected low insertion rate of the DNA in the fast-dividing early 
embryo or due to a complete failure of insertion.     
To bias the amplification of the insertion positive cells, two sets of primers were designed 
that promoted the amplification of DNA samples containing the inserted DNA. These 
primers amplified two fragments. One PCR reaction amplified the 5’ end of the insert and 
the other set the 3’ end of the sequence. The primers were designed so the products 
would also contain the junction between the insert and the genomic DNA, allowing the 
identification of frogs containing an in-frame insertion and those in which the insertion is 
out of frame (Figure 7.19 and Figure 7.20).   
Upon positive PCR amplification, samples were cloned into pGemTeasy as described in 
the methods section (see 2.1.4, 2.1.6). Multiple colonies from each plate were analysed, 
since the mosaicism of the embryo would be represented in the amplified DNA. The 
insertion rate was 11.3 %, with some fragments inserted correctly and some fragments 
out-of-frame (Figures 7.21, 7.22 and 7.23).  
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Figure 7. 20. Cas9 protein (NEB) and sgRNA #4 injected embryos. 
Embryos were co-injected at the one-cell stage with sgRNA #4 and cas9 protein, and allowed to 
develop to stage 40. DNA was extracted from tail clips, target sequence amplified by PCR and 
visualised by agarose gel electrophoresis. Cas9 protein was injected on its own as a no DNA and 
no sgRNA negative control. Each lane represents a single embryo were 7/10 tested positive for 
an insertion. The PCRs were designed to enrich for the positive cells (Figure 7.19), as the primers 
were designed to amplify the insert from the HA tag to the genomic sequence. The cas9 protein 
injection gave no signal, while the positive control (a previously analysed sample) also behaved 
as expected.  
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7.3 Discussion 
This study aimed to endogenously tag the gata2 locus so that the Gata2 protein could 
be visualised and isolated. To do this, the 3’ end of the endogenous Xenopus laevis 
gata2 was successfully tagged; an HA tag was inserted via CRISPR/cas9 technology 
and tested by PCR and sequencing. We do not know exactly how efficient this process 
was, although from one experiment of around 10000 injections, only 106 froglets 
survived, and 12 displayed the correct size band when analysed by T7 endonuclease. 
This is an 11.3% insertion rate, from which only 8 grown to adulthood. The in frame 
insertion and germ line transmission efficiency of these frogs still has to be tested. 
The method employed in this study required very high numbers of micro-injections, DNA 
extractions, PCR and sequencing, and due to husbandry requirements tadpoles could 
not be in isolation for a long enough time to distinguish individuals with in-frame 
insertions from those out-of-frame. Nevertheless, we hypothesise that biology has acted 
to favour this study by naturally selecting heterozygous embryos with non-lethal genetic 
modifications to survive. Also, the percentage of embryos that survived suggest that the 
combination of cas9 and sgRNA induced either very efficient molecular changes in the 
gata2 gene, making most of these embryos homozygous for mutated gata2 (lethal to the 
embryos if non-functional), or that cas9 and sgRNA modified other parts of the genome 
causing lethality. More so, there are controversies regarding epitope tagging of the 
endogenous locus, as is believed that the use of such tags might not accurately reflect 
the cellular localization of modified proteins (Brothers et al., 2003), if true in this study, it 
might contribute to the high mortality rate at the early stages.  
Towards the end of this study, a potentially revolutionary paper was published by Aslan 
et al. (Aslan, Tadjuidje, Zorn, & Cha, 2017) which describes, as the title of the article 
suggests, a “High-efficiency non-mosaic CRISPR-mediated knock-in and indel mutation 
in F0 Xenopus”. This report described the success of a method by which oocytes were 
injected with the cas9, sgRNA, and ssDNA and incubated with DNA ligase IV inhibitor to 
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promote homology-directed repair (HDR) over nonhomologous end joining (NHEJ). This 
method is advantageous as the rate of insertion is increased, the chances of re-editing 
the already inserted change are decreased, and in consequence, the embryos were not 
mosaic. The oocytes were incubated for three days after CRISPR/cas9 co-injection, 
which gives time for the cas9 and sgRNA to degrade, thus when the oocyte is matured 
and fertilised, the embryo can develop without the risk of cas9 altering the genome. The 
main drawbacks of the method were technical as the rate of survival after sperm nuclear 
transfer are very low. These type of techniques, to encourage HDR-induced point 
mutations are quickly evolving also in zebrafish (Y. Zhang, Zhang, & Ge, 2018) where 
the focus also was to increase the germline transmission and establish lines. 
In the experiments described in this thesis, fifteen positive frogs grew to adulthood. 
These frogs need to be tested to discover if the insertion is in-frame. Following this, the 
frogs need to be outbred to test germline transmission. Blood from the frogs can also be 
used in western blots to determine whether the tagging has been useful in providing a 
model in which to study the Gata2 protein, something which has not so far been possible. 
These frogs are being held at the EXRC, and studies are underway to analyse them, 
however, breeding and analysis of the offspring will take over a year.  
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8 General discussion and further work 
Scientific knowledge is an accumulative process, where new studies either confirm, 
enhance or reform previously obtained knowledge. Often, scientists re-visit and new 
studies occur as new techniques develop and inter-disciplinary strategies are 
incorporated and associated with a research area. In recent years has become evident 
that many aspects of biology, such as developmental, genetic and biochemical studies 
require the understanding of proteins, their function, structure and localisation, and for 
some studies, at a specific time point in development.  
By stage 33 a Xenopus tadpole has formed blood, heart tube and muscles, the kidney is 
differentiating, the eye is partially formed and it has the ability to swim away from stimuli. 
Despite all this, at stage 33 fewer than half of its proteins present in the Xenopus embryo 
were generated from zygotic transcripts (Peshkin et al., 2015) and not from embryonic 
translation. The critical need to be able to study the levels, control and function of 
proteins, in addition to RNA in the early embryo is therefore clear. 
With limited number of commercially available Xenopus-specific reagents, the poor 
cross-reactivity of reagents raised against other models with Xenopus, and the revelling 
knowledge about the proteins’ origin, the importance of obtaining a well characterized 
pool of Xenopus-specific reagents became clear. To address this growing issue, the 
EXRC was founded by BBSRC to generate and supply the community with Xenopus-
specific reagents, specially plasmids and antibodies. During this project, we worked 
closely with the community through the EXRC’s network to obtain a list of target proteins 
of significant interest and we had invaluable support and experience provided by the 
EXRC’s Strategy Board team, a team of 10 – 12 experience Xenopus researchers. 
From the experience shared by the Strategy board members, which included Prof E 
Jones, and the literature at the time, the production of single chain antibodies was 
suggested as a good way forwards. Importantly, VHH libraries have shown to have a 
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very profound impact on the fields where they have been applied. The popularity of VHHs 
and the chance to collaborate with the Sokols’ laboratory which facilitated the training 
and knowledge to work with VHHs made this approach possible. Upon screening the 
libraries obtain from the Sokols’ lab, it was found that the complexity of the libraries had 
a significant effect on the ease of screening. These libraries generated many positive 
results when screened against VHHs. However, there were no Xenopus-specific VHHs 
found in our hands. At Sokols’ lab, a VHH against a Xenopus yolk protein was 
successfully isolated, highlighting, even more, the importance of the purity of the 
immunogens used.  
The generation of pure proteins for immunisation became our priority. By the use of the1-
Step Human High-Yield Mini IVT Kit, proteins were successfully expressed. However the 
small yield and price per reaction at the time, suggested we looked at other approaches. 
Since the time this method was used (2014), the price of this experiments has been 
reduced in such way that if this approach could now be re-visited. 
A more efficient way of protein production is the established method of protein production 
via transfection of a plasmid into HEK cells, which became a suitable option. This method 
provides with large amounts of proteins that easily purify when secreted to the cell’s 
media. By the use of the In-Fusion system, we were able to express proteins which 
emitted a strong signal when tested by western blot and Coomassie stain. This method 
was promising. However, the proteins we worked with were mainly transcription factors 
and DNA binding proteins, which were found to be extremely difficult to solubilise and 
purify. We therefore decided to investigate if commercial immunogen production would 
be an option. 
Twenty-six protein sequences were sent to commercial companies for expression or 
synthesis. No companies were willing to express any of the suggested targets in 
mammalian systems; they suggested bacterial expression, however that was not an 
option in this project as any carryover bacterial residue would be very immunogenic in a 
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mammalian host, potentially becoming the prominent VHH found in the library. Other 
systems were also available such as insect cell expression, but we did not consider any 
non-mammalian systems. 
The synthesis of peptides was investigated, were two companies were chosen to work 
with. Alta Bioscience provided with octomeric MAPs, which are recognised as a good 
option when choosing immunogens that are not coupled to any carrier protein. The other 
company was ThermoFisher, which provided us with long peptides of up to 120 AAs. 
The decision to don’t couple the proteins to a carrier was also made considering the 
possibility of the carrier protein producing an immune response.  
Once the targets were chosen, and the most immunogenic but unique peptide sequence 
suggested (by the commercial companies), two llamas were successfully immunised. 
Valentine was immunized with a Cdk1 octomeric MAP and the Sunny with an Ascl1 long 
peptide. A pre-bleed and two immune-bleeds were taken, which show an excellent 
immune response. The library making and VHH isolation from the stored lymphocytes 
remains to be done due to an 18-month delay caused by TB at the llama’s farm.  
For a direct comparison of the protocols to make llama and conventional antibodies, a 
sheep was immunized with the Kash5 octomeric MAP. Ideally we would have used the 
same immunogen in a llama and a ship, but due to the direct link between this project 
and the needs of the community, a Kash5 antibody became a priority. The sheep 
immunization was successful, where a clear response is present from the first bleed 
when tested against an MBP-tag kash5 protein, apparently decreasing in bleed 2 and 3. 
These results need to be confirmed with further analysis of this conventional antibody, 
the detection of the endogenous Xenopus protein has to be optimised, as the detection 
is not easily reproducible.  
Lastly, the successful introduction of an HA-tag into the endogenous Xenopus laevis 
gata2 provides a different way of visualising proteins in the early embryo. The fact that 
the tagging is carried out at a genetic level, allows the targeting of otherwise challenging 
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to differentiate proteins, such as close members of the same family. The efficiency by 
which this tag was inserted was low, however the number of possitive animals needed 
to establish a line is one. New techniques are being developed that potentially allow the 
insertion of this sort of tag more efficiently. These techniques have been published, but 
could not be replicated in-house to date, despite more than a year’s work on them.  
F1 embryos produced from crossing F0 gata2-HA with wild-type Xenopus laevis are 
needed to corroborate the germline transition of the insertion over generations, and these 
will be available in 2019. These embryos then have to be tested via 
immunohistochemistry to confirm the visualisation of the HA-tag on fixed embryos. 
This project contributed to the Xenopus community’s general knowledge about antibody-
making and protein visualisation and detection in embryos. The work involved analysing 
the mixed protein VHH libraries and the methodologies for protein production, although 
it did not provide positive results to date, it still provided knowledge about these 
processes and how to approach them in further experiments.  
The experience obtained while on this doctorate course, encouraged the evaluation of 
the methods used. Primarily, if I was to do this again (and not be restricted by grant 
related expectations), I will choose proteins that have been previously characterized. I 
will also reduce the number of proteins I worked with, and have the same protein raised 
in different media and used to immunize a variety of hosts, as this provides true direct 
comparisons. I will also take extra time purifying and checking the quality of the antigen, 
and when raising the antigen is not feasible, to compare the octomeric MAP and long 
peptide efficiency as immunogen side by side. 
Even with all the refinement that these methods need, we achieved the successful 
immunisation of llamas and sheep, and also provided with material for further studies 
and the successful insertion of the HA-tag in the endogenous gata2 was something 
without precedent.   
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10 Websites used 
10.1.1 Phyre2 - Protein folding prediction tool (Kelly, Mezulis, Yates, Wass, 
& Sternberg, 2015).  
 http://www.sbg.bio.ic.ac.uk/~phyre2/html/page.cgi?id=index 
10.1.2 UniPort - Protein database. 
http://www.uniprot.org/ 
10.1.3 Xenbase - Xenopus model database. 
http://www.xenbase.org/entry/ 
10.1.4 NCBI - Multiple model biotechnological databases and research 
journal database. 
https://www.ncbi.nlm.nih.gov/ 
10.1.5 psipred - Protein folding prediction tool (McGuffin, Bryson, & Jones, 
2000).  
http://bioinf.cs.ucl.ac.uk/psipred/ 
10.1.6 Google - Search engine. 
https://www.google.co.uk/ 
10.1.7 CRISPRscan - gRNA designing tool. 
http://www.crisprscan.org/  
Clustal Omega - Multiple sequence alignment tool (Sievers et al., 2011). 
http://www.clustal.org/omega/ 
10.1.8 BLAST - Basic local alignment search tool (Altschul, Gish, Miller, 
Myers, & Lipman, 1990). 
https://blast.ncbi.nlm.nih.gov/Blast.cgi  
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11 Appendix I 
In-Fusion® HD Cloning Kit User Manual (Clontech® Laboratories, Inc.) 
11.1 pOPIN Vectors Maps 
11.1.1 pOPINF-his tag at the N-terminal (Addgene Plasmid 26042) 
 
Figure I. 1. pOPINF vector map. 
Vector containing a his-tag at the N-terminal. 
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11.1.2 pOPINM-MBP - MBP tag and his-tag (Addgene Plasmid 26044) 
 
Figure I. 2. pOPINM vector map. 
Vector containing an MBP tag, which might enable/ease solubility and purification of the target 
protein. 
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11.1.3 pOPINJ-JST – JST tag and his-tag (Addgene Plasmid 26045) 
 
 
Figure I. 3. pOPINJ vector map. 
Vector containing a GST-tag, which might enable/ease solubility and purification of the target 
protein.  
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11.1.4 pOPINE – his-tag at the C-terminal (Addgene Plasmid 26043) 
 
Figure I. 4. pOPINF vector map. 
A vector containing an his-tag at the C-terminal. 
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11.1.5 pOPINTTGneo - his Tag at the C terminal (A kind gift from Ray Owens) 
 
Figure I. 5. pOPINTTGneo vector map. 
A vector containing an his-tag at the N-terminal and a secretion signal. 
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11.1.6 pOPINEneo-3C-2STREP - his tag and strep-tag at the C-terminal (A 
kind gift from Ray Owens) 
 
Figure I. 6. pOPINEneo-3C-2STREP vector map. 
Vector containing 8 x his-tags and 2 x Strep-tags at the C-terminal and a secretion signal. 
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11.1.7 pOPINEneo-3C-3FLAG - his tag and Flag-tag at the C-terminal (A kind 
gift from Ray Owens) 
 
Figure I. 7. pOPINEneo-3C-3FLAG vector map. 
Vector containing 8 x his-tags and 3 x Flag-tags at the C-terminal and a secretion signal. 
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11.1.8 pOPINFS - his tag and Flag-tag at the C-terminal (A kind gift from Ray 
Owens) 
 
Figure I. 8. pOPINFS vector map. 
Vector containing a StrepII-tag and a partial N-terminal his-tags as well as a secretion signal. 
 
  
  
297 
 
11.2 List of Primers 
11.2.1 Vector pOPINE: 
Table I. 1. Primers designed to amplify the desired sequence and anneal to the pOPINE 
vector. 
Insert Length Direction Sequence 
Delta1 FL 
Fw aggagatataccatgatgggacagcagcgca 
Rv gtgatggtgatgttttgtatttttttgtttgatcataagcttaccttgg 
FliI 
FL 
Fw aggagatataccatgatggacggaaccattaaggaagc 
Rv gtgatggtgatgtttgtaaaaaccacctaagtgggactg 
C-term  
Fw same as fl version 
Rv gtgatggtgatgaacctgagaacgttgctgatcccc 
Gata2 
FL 
Fw aggagatataccatgatggaagtggccactgaccag 
Rv gtgatggtgatgttttcccatagccgtcaccatgc 
C-term 
Fw same as fl version 
Rv gtgatggtgatgaacgcaggatctgctcttgctcc 
HairyI 
FL 
Fw aggagatataccatgatgccggctgatgtgatgg 
Rv gtgatggtgatgtttccagggcctccaaacagaat 
C-term 
Fw aggagatataccatggccaactgcatgaaccagatca 
Rv same as fl version 
Lis1 FL 
Fw aggagatataccatgatggtgctgtcacaaagacaaagag 
Rv gtgatggtgatgtttacggcactcccacact 
Ndel1-a 
FL 
Fw aggagatataccatgatggaaaacgaggaaatccctgag 
Rv gtgatggtgatgttttacactaagcggaagcattccc 
C-term 
Fw aggagatataccatgggagagacagacggatggtacaagg 
Rv same as fl version 
NeuroD 
FL 
Fw aggagatataccatgatgaccaaatcgtatggagagaatgg 
Rv gtgatggtgatgtttatcatgaaagatggcatttagctggg 
C-term 
Fw aggagatataccatggagcccagacctggtgt 
Rv same as fl version 
Neurog2 FL 
Fw aggagatataccatgatggtgctgctcaagtgcg 
Rv gtgatggtgatgtttaatgaaagcgctgctggca 
RARα2 FL 
Fw aggagatataccatgatgtatgagaatgtggacgtcagc 
Rv gtgatggtgatgtttgtggttggaactgctccagtg 
Ncor2 FL 
Fw aggagatataccatgacaggcagtggaaaagccaag 
Rv gtgatggtgatgtttctcactgtctgacagagtctcatattgg 
TalI FL 
Fw aggagatataccatgatgtccctaaagatgatggagaggc 
Rv gtgatggtgatgtttccgctgcccactgcc 
Myt1 FL Fw aggagatataccatggatgaatgtagacaatgttaacaa 
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 Rv gtgatggtgatgtttaaaccacaccttgatccctttg 
C-term 
Fw aggagatataccatggaagatcgcaaataccccggaga 
Rv gatggtgatgtttaaccaccttgatccctttgactgcttg 
XicI FL 
Fw aggagatataccatgatggctgctttccacatcgc 
Rv gtgatggtgatgttttcgaatctttttcctgggggtctg 
 
11.2.2 Vector pOPINE-Strep II (C-his tag): 
Table I. 2. Primers designed to amplify the desired sequence and anneal to the pOPINE-
Strep II vector. 
Insert Length Direction Sequence 
Gata2 C-term 
Fw 
AGGAGATATACCATGGGCCTGTGGTCTCTATCACAAAAT
GAAT 
Rv CAGAACTTCCAGTTTAAACGCCAAGTGACCCATAGGAGC 
HairyI C-term 
Fw aggagatataccatggccaactgcatgaaccagatca 
Rev cagaacttccagtttccagggcctccaaacagaatca 
cdk1 FL 
Fw aggagatataccatggatggacgagtacactaaaatagagaagattgg 
Rv cagaacttccagtttaaactttctaatctgattggcgggaaggct 
 
11.2.3 Vectors pOPINF - pOPINM –pOPINJ: 
Table I. 3. Primers designed to amplify the desired sequence and anneal to the pOPINF, 
pOPINM and pOPINJ vectors. 
Insert Length Direction Sequence 
Delta1 FL 
Fw aagttctgtttcagggcccgatgggacagcagcgcat 
Rv ctggtctagaaagctttatgtatttttttgtttgatcataagcttaccttggttaca 
FliI 
 
FL 
Fw aagttctgtttcagggcccgatggacggaaccattaaggaagctc 
Rv ctggtctagaaagctctagtaaaaaccacctaagtgggactgc 
C-term 
Fw same as fl version 
Rv ctggtctagaaagcttctgagaacgttgctgatcccc 
Gata2 
FL 
Fw aagttctgtttcagggcccgatggaagtggccactgacca 
Rv ctggtctagaaagctttatcccatagccgtcaccatgc 
C-term 
Fw same as fl version 
Rv ctggtctagaaagcttggatctgctcttgctcctctgt 
HairyI 
FL 
Fw aagttctgtttcagggcccgatgccggctgatgtgatgg 
Rv ctggtctagaaagctttaccagggcctccaaacagaat 
C-term 
Fw aagttctgtttcagggtaccgccaactgcatgaaccagat 
Rv same as fl version 
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Lis1 FL 
Fw aagttctgtttcagggcccgatggtgctgtcacaaagac 
Rv ctggtctagaaagcttcaacggcactcccacact 
Ndel1-a 
FL 
Fw gttctgtttcagggcccgatggaaaacgaggaaatccct 
Rv ctggtctagaaagcttcatacactaagcggaagcattccc 
C-term 
Fw aggagatataccatgggagagacagacggatggtacaagg 
Rv same as fl version 
NeuroD 
FL 
Fw aagttctgtttcagggcccgatgaccaaatcgtatggagagaatgg 
Rv ctggtctagaaagctttaatcatgaaagatggcatttagctggg 
C-term 
Fw aagttctgtttcagggtaccaaaagcccagacctggtgt 
Rv same as fl version 
Neurog2 FL 
Fw aagttctgtttcagggcccgatggtgctgctcaagtgc 
Rv ctggtctagaaagcttcaaatgaaagcgctgctggc 
RARα2 FL 
Fw aagttctgtttcagggcccgatgtatgagaatgtggacgtcagc 
Rv ctggtctagaaagcttcagtggttggaactgctccagtg 
Ncor2 FL 
Fw aagttctgtttcagggcccgacaggcagtggaaaagccaag 
Rv ctggtctagaaagctctcactgtctgacagagtctcatattgg 
TalI FL 
Fw aagttctgtttcagggcccgatgtccctaaagatgatggagaggc 
Rv ctggtctagaaagcttcaccgctgcccactgcc 
Myt1 
 
FL 
Fw gttctgtttcagggtaccatgaatgtagacaatgttaaca 
Rv tggtctagaaagctttcacaccttgatccctttga 
C-term 
Fw ttctgtttcagggtaccgaagatcgcaaataccccggaga 
Rv ctggtctagaaagcttcaccttgatccctttgactgcttg 
XicI FL 
Fw aagttctgtttcagggcccgatggctgctttccacatcgc 
Rv ttagtctagaaagcttcgaatctttttcctgggggtct 
 
11.2.4 Vector pOPINGM (ss-MBP-C-his tag): 
Table I. 4. Primers designed to amplify the desired sequence and anneal to the pOPINGM 
vector. 
Insert Length Direction Sequence 
Gata2 C-term 
Fw aagttctgtttcagggtacccctgtggtctctatcacaaaatgaatgg 
Rv gtgatggtgatgtttaaacgccaagtgacccataggagc 
HairyI C-term 
Fw aagttctgtttcagggtaccgccaactgcatgaaccagatcaat 
Rv gtgatggtgatgtttaaaccagggcctccaaac 
cdk1 FL 
Fw aagttctgtttcagggtacccatggacgagtacactaaaatagagaagat 
Rv gtgatggtgatgtttaaacttaatttctaatctgattggcgggaaggc 
pOPINGM 
Seq 
  tgcgtactgcggtgatcaacg 
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pOPINGM 
Seq2 
  atgtccgctttctggtatgccg 
 
11.2.5 Vector pOPINTTGneo: 
Table I. 5. Primers designed to amplify the desired sequence and anneal to the 
pOPINTTGneo vector. 
Insert Length Direction Sequence 
Gata2 C-term 
Fw gcgtagctgaaaccggtacctgtggtctctatcacaaaat 
Rv gtgatggtgatgttctgccaagtgacccataggagccat 
Ncor2 C-term 
Fw gcgtagctgaaaccggtaccacaggcagtggaaaagccaa 
Rv gtgatggtgatgtttaaactcactgtctgacagagtctca 
TalI 
N-term 
Fw tagctgaaaccggtaccatgtccctaaagatgatggagag 
Rv gtgatggtgatgtttaaaccagaattcagcagcaggggtt 
C-term 
Fw tagctgaaaccggtaccgaagtggaaatctctgaaggtcc 
Rv gtgatggtgatgtttaaacatgtcttgaagcagttcttgc 
NeuroD 
N-term 
Fw tagctgaaaccggtaccaaaaagaaaaaaatgacgaaagc 
Rv gtgatggtgatgtttaaacctggggttcagctgcagac 
C-term 
Fw gcgtagctgaaaccggtacccctcactcctatggggcgg 
Rv gtgatggtgatgtttaaactcatgaaagatggcatttagc 
Neurog2 C-term 
Fw gcgtagctgaaaccggtaccaagagcggagaaactgtgtt 
Rv gtgatggtgatgtttaaacatgaaagcgctgctggca 
FliI C-term 
Fw gcgtagctgaaaccggtaccagtggccaaattcagctgtg 
Rv gatggtgatgtttaaactcagaaggatatttgtacattga 
XicI 
N-term 
Fw gcgtagctgaaaccggtaccatggctgctttccacatcg 
Rv atggtgatggtgatgtaatggcgttgtgttggcagct 
Fl 
Fw gcgtagctgaaaccggtaccatggctgctttccacatcg 
Rv gtgatggtgatgtttaatcgaatctttttcctgggggtct 
cdk1 
C-term 
Fw gcgtagctgaaaccggtacccccctcttccacggtgact 
Rv gtgatggtgatgaacatttctaatctgattggcgggaagg 
N-term 
Fw gctgaaaccggtaccatggacgagtacactaaaatagaga 
Rv tggtgatggtgatgaacatcgatatactggccgct 
Rv-New tggtgatggtgatgaacatactggccgctgggta 
Fl 
Fw gctgaaaccggtaccatggacgagtacactaaaatagaga 
Rv gtgatggtgatgaacatttctaatctgattggcgggaagg 
Sequencing 
primer 
 Fw cgctgctctccctcgtgagcct 
 Rv cggccgcctgcacctgaggttaat 
Sequencing 
primer 2 
 Fw acaatcaaaggagatataccatggggatccttccc 
 Rv tgaaaataaatttcctttattagccagaggtcgaggtcgg 
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pTT-fwd   TCC ACA GGT GTC CAC TCC 
 
11.2.6 Vector pOPINE-Flag3 (C-his tag) 
Table I. 6. Primers designed to amplify the desired sequence and anneal to the pOPINE-
Flag3 vector. 
Insert Length Direction Sequence 
Gata2 C-term 
Fw aggagatataccatggcctgtggtctctatcacaaaatgaat 
Rv cagaacttccagttttgccaagtgacccataggagc 
HairyI FL 
Fw aggagatataccatgatgccggctgatgtgatgg 
Rv cagaacttccagtttccagggcctccaaacagaatca 
cdk1 FL 
Fw aggagatataccatgatggacgagtacactaaaatagagaagattgg 
Rv cagaacttccagtttatttctaatctgattggcgggaagg 
HairyI C-term 
Fw aggagatataccatggccaactgcatg 
Rv cagaacttccagtttccagggcctccaaacag 
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11.3 In-Fusion reaction overview 
  
Figure I. 9. Outline of In-Fusion PCR Cloning System. 
Linear vector and PCR products with extended regions are cloned and finally transformed into 
competent cells. 
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11.4 Protein expression via transfection into HEK293T 
cells 
11.4.1 Cdk1 
Table I. 7. CDK1 protein expression via transfection into HEK293T cells. 
Target 
protein 
Insert Vector PCR 
Sequenced 
clones 
Expression 
Cdk1 N-Term pOPINTTGneo 
no 
amplification 
    
Cdk1 C-Term pOPINTTGneo 
no 
amplification 
    
Cdk1 FL pOPINTTGneo 
no 
amplification 
    
Cdk1 C-Term pOPINTTGneo OK Miss-matches   
Cdk1 N-Term pOPINTTGneo OK Miss-matches   
Cdk1 FL pOPINTTGneo OK Miss-matches   
Cdk1 C-Term pOPINTTGneo OK Miss-matches   
Cdk1 FL pOPINTTGneo OK Miss-matches   
Cdk1 FL pOPINGM OK OK no expression  
Cdk1 FL pOPINFS OK OK no expression  
Cdk1 FL pOPINE-StrepII  OK OK no expression  
Cdk1 FL pOPINE-Flag3 OK OK no expression 
Cdk1 FL pOPINGM OK Miss-matches   
Cdk1 FL pOPINGM OK Miss-matches   
Cdk1 FL pOPINGM OK 1 changes in AAs    
Cdk1 FL pOPINGM OK OK no expression  
Cdk1 FL pOPINGM OK OK no expression  
Cdk1 FL pOPINGM OK Miss-matches   
Cdk1 FL pOPINGM OK Miss-matches   
Cdk1 FL pOPINGM OK Miss-matches   
Cdk1 FL pOPINGM OK Miss-matches   
Cdk1 FL pOPINGM OK Miss-matches   
Cdk1 FL pOPINFS OK OK no expression  
Cdk1 FL pOPINFS OK Miss-matches   
Cdk1 FL pOPINFS OK Miss-matches   
Cdk1 FL pOPINFS OK OK no expression  
Cdk1 FL pOPINFS OK OK no expression  
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Cdk1 FL pOPINFS OK OK  no expression 
Cdk1 FL pOPINFS OK OK Band 
Cdk1 FL pOPINFS OK Miss-matches   
Cdk1 FL pOPINFS OK OK Band 
Cdk1 FL pOPINFS OK OK Band 
Cdk1 FL pOPINE-Flag3 OK OK  no expression  
Cdk1 FL pOPINE-Flag3 OK 
1 point mutations 
no changes in AAs  
no expression  
Cdk1 FL pOPINE-Flag3 OK Empty vector   
Cdk1 FL pOPINE-Flag3 OK Miss-matches   
Cdk1 FL pOPINE-Flag3 OK OK  Band 
Cdk1 FL pOPINE-Flag3 OK 1 changes in AAs  no expression  
Cdk1 FL pOPINE-Flag3 OK Empty vector   
Cdk1 FL pOPINE-Flag3 OK OK no expression  
Cdk1 FL pOPINE-Flag3 OK OK no expression  
Cdk1 FL pOPINE-Flag3 OK Empty vector   
Cdk1 FL pOPINE-StrepII  OK Miss-matches   
Cdk1 FL pOPINE-StrepII  OK 
1 point mutations 
no changes in AAs  
no expression  
Cdk1 FL pOPINE-StrepII  OK Miss-matches   
Cdk1 FL pOPINE-StrepII  OK Miss-matches   
Cdk1 FL pOPINE-StrepII  OK 
1 point mutations 
no changes in AAs  
no expression  
Cdk1 FL pOPINE-StrepII  OK 
1 point mutations 
no changes in AAs  
no expression  
Cdk1 FL pOPINE-StrepII  OK Miss-matches   
Cdk1 FL pOPINE-StrepII  OK OK no expression  
Cdk1 FL pOPINE-StrepII  OK Miss-matches   
Cdk1 FL pOPINE-StrepII  OK Miss-matches   
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Cdk1 FL pOPINFS OK OK no expression  
Cdk1 FL pOPINFS OK OK no expression  
Cdk1 FL pOPINE-Flag3 OK OK no expression  
Cdk1 FL pOPINE-Flag3 OK OK no expression  
Cdk1 FL pOPINE-StrepII  OK OK no expression  
Cdk1 FL pOPINE-StrepII  OK OK no expression  
Cdk1 FL pOPINFS OK OK no expression  
Cdk1 FL pOPINFS OK OK no expression  
Cdk1 FL pOPINFS OK Miss-matches   
Cdk1 FL pOPINFS OK Miss-matches   
Cdk1 FL pOPINE-Flag3 OK OK no expression  
Cdk1 FL pOPINE-Flag3 OK OK no expression  
Cdk1 FL pOPINFS OK Miss-matches   
Cdk1 FL pOPINFS OK Miss-matches   
Cdk1 FL pOPINFS OK Miss-matches   
Cdk1 FL pOPINFS OK OK   
Cdk1 FL pOPINFS OK OK   
Cdk1 FL pOPINFS OK OK   
Cdk1 FL pOPINE-Flag3 OK OK   
Cdk1 FL pOPINE-Flag3 OK OK   
Cdk1 FL pOPINE-Flag3 OK OK   
Cdk1 FL pOPINFS OK OK   
Cdk1 FL pOPINFS OK OK   
Cdk1 FL pOPINFS OK OK   
Cdk1 FL pOPINE-StrepII  OK OK   
Cdk1 FL pOPINE-StrepII  OK OK   
Cdk1 FL pOPINE-StrepII  OK OK   
Cdk1 FL pOPINE-Flag3 OK OK   
Cdk1 FL pOPINE-Flag3 OK OK   
Cdk1 FL pOPINE-Flag3 OK OK   
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11.4.2 Delta1 
Table I. 8. Delta1 protein expression via transfection into HEK293T cells. 
Target 
Protein  
Insert Vector PCR Sequenced clones Expression 
Delta 1 FL pOPINF  
2 bands, 
900 bp and 
1800 bp 
OK match with 
different region of 
DNA 
 
Delta 1 FL pOPINE 400 bp band    
Delta 1 FL pOPINJ 
2 bands, 
900 bp and 
1800 bp 
   
11.4.3 FliI 
Table I. 9. FliI protein expression via transfection into HEK293T cells. 
Target 
Protein  
Insert Vector PCR 
Sequenced 
clones 
Expression 
FliI FL pOPINE 
no 
amplification 
    
FliI FL pOPINF  
no 
amplification 
    
FliI FL pOPINE 
OK - new 
template  
1 mismatch 
generated one stop 
codon 
no expression 
FliI FL pOPINF  
OK - new 
template  
mega prep too low 
yield 
  
FliI C-Term pOPINF OK OK  no expression 
FliI C-Term pOPINE OK mismatches   
FliI C-Term pOPINJ OK mismatches   
FliI C-Term pOPINTTGneo 
no 
amplification 
    
FliI C-Term pOPINTTGneo 
Temp 
gradient - no 
amplification 
    
FliI C-Term pOPINTTGneo 
no 
amplification 
    
FliI C-Term pOPINTTGneo 
no 
amplification 
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11.4.4 Gata2 
Table I. 10. Gata2 protein expression via transfection into HEK293T cells. 
Target 
Protein  
Insert Vector PCR 
Sequenced 
clones 
Expression 
Gata2 FL pOPINE 
increase 
extension to 
2'/gel extract 
the 
band/design 
short 
version 
    
Gata2 FL pOPINF  
increase 
extension to 
2'/gel extract 
the 
band/design 
short 
version 
    
Gata2 FL pOPINF OK  OK no expression  
Gata2 FL pOPINE OK  OK  no expression  
Gata2 FL pOPINF  
no 
amplification 
    
Gata2 FL pOPINE 
no 
amplification 
    
Gata2 FL pOPINJ OK empty vector   
Gata2 C-Term pOPINTTGneo OK miss matches   
Gata2 C-Term pOPINTTGneo OK OK 
very good 
expression 
Gata2 C-Term pOPINGM OK OK no expression  
Gata2 C-Term pOPINFS OK OK no expression 
Gata2 C-Term pOPINE-StrepII  OK 
OK 
no expression  
Gata2 C-Term pOPINE-Flag3 OK OK no expression  
Gata2 C-Term pOPINGM OK 
Reads through 
AMPr  
 
Gata2 C-Term pOPINGM OK 2 changes in AAs   
Gata2 C-Term pOPINGM OK 
Reads through 
AMPr  
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Gata2 C-Term pOPINGM OK 
Reads through 
AMPr  
  
Gata2 C-Term pOPINGM OK 2 changes in AAs    
Gata2 C-Term pOPINGM OK 
Reads through 
AMPr  
  
Gata2 C-Term pOPINGM OK 
Reads through 
AMPr  
  
Gata2 C-Term pOPINGM OK 
Reads through 
AMPr  
  
Gata2 C-Term pOPINGM OK 
Reads through 
AMPr  
  
Gata2 C-Term pOPINGM OK empty vector   
Gata2 C-Term pOPINFS OK Miss-matches   
Gata2 C-Term pOPINFS OK 4 changes in AAs   
Gata2 C-Term pOPINFS OK Miss-matches   
Gata2 C-Term pOPINFS OK Miss-matches   
Gata2 C-Term pOPINFS OK 2 changes in AAs   
Gata2 C-Term pOPINFS OK Miss-matches   
Gata2 C-Term pOPINFS OK OK 
Not 
transfected 
Gata2 C-Term pOPINFS OK Miss-matches   
Gata2 C-Term pOPINFS OK Miss-matches   
Gata2 C-Term pOPINFS OK OK no expression  
Gata2 C-Term pOPINE-Flag3 OK Miss-matches   
Gata2 C-Term pOPINE-Flag3 OK Miss-matches   
Gata2 C-Term pOPINE-Flag3 OK Miss-matches   
Gata2 C-Term pOPINE-Flag3 OK 2 changes in AAs   
Gata2 C-Term pOPINE-Flag3 OK 2 changes in AAs   
Gata2 C-Term pOPINE-Flag3 OK Miss-matches   
Gata2 C-Term pOPINE-Flag3 OK Very low yield   
Gata2 C-Term pOPINE-Flag3 OK Very low yield   
Gata2 C-Term pOPINE-Flag3 OK Very low yield   
Gata2 C-Term pOPINE-Flag3 OK Very low yield   
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Gata2 C-Term pOPINE-StrepII  OK Miss-matches   
Gata2 C-Term pOPINE-StrepII  OK Miss-matches   
Gata2 C-Term pOPINE-StrepII  OK Miss-matches   
Gata2 C-Term pOPINE-StrepII  OK Miss-matches   
Gata2 C-Term pOPINE-StrepII  OK Miss-matches   
Gata2 C-Term pOPINE-StrepII  OK Miss-matches   
Gata2 C-Term pOPINE-StrepII  OK Very low yield   
Gata2 C-Term pOPINE-StrepII  OK Miss-matches   
Gata2 C-Term pOPINE-StrepII  OK Very low yield   
Gata2 C-Term pOPINE-StrepII  OK 2 changes in AAs   
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
 
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
 
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
 
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
 
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
 
Gata2 C-Term pOPINE-StrepII  OK  1 changes in AAs   
Gata2 C-Term pOPINFS OK OK no expression  
Gata2 C-Term pOPINFS OK OK no expression  
Gata2 C-Term pOPINE-StrepII  OK 2 changes in AAs   
Gata2 C-Term pOPINE-StrepII  OK 2 changes in AAs   
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
  
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
  
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
  
Gata2 C-Term pOPINE-StrepII  OK 2 changes in AAs    
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Gata2 C-Term pOPINE-StrepII  OK 2 changes in AAs    
Gata2 C-Term pOPINE-StrepII  OK 2 changes in AAs    
Gata2 C-Term pOPINFS OK OK 
Not 
transfected 
Gata2 C-Term pOPINFS OK OK 
Not 
transfected 
Gata2 C-Term pOPINFS OK OK 
Not 
transfected 
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
  
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
  
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
  
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
  
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
  
Gata2 C-Term pOPINE-StrepII  OK 
 1 changes in AAs  
  
  
11.4.5 HairyI 
Table I. 11. HairyI protein expression via transfection into HEK293T cells. 
Target 
Protein  
Insert Vector PCR Sequenced clones Expression 
HairyI FL pOPINE 
need temp 
gradient/not 
good/ 
designed 
short 
version 
    
HairyI FL pOPINF  
need temp 
gradient/not 
good/ 
designed 
short 
version 
    
HairyI C-Term pOPINF  OK OK  no expression  
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HairyI C-Term pOPINE OK OK  
Good 
expression - 
faint in lysate 
but most stuck 
in cells 
HairyI C-Term pOPINJ OK miss-matches   
HairyI C-Term pOPINGM OK OK  no expression 
HairyI C-Term pOPINFS OK OK  no expression  
HairyI C-Term pOPINE-StrepII  OK OK  no expression  
HairyI C-Term pOPINE-Flag3 OK OK  no expression  
HairyI FL pOPINE-Flag3 
band wrong 
size 
    
HairyI C-Term pOPINGM OK miss-matches   
HairyI C-Term pOPINGM OK miss-matches   
HairyI C-Term pOPINGM OK OK no expression  
HairyI C-Term pOPINGM OK miss-matches   
HairyI C-Term pOPINGM OK OK no expression  
HairyI C-Term pOPINGM OK miss-matches   
HairyI C-Term pOPINGM OK miss-matches   
HairyI C-Term pOPINGM OK miss-matches   
HairyI C-Term pOPINGM OK miss-matches   
HairyI C-Term pOPINGM OK miss-matches   
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINFS OK 1 changes in AAs   
HairyI C-Term pOPINFS OK OK no expression  
HairyI C-Term pOPINFS OK Miss-matches  
HairyI C-Term pOPINFS OK Miss-matches  
HairyI C-Term pOPINE-StrepII  OK 1 changes in AAs   
HairyI C-Term pOPINE-StrepII  OK OK no expression  
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HairyI C-Term pOPINE-StrepII  OK OK Good Band 
HairyI C-Term pOPINE-StrepII  OK OK Band 
HairyI C-Term pOPINE-StrepII  OK OK no expression  
HairyI C-Term pOPINE-StrepII  OK Miss-matches   
HairyI C-Term pOPINE-StrepII  OK OK 
good 
expression 
HairyI C-Term pOPINE-StrepII  OK OK 
good 
expression 
HairyI C-Term pOPINE-StrepII  OK OK no expression  
HairyI C-Term pOPINE-StrepII  OK OK 
good 
expression 
HairyI C-Term pOPINE-Flag3 OK OK no expression  
HairyI C-Term pOPINE-Flag3 OK miss-matches   
HairyI C-Term pOPINE-Flag3 OK miss-matches   
HairyI C-Term pOPINE-Flag3 OK miss-matches   
HairyI C-Term pOPINE-Flag3 OK miss-matches   
HairyI C-Term pOPINE-Flag3 OK 1 changes in AAs   
HairyI C-Term pOPINE-Flag3 OK OK 
good 
expression 
HairyI C-Term pOPINE-Flag3 OK OK 
good 
expression 
HairyI C-Term pOPINE-Flag3 OK OK 
good 
expression 
HairyI C-Term pOPINE-Flag3 OK Miss-matches   
HairyI C-Term pOPINFS OK OK no expression  
HairyI C-Term pOPINFS OK OK no expression  
HairyI C-Term pOPINFS OK OK no expression  
HairyI C-Term pOPINFS OK OK no expression  
HairyI C-Term pOPINFS OK OK no expression  
HairyI C-Term pOPINFS OK OK no expression  
HairyI C-Term pOPINFS OK OK no expression  
HairyI C-Term pOPINFS OK OK no expression  
HairyI C-Term pOPINE-StrepII  OK OK 
good 
expression 
HairyI C-Term pOPINE-StrepII  OK OK 
good 
expression 
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HairyI C-Term pOPINE-StrepII  OK OK 
good 
expression 
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINFS OK miss-matches   
HairyI C-Term pOPINE-StrepII  OK OK   
HairyI C-Term pOPINE-StrepII  OK OK   
HairyI C-Term pOPINE-StrepII  OK OK   
HairyI C-Term pOPINFS OK 1 changes in AAs    
HairyI C-Term pOPINFS OK 1 changes in AAs    
HairyI C-Term pOPINFS OK 1 changes in AAs    
HairyI C-Term pOPINFS OK OK   
HairyI C-Term pOPINFS OK OK   
HairyI C-Term pOPINFS OK OK   
 
11.4.6 Myt1 
Table I. 12. Myt1 protein expression via transfection into HEK293T cells. 
Target 
Protein  
Insert Vector PCR Sequenced clones Expression 
MytI FL pOPINF  
no 
amplification 
   
MytI FL pOPINE 
no 
amplification 
   
MytI FL pOPINF  
need to 
increase 
extension to 
3' 
empty vector  
MytI FL pOPINE 
need to 
increase 
extension to 
3' 
empty vector  
MytI FL pOPINJ OK empty vector  
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MytI C-Term 
pOPINF - 
pOPINM -
pOPINJ 
tried 2 
different 
templates-
none work 
   
MytI C-Term pOPINE 
tried 2 
different 
templates-
none work 
   
MytI C-Term 
pOPINF - 
pOPINM -
pOPINJ 
different 
polymerase 
- did not 
amplify 
   
MytI C-Term pOPINE 
Tried 
different 
polymerase 
- did not 
amplify 
   
MytI C-Term 
pOPINF - 
pOPINM -
pOPINJ 
Temp 
gradient - 
did not 
amplify 
   
MytI C-Term pOPINE 
Temp 
gradient - 
did not 
amplify 
   
 
11.4.7 NeuroD 
Table I. 13. NeuroD protein expression via transfection into HEK293T cells. 
Target 
Protein  
Insert Vector PCR Sequenced clones Expression 
NeuroD FL pOPINE OK     
NeuroD FL pOPINF  OK     
NeuroD Short pOPINE OK OK  
faint 
expression on 
Lysate 
NeuroD Short pOPINF  OK OK  
faint 
expression on 
Lysate 
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NeuroD Short pOPINJ OK miss-matches   
NeuroD N-Term pOPINTTGneo OK     
NeuroD  C-Term pOPINTTGneo OK     
 
11.4.8 Neurog2 
Table I. 14. Neurog2 protein expression via transfection into HEK293T cells. 
Target 
Protein  
Insert Vector PCR 
Sequenced 
clones 
Expression 
Neurog2 C-Term pOPINTTGneo 
no 
amplification 
   
Neurog2 C-Term pOPINTTGneo 
temp 
gradient - 
did not 
amplify 
   
Neurog2 FL pOPINE 
no 
amplification 
   
Neurog2 FL pOPINF  
no 
amplification 
   
Neurog2 C-Term pOPINTTGneo 
no 
amplification 
   
Neurog2 C-Term pOPINTTGneo OK OK 
good 
expression 
Neurog2 C-Term pOPINTTGneo 
no 
amplification 
   
Neurog2 C-Term pOPINTTGneo OK no colonies  
Neurog2 C-Term pOPINTTGneo OK no colonies  
 
11.4.9 Rarα2 
Table I. 15. Rarα2 protein expression via transfection into HEK293T cells. 
Target 
Protein  
Insert Vector PCR Sequenced clones Expression 
Rarα2 Short pOPINE OK OK  no expression 
Rarα2 Short pOPINF  OK OK  no expression 
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11.4.10 Ncor2 
Table I. 16. Ncor2 protein expression via transfection into HEK293T cells. 
Target 
Protein  
Insert Vector PCR 
Sequenced 
clones 
Expression 
Ncor2 Short pOPINE OK OK  no expression 
Ncor2 Short pOPINF  
no 
amplification 
    
Ncor2 Short pOPINTTGneo OK miss-matches   
Ncor2 Short pOPINTTGneo OK OK no expression 
 
11.4.11 TalI 
Table I. 17. TalI protein expression via transfection into HEK293T cells. 
Protein 
Target 
Insert Vector PCR 
Sequenced 
clones 
Expression 
TalI FL pOPINE 
faint shorter 
band than 
expected - 
tried 2 
templates 
   
TalI FL pOPINF  
faint shorter 
band than 
expected - 
tried 2 
templates 
   
TalI FL pOPINE 
multiple 
bands - not 
the correct 
size 
   
TalI FL pOPINF 
multiple 
bands - not 
the correct 
size 
   
TalI N-Term pOPINTTGneo 
no 
amplification 
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TalI C-Term pOPINTTGneo 
no 
amplification 
   
TalI N-Term pOPINTTGneo 
Temp 
gradient - 
did not 
amplify 
   
TalI C-Term pOPINTTGneo 
Temp 
gradient - 
did not 
amplify 
   
TalI N-Term pOPINTTGneo 
no 
amplification 
   
TalI C-Term pOPINTTGneo 
no 
amplification 
   
TalI N-Term pOPINTTGneo OK no colonies  
TalI C-Term pOPINTTGneo 
no 
amplification 
   
  
11.4.12 XicI 
Table I. 18. XicI protein expression via transfection into HEK293T cells. 
Target 
Protein  
Insert Vector PCR Sequenced clones Expression 
XicI FL pOPINE OK OK  
no 
amplification 
XicI FL pOPINF  
wrong size 
band 
    
XicI N-Term pOPINTTGneo OK miss-matches   
XicI FL pOPINTTGneo OK miss-matches   
XicI N-Term pOPINTTGneo OK OK 
no 
amplification 
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12 Appendix II 
Some of the most common primers used to amplify VHH specific sequences for the 
development of libraries: 
CALL001: 5’ GTC CTG GCT GCT CTT CTA CAA GG 3’ (Rothbauer, et al., 2006); 
(Pardon, et al., 2014) 
CALL002: 5’ GGT ACG TGC TGT TGA ACT GTT CC 3’ (Rothbauer, et al., 2006); 
(Pardon, et al., 2014) 
VHH-Back: 5’ GAT GTG CAG ctg cag GAG TCT GGR GGA GG 3’ (PstI) (Pardon, et al., 
2014) 
VHH-For: 5’ CTA GTG CGG CCG CTG GAG ACg gtg acc TGG GT 3’ (Eco91I) (Pardon, 
et al., 2014) 
MP57: TTA TGC TTC CGG CTC GTA TG 3’ (Pardon, et al., 2014) 
GIII: 5’ CCA CAG ACA GCC CTC ATA G 3’ (Pardon, et al., 2014) 
SM017: 5’ CCA GCC GGC CAT GGC TCA GGT GCA GCT GGT GGA GTC TGG 3’ 
(Rothbauer, et al., 2006) 
SM018: 5’ CCA GCC GGC CAT GGC TGA TGT GCA GCT GGT GGA GTC TGG 3’ 
(Rothbauer, et al., 2006) 
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12.1 Insert verification by sequence BLAST 
(Xenbase.org) 
The sequence of interest was isolated and amplified from the original vectors by PCR, 
which in turn added ends to a product which is homologous to the destination vector. 
These were cloned by In-Fusion reaction and verified by plasmid prep followed by 
sequencing. The sequences were confirmed using the BLAST tool from Xenbase.   
12.1.1.1 pOPINF-RARα2 
 
Figure II. 1. pOPINF-RARα2 plasmid sequence verification. 
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12.1.1.2 pOPINF-NeuroD 
Figure II. 2.pOPINF-NeuroD plasmid sequence verification. 
 
  
321 
 
12.1.1.3 pOPINF-FliI 
Figure II. 3. pOPINF-FliI plasmid sequence verification. 
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12.1.1.4 pOPINE-RARα2 
 
Figure II. 4. pOPINE-RARα2 plasmid sequence verification. 
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12.1.1.5 pOPINE-NeuroD 
Figure II. 5. pOPINE-NeuroD plasmid sequence verification. 
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12.1.1.6 pOPINE-FliI 
Figure II. 6. pOPINE-FliI plasmid sequence verification. 
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13 Appendix III 
13.1 Protein targets for commercial synthesis 
13.1.1 ascl1  
achaete-scute homolog 1 [Xenopus laevis] 
NCBI Reference Sequence: NP_001079247.1 
aavarrnere rnrvklvnlg fatlrehvpn gaankkmskv etlrsaveyi ralqqlldeh davsaafqsg  
 
13.1.2 ccna1 
cyclin A1 L homeolog [Xenopus laevis] 
NCBI Reference Sequence: NP_001087670.1 
mrrsmvssgh ilttssvvga ssafqnrcla kvevqpnlpq rtvlgvisdn eqhrrsisrg gapakclpgi envlpfpgkf 
lsanpapvvp kpsftvyvde peqptetysi evdcpsldev dsnlvkqnih llldisaasp mvvdasfqts 
qeddsitdpd avavseyide ihqylreael knrpkayymr kqpditsamr tilvdwliev geeyklrtet lylavnyldr 
flscmsvlrg klqlvgtaai llaskyeeiy ppgvdefvyi tddtyskkql lrmehlllkv lafdltvptt sqfllqylqr 
havsvktehl amylaeltlf evepflkyvp sltaaaaycl anyalnkvfw petleaftgy tlseiapcls dmhqaclhap 
yqaqqairek yktpkymqvs llempatlpl n 
 
13.1.3 ccne1  
G1/S-specific cyclin-E3 [Xenopus laevis] 
NCBI Reference Sequence: NP_001081446.1 
hepnptsyph faslrfspvs asplprlgwa nqddvwrnml nkdriylrdk nffekhpqlq pnmrailldw 
lmevcevykl hretfylaqd ffdrfmatqk nviksrlqli gitslfiaak meeiyppklh qfafitdcac tedeitsmel 
iimkdldwcl spmtmvswfn vflqvayire lqhflrpqfp qevyiqivql ldlcvldicc ldypygvlaa salyhfscpe 
lmekvsgfkl telqgcikwl vpfamaikdg gksklkffkg vdiedvhniq thtgclelme 
 
13.1.4 cdk1 
cyclin-dependent kinase 1-B [Xenopus laevis] 
NCBI Reference Sequence: NP_001080093.1 
mdeytkieki gegtygvvyk grhkatgqvv amkkirlene eegvpstair eisllkelqh pnivclldvl mqdsrlylif 
eflsmdlkky ldsipsgqyi dtmlvksyly qilqgivfch srrvlhrdlk pqnllidnkg vikladfgla rafgipvrvy 
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thevvtlwyr asevllgsvr ystpvdvwsv gtifaeiatk kplfhgdsei dqlfrifrsl gtpnnevwpe veslqdyknt 
fpkwkggsls snvknidedg ldllskmlvy dpakrisark amlhpyfddl dksslpanqi rn 
 
13.1.5 cdk2 
cyclin-dependent kinase 2 [Xenopus laevis] 
NCBI Reference Sequence: NP_001084120.1 
menfqkveki gegtygvvyk arnretgeiv alkkirldte tegvpstair eisllkelnh pnivklldvi htenklylvf 
eflnqdlkkf mdrsnisgis lalvksylfq llqglafchs hrvlhrdlkp qnllinsdga ikladfglar afgvpvrtft 
hevvtlwyra peillgckfy stavdiwslg cifaemitrr alfpgdseid qlfrifrtlg tpdevswpgv ttmpdykstf 
pkwirqdfsk vvppldedgr dllaqmlqyd snkrisakva lthpffrdvs rptphli 
 
13.1.6 cdknx 
cyclin-dependent kinase inhibitor XicI S homeolog [Xenopus laevis] 
NCBI Reference Sequence: NP_001108275.1 
maafhialqe emisapavlp rlsagtgrga crnlfgpidh demrselkrq lkeiqasdcq rwnfdfetgt 
plkgifcwep veskdmpsfy sqnrsiaant 
 
13.1.7 dazl 
deleted in azoospermia-like-A [Xenopus laevis] 
NCBI Reference Sequence: NP_001081772.1 
msgkeessny aataeeeavn qgfvlpegei mpntvfvggi ditmdeieir dfftrfgnvk evkiitdrtg vskgygfisf 
sdevdvqkiv ksqisfhgkk lklgpairki ctyvqprpvv 
 
13.1.8 etv2 
ets variant 2 L homeolog [Xenopus laevis] 
NCBI Reference Sequence: NP_001089600.1 
dkkplptass gpiqlwqfll ellqdsscqk liswtgngwe fklsdpneva rrwgrrknkp rmnyeklsrg lryyyhknii 
hktggqryvy rfvcdlqdll srptqtsqpp tktqrsriq 
 
13.1.9 fli1 
retroviral integration site protein Fli-1 homolog [Xenopus laevis] 
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NCBI Reference Sequence: NP_001084371.1 
vdcsinkcsk liggsegnam tytymdekng ppppnmttne rrvivpadpa lwsqdhvrqw lewaikeygl 
veidcslfqn idgkelckms kedflrstsi yntevllshl nylrdssssl gyntqahtdq ssrltakedp syeavrrsgw 
gnsmsspvtk sppmggtqnv nksgdqqrsq pdpyqilgpt ssrlanpgsg qiqlwqflle llsdssnasc 
itwegtngef kmtdpdevar rwgerkskpn mnydklsral ryyydksimt kvhgkryayk fdfhgiaqal qphpt 
 
13.1.10 fus1 
FUS RNA binding protein L homeolog [Xenopus laevis] 
NCBI Reference Sequence: NP_001080383.1 
gfskfggphe gggpprnema eqdnsdnnti fvqglgenvt vesvadyfkq igiikinkkt gqpminlytd 
retgklkgea tvsfddppsa kaaidwfdgk efsgnpikvs fatrradfns rgggngrgrg rggpmgrggf 
ggppggsssr ggsggypsgg ggqqragdwk cpnpgcenmn fswrnecnqc kapkpegpgg 
 
13.1.11 gata2 
GATA-binding factor 2 [Xenopus laevis] 
NCBI Reference Sequence: NP_001084043.1 
Hdyssglfhp gsllggpass ftpkqrsksr scsegrecvn cgatatplwr rdgtghylcn acglyhkmng 
qnrplikpkr rlsaarragt ccancqtstt tlwrrnangd pvcnacglyy klhnvnrplt mkkegiqtrn rkmsnkskkn 
 
13.1.12 hes1 
transcription factor HES-1-A [Xenopus laevis] 
NCBI Reference Sequence: NP_001081396.1 
mpadvmekns sspvaatpas vsntpdkpkt asehrksskp imekrrrari neslgqlktl ildalkkdss 
rhsklekadi lemtvkhlrn lqrvqmsaal stdpsvlgky ragfsecmne vtrflstceg vntdvrtrll ghlancmnqi 
 
13.1.13 lis1 
lissencephaly-1 homolog [Xenopus laevis] 
NBI Reference Sequence: NP_001083934.1 
mvlsqrqrde lnraiadylr sngyeeaysv fkkeaeldmn eeldikyagl lekkwtsvir 
lqkkvmeles klneakeeft sggpigqkrd pkewiprppe 
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13.1.14 myt1 
myelin transcription factor 1 [Xenopus laevis] 
NCBI Reference Sequence: NP_001081661.1 
rpidtmrksf ydagrpekrd ikcptpgcdg tghvtglyph hrslsgcphk drippeilam henvlkcptp 
gctgqghvns nrnthrslsg cpiaaaeklt rshekqqqpg dlsksssnsd rilrpmcfvk qleipqygsy 
rpnmapatpr anlakeleky skvtfdyasf daqvfgkrll apkipssets pkafkskpfp kasspchsps 
ssyikstsss sssgfdythd aeaahmaata ilnlstrcwe mpenlstkqq dtpsksseie vdengtldls 
mnkhrkrest fpsssscsss psmkspdqsq rqnctsatss nmtsphssqt srqddwdgpi dytkpnrqre 
eepeemepaa asfassevde qemqemqemq emqeesyedr kypgdvtltn fklkflskds kkellscptp 
gcdgsghitg nyashrslsg cpladkslrn lmaahsadlk cptpgcdgsg hitgnyashr slsgcprakk 
sglkitptkd dkddpdlmkc pvpgcdglgh isgkyashrs asgcplaarr qkegalngsa fswkslkteg 
pscptpgcdg sghangsflt hrslsgcpra sfagkkgkis gdellgtnfk tsdvlendee ikqlnkeine 
lnesnsemea dmvnlqsqit tmeknlknie eenkvieeqn ealfvelsgl sqalirsltn 
 
 
13.1.15 ncor2 
nuclear receptor corepressor 2 S homeolog [Xenopus laevis] 
NCBI Reference Sequence: NP_001084492.1 
aevkrprlei lhdplirhsp litqnqhatg eelnkdhrma gklepvspss ppladgdldl lparlskeel iqnmdrvdre 
iimveqqisk lkkkqqqlee eaakplepek pvspppvesk hrslvqiiyd enrkkaeaah rileglgphv 
elplynqpsd tkqyheniki nqtmrkklil yfkrrnhark qweqklcqry dqlmeawekk veriennprr 
rakeskirey yekqfpeirk qrelqermqr vgqrgsgltl saarsehevs eiidglseqe nlerqmrqla 
vippmlfdae qqrirfinmn glmddpmkvy kerqvmnmws eqekdtfrek fiqqpknfvf iasflerktv 
sdcvlfyylt kknenyknli rrnyrrrgkn qqmprtnqee kdekekegek eeykqdldne kdepgkeknd 
dtsgdenddk eavmakgrkt ansqgrrkgr itrsmanean eestapqhyt dlatmemnes srwteeemet 
akkglfeygr nwsaiarmvg sktvsqcknf yfnykkrqnl dgilqqhklk mekernnrrk kkknpqmeee 
tpyppalede emeasgmsgn eeemadegda 
 
13.1.16 ndel1 
nuclear distribution protein nudE-like 1-A [Xenopus laevis] 
NCBI Reference Sequence: NP_001086332.1 
meneeipefl spkeeivywr elskrlkqsy qeardelief qegsreleae letqlvqaeq rnrdllsdnq rlkceveslk 
eklehqyaqs ykqvsllede lararsikdq lhkyvreleq anddlerakr ativsledfe qrlnqaiern afleseldek 
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esllvsvqrl kdeardlrqe lavrerqtdg trksapsspt ldcdktdsav qaslslpatp vgkicdnsft spkgipngfg 
ttpltpsari salnivgdll rkvgaleskl aacrnfakdq asrksytpvn lnsnssssvl 
 
13.1.17 neurod1 
neurogenic differentiation factor 1 [Xenopus laevis] 
NCBI Reference Sequence: NP_001079263.1 
kvrrmkanar ernrmhglnd aldslrkvvp cysktqklsk ietlrlakny iwalseilrs gkspdlvsfv qtlckglsqp 
ttnlvagclq lnprtflpeq sqdiqshmqt asssfplqgy pyqspglpsp pygtmdsshv fhvkphsyga 
alepffdsst vtectspsfd gplspplsvn gnftfkhehs eydknytftm 
 
13.1.18 neurog2 
neurogenin 2 L homeolog [Xenopus laevis] 
NCBI Reference Sequence: NP_001081802.1 
sgetvlkikk trrvkannre rnrmhnlnsa ldslrevlps lpedakltki etlrfaynyi walsetlrlg dpvhrsast 
 
13.1.19 ngn3 
neurogenin 3 S homeolog [Xenopus laevis] 
NCBI Reference Sequence: NP_001128257.1 
vkqrrnrrvk andrernrmh nlnsaldalr silptfpdda kltkietlrf ahnyiwalse tlrmadqsll 
13.1.20 ppp2r5a 
protein phosphatase 2 regulatory subunit B', alpha [Xenopus laevis] 
NCBI Reference Sequence: NP_001108316.1     
eieeildvie ptqfkkiqep lfkqiskcvs sshfqvaera lyfwnneyil slieenidki lpimfgslyk iskehwnpti 
valvynvlkt lmemngklfd eltgsykaer qrekkkeler  
 
13.1.21 rara2 
retinoic acid receptor, alpha L homeolog [Xenopus laevis] 
NCBI Reference Sequence: NP_001083723.1 
myenvdvspt hyhmmdfysh nrqclwpekr inpygtplgt qhwsssnh 
 
13.1.22 rarb 
retinoic acid receptor beta, partial [Xenopus laevis] 
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GenBank: ABE96637.1 
pppppriykp cfvcqdkssg yhygvsaceg ckgffrrsiq knmvytchre kncvinkvtr nrcqycrlqr 
cfevgmskes vrndrnkkkk epskqecies yemtaelddl tekirkahqe tfpslcqlgk yttnssadhr 
vrldlgfwdk fselatkcii kivefakrlp gftsltiadq itllkaacld ililrictrf tpeqdtmtfs dgltlnrtqm hnagfgpltd 
lvftfanqfl plemddtetg llsaiclice drqdleepak vdklqeplle alkiyirkrr pnkphmfpki lmkit 
 
13.1.23 ror2 
receptor tyrosine kinase-like orphan receptor 2 L homeolog precursor [Xenopus laevis] 
NCBI Reference Sequence: NP_001082312.1 
Lgatprgyyl tflepvnnit ivqgqaatlh ckvsgnplpn vkwlkndapv vqepkritir ktdygsrlri qdldttdtgy 
yqcvatngik titatgvlfv rlgptnspnp niqddyhkdg fcqpyrgiac arfignrtiy vdslqmqgei enritaaftm 
igtsthlsdq csqfaipsfc hfvfplcddq tskprelcrd ecevlendlc rqeyniarsn plilmqlhlp nceelplpes 
peaancmrig ipveklnryq qcyngtgtdy rgsvsvtksg hqcqpwshqv phshslsnad ypeiggghsy 
crnpggqmeg pwcftqnknv rmelcdipac rtrdntkmei 
 
13.1.24 tal1 
T-cell acute lymphocytic leukemia protein 1 [Xenopus laevis] 
NCBI Reference Sequence: NP_001081746.1 
pertvelsgv kegaapnspp ravpviellr rgeglgnika reqelrlqni rttelcratl tpatelcrap ltpttelcra 
pltpttelcr apltpttelc rppltpaaef crasltpase lcrapssvtg psltattelc rppiplptps tgppaeqave 
armvqlspta slplqaagrt mlyglnqpla sdnsgyfgdp dtfpmytsns rakrrpgpie veisegpqpk 
vvrriftnsr erwrqqnvng afaelrklip thppdkklsk neilrlamky inflaklldd qeeegnqrnk 
 
13.1.25 tra2b 
Splicing factor, arginine/serine-rich 10 [Xenopus laevis] 
NCBI Reference Sequence: NP_001082402.1 
Hignranpdp ncclgvfgls lytterdlre vfskygplsd vsivydqqsr rsrgfsfvyf envddakeak 
erangmeldg rrlrvdfsit krphtptpgi 
13.1.26 wnt4b 
Protein Wnt-4 isoform 2 precursors [Xenopus laevis] 
NCBI Reference Sequence: NP_001239014.1 
mtpeyflrsl lmmilavfsa nasnwlylak lssvgsisee etceklkgpi qrqvqmckrn levmdsvrrg 
aqlaieecqy qfrnrrwncs tldtlpvfgk vvtqgtreaa fvyaissagv afavtracss gdlekcgcdr tvhgvspqgf 
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qwsgcsdnil ygvafsqsfv dvrerskggs ssralmnlhn neagrkailn nmrveckchg vsgscevktc 
wkamptfrkv gnvlkekfdg ateveqkkig stkvlvpkns qfkphtdedl vyldsspdfc dhdlkngvlg 
ttgrqcnkts kaidgcelmc cgrgfhteev eivercsckf hwccfvkckq chkvvemhtc r 
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14 Literature Search techniques and sources 
employed 
The main source of information has been gathered searching the NCBI database 
(http://www.ncbi.nlm.nih.gov/) and the Xenopus model organism database Xenbase 
(http://www.xenbase.org/). Once a paper of interest was found, occasionally references 
within that text were followed, to archive an insight into some detail. Scientific articles not 
freely available were requested as inter-library loans at the university.  
 
